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ABSTRACT
Tum our hypoxia is a well described phenom enon which is 
p r im arily  created  by an inadequate  and n o n -un ifo rm  vascu lar 
network. Importantly, hypoxia within certain solid tumours has been 
linked to the failure of conventional therapy, including radiotherapy 
and chemotherapy. For this reason, many attempts have been made 
to identify, characterise, and quantify hypoxic cells w ithin  these 
tumours as a prelude to the design of rational therapies aimed to kill 
all the cancer cells present w ithin tumours. The use of 2- 
n itro im idazoles containing appropriate  labels as m arkers for the 
detection of hypoxic cells, is based on the ability of these compounds 
to undergo selective n itroreduction and adduct form ation  within 
hypoxic cells.
The fluorina ted  2 -n itro im idazo le , SR -4554, was ra tionally  
designed as a non-invasive hypoxia probe with low toxicity and high 
sensitivity for detection by magnetic resonance spectroscopy (MRS) 
and imaging (MRI). SR-4554 was demonstrated to be enzymatically 
reduced by mouse liver microsomes, SCCVII tumour homogenates and 
purified rat and human NADPH: cytochrome P450 reductase under 
hypoxia. In this regard, NADPH: cytochrome P450 reductase was 
found to be the major enzyme involved in this bioreduction of SR- 
4554. In a panel of murine and human tumour xenografts, only a 3 
fold variation in NADPH: cytochrome P450 reductase activities was 
observed. These differences in NADPH: cytochrome P450 activities 
are unlikely to significantly influence SR-4554 adduct formation in  
v i v o .  Im portantly , the reduction of SR-4554 by m ouse liver 
microsomes showed a characteristic oxygen dependence with a half- 
maximal inhibition of 0.48%. Using a high resolution nuclear
m agnetic  resonance (NMR) technique, soluble hypox ia-dependen t 
m etabolites of various fluorinated 2-nitroim idazoles, including SR- 
4554, were identified. The chemical shifts of these metabolites were 
found to be less than those required to give resolved peaks in in vivo 
MRS studies. Determination of the possible regions of SR-4554 adduct 
form ation within A2780 human ovarian multicellular spheroids was 
achieved by electron energy loss spectroscopic imaging. Using this 
technique, an 8 fold differential between the fluorinated probe levels 
retained in the inner hypoxic regions of the spheroid vs the outer 
more aerobic regions was observed. SR-4554 was localised mainly to 
the nuclear periphery, nucleus and cytoplasm within cells from the 
hypoxic region of the spheroids.
The toxicity and pharmacokinetics of SR-4554 was studied in 
mice as a prelude to non-invasive MRS/MRI studies. SR-4554
was found to be non-toxic in mice up to a dose of 1300 mg/kg. 
Pharmacokinetics of SR-4554 fitted either a one compartment or two
compartm ent open model depending on the route of administration. 
The probe was characterised by a relatively short half-life, linear 
kinetics, high urinary excretion, high oral bioavailability  and low 
plasma protein binding. Importantly, the brain to plasma ratio of SR- 
4554 was lower than previously reported trends in the literature, 
thus confirming its potentially low toxicity.
As a consequence  of the low tox ic ity  and favourab le  
pharm acokinetic properties of SR-4554, a non-invasive m ulti-tuned
MRS technique was implemented to detect this compound in 
tissues. Using this MRS technique, SR-4554 was found to be 
selectively retained in both murine and human tumour xenografts. 
Importantly the retention index was found to correlate with the
reported radiobiological hypoxic fraction of the tumours used. This 
l ^ F  retention index was also found to be higher in larger tumours but, 
interestingly, did not correlate with the bioenergetic status of the 
tum ours, as determined by 3 1 p  MRS. M anipulation of tumour 
m icroenvironm ent to affect the degree of hypoxia  w ithin  these 
tumours was studied in vivo. In mouse tumours for instance, the 
retention index increased 2 fold compared to control values, following 
hydralazine pre-treatment, and decreased by 6 fold com pared to 
control values, following carbogen breathing. Important to the clinical 
development of SR-4554, 19p MRI techniques showed localisation of 
SR-4554 in the bladder, tumour and liver of mice. This technique 
was, however, limited by low sensitivity due to the extremely short 
transverse relaxation, time of the probe in tissues.
Finally this thesis has demonstrated that SR-4554 has suitable 
metabolic, pharmacological and MRS properties for its use in the 
quantification of critical levels of hypoxia within human tumours. As 
a consequence, this compound has been approved by CRC phase I/II 
committee for clinical development.
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CHAPTER 1
I n t r o d u c t i o n
1 . 1  NATURE OF CANCER
A cancer can be defined as a group of cells within the body that 
escapes from  normal, orderly homeostatic control, and m ultiplies 
until, unless treated, it leads to organ dysfunction or death of the host. 
Normal cells proliferate in a controlled fashion due to the presence of 
feedback mechanisms which stimulate or inhibit cell division (Pera, 
1995). In contrast, however, cancer cells lose this regulation of cell 
p roliferation leading to the formation of a tumour mass and, in 
addition, may also loose the ability to differentiate (Pera, 1995).
A tumour may be classified as being benign or malignant. In 
this regard, malignant tumours differ from benign tumours in their 
ability to spread from their primary sites to d istant tissues from 
where they can grow into new tumours (metastasis) (Tarin, 1995). 
Importantly, in most cases, it is this metastasis which causes the 
progression of tumours resulting in death of the host.
The annual inc idence  rates of c an ce r  (c rude  and age 
standardised) and also the numbers of new cases of 18 different 
cancers have been estimated, for the year 1985, in 24 areas of the 
world (Parkin et al., 1993). The total number of new cases was 7.6 
million, 52% of which occured in developing countries (Parkin et al.,
1993). Lung cancer is the most common cancer, followed by stomach 
cancer and then breast cancer (Parkin et al ., 1993). The trends in 
cancer m ortality in different parts of the world have also been 
reported (Franceschi et al ., 1994; La Vecchia et a l ., 1993a; La Vecchia 
et a l ., 1993b; La Vecchia et al ., 1992; Parkin et a l . , 1993). For 
instance, the overall age-standardised rates for breast cancer in the 
late 1980's in most European countries, were between 20 and 30 per
100,000 (La Vecchia et al., 1992).
In spite of recent advances in the treatment of cancers, there 
are still a lot of obstacles. One of the m ost important of these 
obstacles is the resistance of tumours to conventional therapy, in 
particu la r  chem otherapy and radiotherapy. One such resistance 
mechanism, tumour hypoxia, which is a result of the physiological 
status of the tumour, is the basis of this thesis and will be described 
in more detail in section 1.2.
1
1 .2  PHYSIOLOGICAL PROPERTIES OF TUMOURS
1 . 2 . 1  T u m ou r h yp ox ia
Oxygen provides cells with their major source of cellular energy 
through oxidative phosphorylation. Tissue hypoxia results from an 
inhibition of oxygen supply to cells and may occur in vascular disease, 
such as during a stroke, or in tumours. Structural and functional 
abnorm alities  of the tum our vasculature  m ay accoun t for the 
existence of hypoxic cells within tumours (Vaupel et a l ., 1989). 
G enera lly , tum our cells adjacent to cap illa r ies  are adequate ly  
oxygenated and capable of normal aerobic m etabo lism  and cell
division. Since oxygen must be carried to distant cells by diffusion, 
however, cell respiration reduces the oxygen tension with increasing 
distance from capillaries. Thus hypoxic cells may be defined as cells 
existing at an intermediate oxygen tension between well oxygenated 
cells (oxic population) and those cells with insufficient oxygen to 
support viability (anoxic or necrotic population). Cells existing under 
an oxygen tension (pC>2) of 0.1% or less are specifically referred to as 
radiobiologically hypoxic cells, due to the resistance of such cells to 
radiation treatment (see section 1.3).
Tum our hypoxia may present as an ir revers ib le  diffusion
limited (chronic) (Thomlinson & Gray, 1955) or a reversible perfusion 
limited (acute) (Brown, 1979; Chaplin et al., 1987) form. These two 
forms of hypoxia are illustrated in Fig. 1.1. Chronic hypoxia which is 
the classical model of tumour hypoxia occurs when solid tumours out­
grow their supportive vasculature (Thomlinson & Gray, 1955; Vaupel, 
1992). The diffusion distance of molecular oxygen is limited, by 
metabolic consumption, to 150-200 |im  from the nearest capillary. 
Beyond this diffusion distance, cells are non-viable and become 
necrotic. Immediately proximal to the necrotic zone is a layer of 
hypoxic cells which are oxygen deprived and yet viable. These cells 
which are a result of the diffusion limitation of oxygen, remain 
hypoxic until they become reoxygenated or die, and hence are 
referred  to as chronically  hypoxic cells. Such cells are also
characterised by their low rate of metabolism, low levels of glucose
and adenosine triphosphate (ATP), and high levels of catabolites such 
as lactate (Vaupel, 1992).
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Fig. 1.1. A schematic representation of the two types of hypoxia 
present within solid tumours. Chronic hypoxia, as described by 
Tomlinson and Gray (1955), results from the exhaustion of oxygen by 
metabolism as it diffuses from the supportive vasculature. Acute 
hypoxia is a more transient effect and results from the intermittent 
closing and reopening of tumour vessels. Taken from Workman 
(1992).
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The second type of hypoxia occurs when blood flowing through 
a vessel is transiently stopped, resulting in oxygen deprivation of all 
the normally oxic cells down-stream of the occlusion (Brown, 1979; 
Chaplin et al., 1987; Trotter et al ., 1989). These cells are considered 
acutely hypoxic because they only remain hypoxic as long as the 
occlusion continues, becoming oxygenated again when blood flow 
resum es. Prolonged vascular occlusion can, how ever, lead to 
decreased cell survival and death (Denekamp et a l ., 1983). Current 
lite ra ture  indicates that significant variations in the oxygenation 
status of tumours can occur, between different locations within a 
tumour, and between tumours of the same grading and clinical 
staging (Vaupel, 1992).
1 . 2 . 3  Cell cycle regulation o f  hypoxic cells
Reduced oxygenation can affect the processes of cell growth and 
cell cycle control. There is evidence to suggest that in some tumours 
cells can arrest in G2 or M-phase under hypoxia (Shrieve & Begg, 
1985; Shrieve et al., 1983). In general, however, existing data 
indicate that cells in S-phase immediately arrest following exposure 
to extreme hypoxia, while cells in other phases of the cell cycle 
proceed through the cell cycle and become arrested in late G i 
(Amellem & Pettersen, 1993; Bedford & Mitchell, 1974; Koch et al ., 
1973). This oxygen-dependent G i check-point is certainly different 
from the quiescent Go phase exhibited by non-cycling aerobic cells 
and may act to protect cells from the lethal effect of extreme hypoxia 
in S-phase (Amellem & Pettersen, 1991; Spiro et a l ., 1984). In 
addition, although hypoxia can induce the tumour suppressor protein 
p53, the hypoxia induced G i-checkpoint is independent of p53 status 
(Graeber et al., 1994). More recently, hypoxia and reoxygenation of 
hypoxic tumour cells (section 1.3.3) have also been demonstrated to 
act as signals for the programmed cell death (apoptosis) of these cells 
(Yao et al ., 1995).
1 . 2 . 4  M olecular response of cancer cells to hypoxia
In recent years, the response of cancer cells to hypoxia and 
reoxygenation  has been evaluated at the m olecu lar level. The 
transcrip tiona l activation and expression of various genes and 
proteins are considered as adaptive response of these cells to the
3
hypoxic stress. Genes and proteins shown to be m odulated by 
hypoxia include oxygen regulated proteins (Heacock & Sutherland,
1986), glucose regulated proteins (Koong et a l ., 1994a), heat shock 
proteins (Giaccia et a l., 1992), vascular endothelial growth factor 
(Shweiki et al., 1992), erythropoietin (Madan & Curtin, 1993), lactate 
dehydrogenase (Firth et al., 1994), phoshphoglycerate kinase 1 (Firth 
et al., 1994), and also the enzyme DT-diaphorase (Robertson et al.,
1994). T ranscriptional factors regulated by hypoxia include the
hypoxia inducible factor 1 (Wang et al., 1995), the bifunctional redox 
protein/endonuclease Ref-1 (Yao et al., 1994), the proto-oncogenes 
jun and fos (AP-1) (Yao et al., 1994), the nuclear transcription factor 
kB (Koong et al., 1994b), and the tumour suppressor gene p53 
(G raeber et al., 1994). In addition, it also appears that reduced d e  
n o v o  synthesis of deoxynucleotides may play a part in the cell cycle 
regulation of hypoxic cells (Amellem et al., 1994).
1.3.  THERAPEUTIC IMPORTANCE OF TUMOUR 
HYPOXIA
1 . 3 . 1  R a d io res is ta n ce  and c h e m o r es is ta n c e  o f  
hyp oxic  cells
The presence within tumours of hypoxic cells has long been 
considered as a problem in cancer therapy due to the radio- and 
chemoresistance of hypoxic cells (Bush et al., 1978; Coleman, 1988; 
G atenby et al., 1988; Hall, 1988; W orkman, 1983a). Following 
therapy, these cells can repopulate and cause relapse of the cancer. 
For instance, hypoxic cells are 2-3 times more resistant to cell killing 
by radiation compared to well oxygenated or aerobic cells (Coleman, 
1988; Hall, 1988). Unlike hypoxic cells, oxic cells are sensitive to 
radiation because m olecular oxygen is capable of interacting with 
radiation-induced radicals in DNA, leading to irreversible fixation of 
the damage (Hall, 1988). In addition, oxygen competes with reducing 
species present within cells, such as thiols, which can restore the 
target molecule to the original undamaged form (Hall, 1988). As a 
consequence, the lower levels of oxygen within hypoxic cells make 
them more resistant to radiation.
Hypoxic cells are also resistant to certain chem otherapeutic 
agents, including bleomycin and some alkylating agents (Workman, 
1983a). Chemoresistance may arise within these cells through the
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impairm ent of drug delivery, non-cycling cell kinetic status of the 
cells due to reduced oxygen levels, involvement of m olecular oxygen 
in the mechanism of action of the drug, as well as changes in the pH of 
hypoxic regions and its subsequent effect on the drug ionisation state 
(Wilson, 1992). It could also be envisaged that, the up- or down- 
regulation of certain proteins (including potential drug m etabolising 
enzym es) during exposure to hypoxia and/or reoxygenation  may 
affect response to therapy. For example, cell lines containing high 
levels of DT-diaphorase were found to be more sensitive to the 
bioreductive drugs mitomycin C and E 09 , compared to low diaphorase 
expressing cell lines (Fitzsimmons et al., 1995). In addition, relatively 
transient hypoxia can lead to an enhanced frequency of dihydrofolate 
reductase gene amplification and hence to m ethotrexate  resistance 
(Rice et al., 1986).
1 . 3 . 2  T reatm ent o f  hypoxic cells
Due to the co-existence of both aerobic and hypoxic cells within 
tumours, rational therapies devised to deal with hypoxic tumours will 
involve the combination of hypoxic cell-targeted strategies, alongside 
those aimed to eradicate the oxic population such as radiotherapy. 
Some of such approaches are summarised below:
1. Increased oxygen delivery
Various methods have been employed to m anipulate  oxygen 
delivery to tissues as a means of increasing radiosensitivity. These 
methods have been reviewed by Coleman (1988), and include altering 
the oxygen carrying capacity by the use of blood transfusion and the 
adm in istra tion  of perfluorochem icals or hyperbaric  oxygen. In 
addition, the administration of nicotinamide and carbogen can lead to 
improved radiosensitization by overcoming acute and chronic hypoxia 
respectively (Horsman et al., 1994).
2. Bioreductive agents
The use of electron affinic drugs to sensitize tum our cells to 
rad ia tio n  or a lte rna tive ly  as h ypo x ia-se lec tive  c y to to x in s , has 
received a lot of attention in recent times (Wilson, 1992; W orkman, 
1989; Workman & Stratford, 1993). These drugs, collectively referred 
to as bioreductive agents, are pro-drugs often containing nitro, N- 
oxide and quinone groups, which are selectively activated under 
hypoxia. Typical examples of clinically used and investigational
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bioreductive agents are illustrated in Fig. 1.2. Enhanced antitumour 
effect can also be achieved by a combination of these bioreductive 
agents with vasoactive agents, such as hydralazine (Chaplin & Acker,
1987), which decrease tumour blood flow and increase  tumour 
hypoxia .
1 . 3 . 3  R eoxygenation  o f  hypoxic  cells
There is experimental evidence to suggest that the oxygenation 
of surviving hypoxic tumour cells can improved after irradiation (Hall,
1988). The term reoxygenation was introduced to describe the 
reacquisition of tumour radiosensititivity due to such oxygenation of 
hypoxic cells, and is believed to be a major reason why fractionated 
rad io therapy  leads to better  c lin ica l resu lts  than single dose 
radiotherapy (Kallman, 1972). Depending on the tumour type, this 
process may take from only a few minutes to several hours (Grau & 
Overgaard, 1990; Javed Afzal et a l ., 1991; Kallman, 1972; Rofstad,
1989). Factors which may be responsible for this reoxygenation of 
hypoxic cells include: removal of radiation damaged (oxic) cells so that 
hypoxic cells become closer to functional blood vessels; reduced 
oxygen utilisa tion by radiation damaged cells and; increase or 
redistribution of blood flow to hypoxic cells caused by reduced 
in tra tum our pressure (Rofstad, 1989). It is also possib le  that
reoxygenation of acutely hypoxic cells may arise from resumption of
blood flow in transiently non-functioning vessels, a process which is 
independent of therapy (Chaplin et a l ., 1987).
Since the measurement of the degree of hypoxia within tumours 
is im portant to the design of appropriate therapeutic schedules for 
| these particular tumours, the next section will focus on methods used
1 to evaluate tumour hypoxia.i
\
1 .4  MEASUREMENT OF TUMOUR HYPOXIA
The association of tumour hypoxia with treatment failure has
led to the search for clinically relevant detection techniques to enable 
the selection of patients who will benefit from manoeuvres aimed at 
c ircum venting the hypoxic effect. The p 0 2  of venous blood is 
approxim ately 5%, thus providing nearly full radiation sensitivity. 
The oxygen tension at which cells display sensitivity midway between 
nitrogen and air or oxygen (Km value), however, falls between 0.3
6
Fig. 1.2. Chemical structure of some bioreductive agents. These 
compounds undergo selective activation under hypoxia to potential 
cytotoxic species.
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(e) RB 6145
n o 2hn
(f) SN 23862
(g) Nitracrine N-oxide (h) SN 24771
and 0.5% (Hall, 1988; Koch et al ., 1984). This implies that oxygen 
levels far below those encountered in normal tissues need to be 
m easured. Apart from dynamic range lim itations, the ability to
measure hypoxia on a cell to cell basis is also im portant, since 
histological evaluation of solid tumours has suggested that significant 
changes in cellular oxygen levels can occur over dimensions of a few 
cell diameters (Urtasun et a l ., 1986a). Other factors such as degree of 
in v a s iv e n e s s  o f the tech n ique , re so lu tio n ,  the m ea su re m e n t 
parameters used (and their relationship with the oxygen tension), the 
to x ic i ty  and the stab ili ty  of probes used and f in a lly  cost
considerations, are all relevant to the developm ent of c linically  
a pp ro p ria te  techn iques to de tec t hypoxia  in v iv o . Table 1.1 
sum m arises some of the techniques designed to m easure hypoxia 
within tumours which have being investigated to date. Techniques 
that measure nitroimidazole binding act as, 'no oxygen detectors', i.e. 
they show maximal response under complete anoxia (no oxygen), and 
a lowering of response with increasing pC>2 . The binding of these 
agents, therefore, mimics radioresistance of tumour cells and has a 
suitable dynamic range for measuring hypoxia within tumours (Koch 
et a l ., 1984). Since 2-nitroimidazole binding is sensitive to differences 
in ce llu la r  reductive  enzym es (Joseph et a l ., 1994; W alton &
W orkman, 1987; Workman & Walton, 1990), however, these probes 
may be more suited to the measurement of changes in tumour 
oxygenation or providing a predictive index which can be used in the 
selection of patients likely to benefit from bioreductive therapy, 
rather than the measurement of absolute tumour p 0 2 -  Interestingly, 
n itroim idazoles may be detected by both invasive or non-invasive
methods (Table 1.1). In both cases, however, the results represent 
m easurement of oxygenation at the cell to cell level (heterogeneity), 
including discrim ination between tumour and adjacent vascularised
strom al t issue  (F ranko  et a l ., 1987; U rtasun  et a l ., 1986b).
Nitroimidazole probes are also relatively cheap to produce and have a 
fairly predictable pharmacokinetic and toxicity profile (Stone et al., 
1993; Workman & Brown, 1981).
Since most of the measurement techniques described to date 
(Table 1.1) are based on nitroimidazole binding, the physicochemical 
properties of these agents, as well as their use as hypoxia probes, will 
be described in section 1.5.
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1 .5  PHYSICOCHEMICAL AND BIOLOGICAL 
PROPERTIES OF 2-NITROIMIDAZOLES
1 . 5 . 1  S tr u c tu r e  o f  2 -n i t r o im id a z o le s
Fig. 1.3 shows the general structure o f 2 -n itro im idazo les ,
to g e th e r  with specific 2 -n itro im idazoles  and th e ir  side chain
substituents. Although the structures of most of these compounds are 
based on the prototype 2 -nitroimidazole, misonidazole, the structures 
of some recently synthesised 2-nitroimidazoles are centred on the 
amide nitroimidazole etanidazole. Various m isonidazole  analogues 
containing radioisotopic forms of hydrogen, halogens, and carbon exist 
and have been widely used particularly as hypoxia probes. The list is 
by no means exhaustive and it continues to increase with the search 
for 2 -nitroimidazoles that are less lipophilic than misonidazole.
1 . 5 . 2  M eta b o l i sm  o f  2 -n i t r o im id a z o le s
The m etab o lism  and hypox ia  se lec tiv e  b in d in g  of 2- 
nitroimidazoles has been investigated extensively with m isonidazole
(Franko, 1986). Misonidazole can be metabolised under aerobic or 
hypoxic conditions. Under aerobic conditions misonidazole undergoes 
both O-demethylation of the terminal methoxy group, as well as 
glucuronidation of the side chain hydroxyl group predom inantly  in 
the liver (Workman, 1983b). Misonidazole can also be metabolised by 
cellular electron donors, and enzymes, to the nitro radical anion (Fig. 
1.4.) (Biaglow et al., 1986; Mason & Holtzman, 1975; W ardman & 
Clarke, 1976). In the presence of molecular oxygen, the nitro radical 
anion ( 1-electron reduced product) is back-oxidised to form  the 
original parent compound and superoxide (and resulting toxic species, 
such as hydroxyl radicals). This establishes a futile cycle in aerobic 
cells with no net nitroreduction of the parent compound. Under 
hypoxia, however, the radical anion can be further reduced to the 
hydroxylam ine (4-electron product) and amine (6-electron product) 
presum ably via the nitroso intermediate (2-electron) (Rauth, 1984). 
O ther products including mercapturic acid and glutathione adducts 
have also been identified (Smith & Born, 1984; Varghese, 1983). In 
addition, fragmentation products such as glyoxal (Fig. 1.5), as well as 
species obtained from the reaction of the hydroxylamine intermediate 
with water have been identified and may partly account for the
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Fig. 1.3. General structure of 2-nitroimidazoles and constitution of 
the R-side chain. The 2-nitroimidazoles can be grouped into two main 
classes: misonidazole analogues and etanidazole analogues depending 
on the side chain composition at the N-l position. Misonidazole 
analogues have a hydroxypropyl side chain, whilst etanidazole 
analogues possess an amide side chain. The fluorinated 2- 
nitroimidazole developed pre-clinically in this thesis as a hypoxia 
probe SR-4554 (shown in bold letters), is an etanidazole analogue.
NO
R
R-group Compound
Misonidazole analogues
—CH2CH(OH)CH2OMe 
—CH2CH(OH)CH2OEt 
—CH2CH(OH)CH2OH 
-C H 2CH(0H)CH2C1 
-C H 2CH(OH)CH2N~~> 
-C H 2CH(OH)CH2F 
-C H 2CH(OH)CH2OCH2CF3 
-C H 2CH(OH)CH2OCH(CF3)2
Etanidazole analogues
-C H 2CONHCH2CH2OH 
-C H 2CON(CH2OH)2 
-C H 2CONHCH2CH(OH)CH2OH 
—CH2CONHCH2CH2Ph 
-C H 2CF2CONHCH2CH2OH
- ch2conhch2ch2cf2cf3
Misonidazole (Ro 07-0528) 
Ethylmisonidazole (Ro 07-0913) 
Desmethylmisonidazole (Ro 05-9963) 
Chloromisonidazole (Ro 07-0269) 
Pimonidazole (Ro 03-8799) 
Fluoromisonidazole (Ro 07-0741) 
Trifluoropropanal (Ro 07-2044) 
CCI-103F
Etanidazole (SR-2508)
SR-2555
SR-2530
Benznidazole (Ro 07-1051)
KU-2285
EF5
-  CH2CONHCH2CH( OH) CF, SR-4554
Fig. 1.4. Nitroreductive bioactivation of 2-nitroimidazoles. a, b, c, d, 
e, and f, represent the parent nitro compound, nitro anion radical, 
nitroso compound, hydronitroxide radical, hydroxylamine and 
primary amine derivatives respectively. The reactive intermediates 
are capable of forming covalent adducts under hypoxia. The figure 
also illustrates the phenomenon of futile recycling, a competing 
reaction within aerobic cells which leads to the formation of the toxic 
superoxide anion.
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Fig. 1.5. Formation of glyoxal from the reactive hydroxylamine 
derivative of 2-nitroimidazoles. The ability of glyoxal to form 
guanine-adducts, may partly explain the cytotoxicity of 2- 
nitroimidazoles.
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toxicity of 2-nitroimidazoles (Franko, 1986; Raleigh & Liu, 1984; 
Varghese & Whitmore, 1984b; Varghese & Whitmore, 1984c).
The ease of reduction of these compounds depend on both their 
electron affinities (or reduction potential) and their ability to act as 
substrates for the various reductases present within cells (Adams e t  
a /.,  1979; Adams et al., 1980). Essentially all nitro(hetero)cycles with 
reduc tion  potentia ls  more positive  than -500 mV are reduced 
metabolically at appreciable rates (Adams, 1992; Wilson, 1992). It is 
worth noting, however, that reduction of the compounds also depends 
on  the degree  of oxygenation (Franko et al ., 1987), as well as non-oxygen 
dependent factors, such as temperature (Chapman et a l ., 1983), 2- 
nitroimidazole concentration (Chapman et al., 1983), and the levels of 
various cellular reductase enzymes (Joseph et aL, 1994).
M ison idazo le  has often been used as the p ro to ty p e  2- 
n i tro im idazo le  to investiga te  the charac te ris tics  o f m etabo lism  
induced  binding. Research in the early 1980's ind ica ted  that
reductive products of misonidazole can bind covalently  to cellular 
m ac ro m o lecu les  and loca lise  se lec tive ly  w ith in  hypox ic  cells  
(Chapman et al., 1981; Chapman et aL , 1983; Miller et a l ., 1982). In 
addition, misonidazole binding was shown to decrease with increasing 
oxygen concentration, resulting in characteristic labelling of cells 
further away from blood vessels in tumours and near the necrotic 
region of spheroids (Urtasun et al., 1986a; Urtasan et al ., 1986b;
Garrecht & Chapman, 1983; Franko et al., 1982; Franko et al., 1987; 
Franko  et a l .y 1992). The oxygen concentra tion w hich  inhibits
misonidazole binding by 50%, between that in nitrogen and air, was 
reported to vary between 0.1 and 0.6% in tumours (Franko, 1986;
F ran k o  et a l ., 1987). In addition, the p 0 2  required  for full 
radiosensitivity (2.5% (Koch et al., 1984)) has been shown to inhibit 
m isonidazole  binding by 90% (Franko et al ., 1987). It therefore 
appears that the inhibition of misonidazole binding by oxygen mimics 
the effect of oxygen on radioresistance. This is relevant with regard 
to the use of 2-nitroimidazoles to predict radiosensitiv ity . These 
experiments have also demonstrated that the compounds can reach, 
and be m etabolically  activated within hypoxic cells. Hence this 
preferential metabolism or adduct formation within hypoxic cells can 
provide an indirect measure of the degree of hypoxia present within 
tu m o u rs .
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The protocols currently being employed for the detection of 
n itro im idazole  binding, are based on experim ents conducted  by 
Garrecht & Chapman (1983), and by Chapman et al. (1983), which 
demonstrated that 1 4 c  labelled misonidazole adducts were cleared 
less rapidly compared to the original drug in EMT6 tumours and cells. 
These experim ent have prom pted the determ ination  of the acid 
insoluble adducts (Miller et al., 1982) of misonidazole observed 24 hr 
post-injection as a measure of hypoxia within tumours (Garrecht & 
Chapman, 1983; Hirst et a l ., 1985; Sasai & Brown, 1994). It is 
believed that this 24 hr period was used to assure complete removal 
of the original parent misonidazole compound. Of interest, however, 
were experim ents performed by Olive and Durand with SCCVII 
tumours (Olive & Durand, 1989) which demonstrated firstly, that the 
use of acid soluble and acid insoluble adducts o f m isonidazole  
predicted hypoxia equally well up to 16 hr post-injection. Secondly, 
the detection of adduct formation at earlier time points was thought 
to minimise the problems associated with cell turnover and hypoxic 
cell lysis, which undoubtedly do occur during the 24 hr experiments, 
and still provide misonidazole binding characteristics similar to those 
obtained at later time points (Olive & Durand, 1989).
W ith regard to the prediction of acute hypoxia  with 2- 
n itro im idazo les , Olive and Durand (1989) have suggested  that, 
provided blood vessels in tumours remained closed for 30 min or 
more, then misonidazole binding should be seen in acutely hypoxic 
cells. In addition, misonidazole binding should occur within acutely 
hypoxic cells, if vessels remained closed for a few minutes at a time, 
but the same vessels opened and closed several times over an hour 
(Olive & Durand, 1989).
The use of 2-nitroimidazoles as markers of hypoxia measures 
the biochem ical process of adduct formation, ra ther than oxygen 
tension (p 0 2 )  directly. The role of the non-oxygen dependent factors 
mentioned above, and therefore the susceptibility of a particular 2 - 
nitroimidazole to these non-oxygen dependent factors, are important 
in the design and choice of a hypoxia marker. Misonidazole is more 
succep tib le  to non-oxygen dependent fac tors than  e tan idazo le , 
a lthough the rate of adduct formation is higher in the case of 
m isonidazo le  (Koch, 1990; Koch et a l ., 1993). As suggested by 
C hapm an et. al. (1983), the rate of adduct formation is probably
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related to the differences in lipophilicity between the two compounds 
and hence their delivery to possible reductive sites. This implies that 
e tan idazo le  analogues designed to have sim ilar lipoh ilic ities  to 
misonidazole will be superior with regard to a combination of high 
reduction rates and minimal non-oxygen dependent binding. For 
instance, SR-4554 (this thesis) and EF5 (Fig. 1.3) (Lord et al ., 1993) 
are e tan idazo le  analogues which have been designed to have 
appreciable rates of reduction comparable to m isonidazole , while 
retaining the oxygen dependent property characteristic of etanidazole. 
In addition, SR-4554 was designed to have three m agnetically  
equivalent fluorine atoms, thus making it sensitive for detection by
non-invasive techniques such as magnetic resonance spectroscopy 
(MRS) and imaging (MRI). The theory of detecting fluorinated 2- 
nitroimidazoles by MRS and MRI will be described in more detail in 
section 1.6 .
1. 6 THEORY OF MRS AND MRI
Nuclear magnetic resonance (NMR) was discovered in 1946 by 
Bloch et al. and by Purcell et al., and has proved to be a very versatile 
tool. Although it was initially applied to physics and chemistry, NMR 
has now been extended to physiology and medicine. In medicine, the 
term s m agne tic  resonance  spectroscopy  (M RS) and m agnetic  
resonance imaging (MRI) have been used to describe  the same
phenomenon (i.e. NMR). In oncology, the application of NMR has 
grown since the observation by Damadian (1971) that l H  properties 
of rat tumours differed from those of normal tissues. Although some 
NM R principles require quantum m echanical form ulation, in most 
cases as shown in this section, a simple diagrammatic illustration can 
be employed.
1 . 6 . 1  M agnetic  properties o f  atomic  nuclei
Atomic nuclei are made up of neutrons and protons collectively 
called nucleons. Protons carry a charge which determines the electric 
charge of the nucleus. Many atomic nuclei possess an intrinsic
angular momentum or spin. Only nuclei with an odd number of 
neutrons and/or protons have a resultant angular m om entum . A 
spinning object which possesses a charge constitutes a circulation of 
electric  current and therefore has an equivalent nuclear magnetic
1 1
m om ent (|i). Nuclei of potential interest in physiology and medicine
include, ^H, 1 5 ^ ,  19p  and 3 1 p  all of which have a spin of 7 .
Other nuclei such as 2 H and 14N have a spin of 1 and have an electric 
quadrupolar moment, i.e. departure of the nuclei from  a spherical 
shape, and are also important in medicine.
W hen placed in a magnetic field (B0 ), a spinning nucleus 
behaves like a tiny bar magnet precessing about its long axis (Fig. 
1.6). The angular frequency of precession (co) is proportional to the 
applied  m agnetic field as shown in the Larm or equation  below 
(Larmor, 1900):
co = yB0
where y is the gyromagnetic ratio i.e. the ratio of the nuclear magnetic 
m om ent to its angular momentum, and is characteristic  of each 
nucleus; the Larm or frequency is defined as co/2n .  The Larmor 
precession of magnetic nuclei is a resonance phenomenon i.e. nuclei 
will absorb the most energy at its resonance frequency. The net 
m agnetization (M) of a population of atomic nuclei (Fig. 1.7) is 
therefore made up of an ensemble of individual nuclear magnetic 
moments, each precessing about the magnetic field B o, which is by 
convention  oriented along the z-axis. In NMR experim ents a 
rad io frequency  field or pulse ( B i )  of appropriate  frequency is 
introduced to flip the magnetization away from the z-axis. For 
instance the application of an appropriate 90° pulse results in a
decrease in longitudinal magnetization and the generation of a new 
m agnetiza tion  (the transverse m agnetization) in the xy-p lane  in 
which all nuclei are in phase. When the radiofrequency field is
removed, the magnetization decays back to the z-axis generating an 
NMR signal or free induction decay (FID), which can be amplified and 
displayed. FID's can be summed to give an enhanced signal to noise 
ratio. The NMR spectrum (or image) can be obtained by mathematical 
tran s fo rm a tio n  of F ID ’s (Fourier transform ) in one or m ore 
d im en sio n s .
1 . 6 . 2  R e l a x a t i o n
The return of magnetization to equilibrium is called relaxation. 
In practice, this is found to be exponential and characterised by two
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Fig. 1.6. The classical precession of a magnetic nucleus with 
nuclear magnetic moment (m) in a magnetic field (Bo).

Fig. 1.7. The effect of a radiofrequency (RF) 90° pulse, (a) In 
equilibrium, the net magnetisation (M)  representing the sum vector of 
magnetic moments is longitudinal and lies along the z-axis ( M z ). (b) 
A 90° pulse flips the magnetisation into the xy-plane generating a 
new transversal magnetisation ( M y ) .  This is process is also associated 
with phase coherence of magnetic spins, (c and d). When the RF 
pulse is switched off, relaxation occurs with loss of phase coherence 
and transversal magnetisation. Relaxation also results in the 
regeneration of longitudinal magnetisation, as well as the generation 
of the free induction decay (FID) in the time domain which can be 
Fourier transformed into the frequency domain (e).
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time constants. The first of these time constant is called T i 
(longitudinal relaxation or spin-lattice relaxation time) and is due to 
return of magnetization along the z-axis which occurs through loss of 
energy to the surrounding environment. This time constan t is 
im portant with regard to time to repeat m easurem ents (TR) for 
summation of FID's. Maximum signal intensity for subsequent FID 
m easurem ents  is only achieved when m agnetiza tion  com plete ly  
returns to equilibrium. Short TR's can therefore lead to incomplete 
return to equilibrium or ’saturation' of NMR signals. The second of 
these time constants is called T2 (transverse relaxation or spin-spin 
relaxation time) and is due to loss of phase coherence between 
magnetic nuclei and subsequent decay of the NMR signal. T2 is
im p o rtan t  in de term in ing  the linew idth  in NM R exp erim en ts  
according to the equation:
where v  j  is the natural linewidth at half peak height. The magnetic
field over a whole sample is not uniform resulting in a spread of 
magnetic fields (5B) or Larmor precession frequencies (5co) within 
various domains within the sample. This instrum ental artefact is 
expressed in a new parameter T2 *, which results from the dephasing 
of the various domains. T2 * is often shorter than T2 and dominates 
the transversal decay. In practice this effect can be m inimised in 
high resolution NMR and in vivo M R-spectroscopic experim ents by 
sample spinning and 'shimming' respectively.
1 . 6 . 3  Spin echoes,  pulse sequences and M R -im aging
The phenomenon of spin echo is very important in MR-studies 
(Hahn, 1950). The spin echo pulse sequence is described in Fig. 1.8. 
This consists of a 90° pulse followed by a (series of) 180° pulse(s). 
After the 90° pulse, spins dephase resulting in the FID which lasts for 
approx im ate ly  2T2*. However, the application of a 180° pulse at a 
time TE/2 (where TE is the echo time) rephases the dephasing protons 
and produces a strong signal (the spin echo) at time TE. The spins 
dephase after the echo and can be rephased again with another 180° 
pulse and so on. Spin echoes refocus dephasing due to chemical shift, 
J-coupling and Bq inhomogeneities (i.e. what makes T2 * < T2 ). Due to
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Fig. 1.8. Three important pulse sequences used in medicine, (a) 
The spin echo sequence can be used to obtain T2-weighted spectra or 
images, (b) The inversion recovery sequence gives spectra or images 
which are Ti-weighted whilst, (c) a partial saturation sequence gives 
spin density-weighted spectra or images. The figure also shows the 
effect of the 90° and 180° pulses on the magnetisation of the spins. 
TR, TE, and TI represent the repetition time, echo time, and time to 
invert respectively.
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T 2 relaxation, however, spin echoes show loss of signal intensity with 
time. This T2 -weighted sequence can therefore be used to determine 
the T2 of a sample and is also important in imaging. Fig. 1.8 also 
shows an inversion recovery sequence which is T i-w eig h ted  and can 
be used to determine the T i  of a sample. These, as well as other 
im portan t  sequences have been recently  described  by A ndrew  
(199 4 ) .
U nlike  spectroscopy, MRI deals with loca lisa tion  o f  spin 
d is tr ibu tion  within a sample. In conventional M RI, d ifferen t 
com binations of three important gradients are used to define the 
region of interest. These include the slice selection, phase encoding 
and read-out gradients (Andrew, 1994). Construction of both planar 
and 3-dimensional images can be obtained with the magnetic nucleus 
of interest.
1 .7  AIMS OF THESIS
The aims of this thesis were two-fold. The first aim was to 
study the in vitro and in vivo pharmacological properties and toxicity 
of the novel, rationally designed, fluorinated 2-nitro im idazole SR- 
4554. In particular this has involved investigation into SR-4554 drug 
lo c a l is a t io n ,  d rug  to le rab i l i ty  s tud ies ,  p h a rm a c o k in e t ic s  and 
m etab o lism .
Using this information, the second aim of this project was to 
assess the ability of MRS (of SR-4554) to detect and quantify 
hypoxia within tumours. This has involved the developm ent and 
validation of both MRS and MRI techniques, to quantify the selective 
retention of SR-4554 within hypoxic tumours. Both aims have been 
met and the results outlined in the following chapters of the thesis.
1. 8 LAYOUT OF THESIS
Several studies have either directly or indirectly demonstrated 
the presence of hypoxia within rodent and human tumours, and also 
how this can affect conventional therapy for cancers. As a 
consequence, this has led to the development of clinically relevant 
markers for hypoxia. The development of one of such markers, SR- 
4554, is described in this thesis.
In order to detect SR-4554 in bio-fluids and tissues, a sensitive 
high performance liquid chromatographic (HPLC) technique has been
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developed and validated (chapter 2). This m ethod is used in 
subsequent chapters to measure SR-4554 levels.
The in vitro and in vivo metabolism of SR-4554, as well as the 
enzymology of reductive activation of this compound necessary for 
the use of SR-4554 as a hypoxia probe have been investigated in 
chapter 3. In addition, both HPLC and high resolution NMR have been 
used to characterise the metabolic properties of a series of fluorinated 
2-nitroimidazoles including SR-4554.
The selective reduction and localisation of SR-4554 within 
multicellular spheroids is described in chapter 4. In this chapter a 
sensitive technique called electron energy loss spectroscopy (EELS) 
has been employed to directly detect fluorine atoms in SR-4554 in 
cells within the spheroids. The subcellular localisation of SR-4554 has 
also been investigated with this technique in order to define the 
interaction of SR-4554 with cellular macromolecules.
For the continued use of SR-4554 in in vivo  MRS studies, 
toxicity studies are required. In chapter 5, a prelim inary toxicity 
study with this compound was performed. In addition, the HPLC 
technique developed in chapter 2 has been used to evaluate  the 
pharmacokinetics of SR-4554 in mice. Various aspects of SR-4554 
pharmacokinetics are described and comparisons made with other 2 - 
n itro im idazo les .
In vivo 19 F MRS and MRI techniques are developed  and 
employed to detected the selective retention of SR-4554 in murine 
and human tumour xenografts in chapter 6 . This MRS technique
has been used as a quantitative measure of hypoxia w ithin  these 
tumours. The relationship between the MRS technique and direct 
m easurement of tumour oxygen tension by oxygen electrodes is also 
d e sc r ib e d .
Finally, the work carried out in this thesis is summarised and 
conclusions made in chapter 7. In addition, future directions for the 
development of superior probes for tumour hypoxia are elaborated.
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CHAPTER 2
Development of a high performance liquid  
chromatographic assay for SR-4554 in 
plasma and tissues
2 .1  INTRODUCTION
Substituted nitroimidazoles have a num ber of structural and 
chem ica l p roperties  which are im portan t w ith  rega rd  to the 
development of methods required to assay their levels in body fluids 
and pharmaceutical preparations (Grimmett, 1980; W ardm an, 1985). 
Levels of 2-nitroimidazoles, and some of their stable m etabolites, 
have previously  been assessed by techniques such as u ltrav io le t 
spectroscopy (De Silva et al., 1970), gas chromatography (Flockhart et  
a l ., 1978a), high performance liquid chromatography (HPLC) (Chacon 
et a l ., 1988; F lockhart et a l., 1978a; F lockhart et a l ., 1978b;
Middlestadt & Rauth, 1982; Workman et al., 1978), polarography (De 
Silva et al., 1970) and various radiochemical techniques (Flockhart e t  
al., 1978b; Middlestadt & Rauth, 1982; Prekeges et al., 1991). Limited 
studies on unstable metabolites of 2-nitroimidazoles have also been 
carried out using electron spin resonance (ESR) techniques (Wardman, 
1985).
Some of the previously reported techniques in the literature, 
however, are limited by sensitivity or selectivity, while others are not 
suitable for routine analysis. For instance, in spite of the high 
sensitiv ity  associated with radiochem ical m ethods, which employ 
liquid  scintilla tion, these methods lack selectiv ity  and will not 
d is t in g u ish  be tw een  the p a ren t  d rug  and any m e ta b o l i te s .
Radiochemical methods which employ HPLC are, however, superior to
HPLC with ultraviolet (UV) detection since such techniques may still
detect non-UV absorbing metabolites. Chromatographic techniques 
which employ mass spectroscopy detection are also useful since they 
provide additional information on the structure of the analytes. It 
should be noted, however, that radiochem ical techniques (which 
employ liquid i sc intilla tion) lack specificity and are limited by their 
requ irem en t for rad io labelled  com pound, w hils t  ch rom atograph ic  
techniques employing mass spectral detection are not suitable for
routine analysis.
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This chapter describes a sensitive and selective method for the 
routine detection of SR-4554 in mouse plasma and tissues as a 
prelude to studying the pharmacokinetics of this compound in mice. 
A full validation for plasma and a working method for tissues are 
d e scr ib ed .
2 .2  MATERIALS AND METHODS
2 . 2 . 1  Chem ica ls  and reagents
N -(2 -H y d ro x y -3 ,3 ,3 - t r i f lu o ro p ro p y l) -2 - (2 -n i t ro - l - im id a z o ly l)  
acetamide (SR-4554), was synthesized (see Appendix A) and supplied 
by SRI International, Menlo Park, CA, USA. The internal standard 
used in the HPLC assay described in this chapter, l - (2 -n i t ro - l -  
im idazolyl)-3-chloro-2-propanol (Ro 07-0269), was synthesized and 
supplied by Roche products, Welwyn Garden City, Herts, UK. The 
compounds (Fig 1.3.) were assessed for chromatographic purity and 
used without further purification. All other reagents were HPLC or 
analytical reagent grade. Female Balb/c mouse plasma was obtained 
from Harlan Olac, Oxon, UK.
2 . 2 . 2  Preparat ion o f  calibration curve and va l idat ion  
s t a n d a r d s
SR-4554 was weighed and dissolved in 1 mM Tris-HCl buffer 
(pH 7.4) to give a 2 mg/ml solution. Other standard stock solutions 
(1000, 500, 125, 50, 12.5, 5, 2.5, 1.25, 0.625, 0.3125, 0.15625, and 
0.0625 pg/ml) were prepared by serial dilution in the same buffer.
The internal standard solution was prepared by dissolving Ro 
07-0269 in methanol to give a 1 mg/ml solution. For the analysis of 
plasma samples, an aliquot (0.5 ml) of this solution was made up to 
500 ml in 1 mM Tris-HCl buffer (pH 8.5) to give a final concentration 
of 1 pg/ml. For the analysis of tissue samples, however, an aliquot 
(1.25 ml) of the 1 mg/ml solution was made up to 100 ml in 0.1 M 
Tris-HCl buffer (pH 7.4) to give a concentration of 12.5 pg /m l.
Calibration standards were prepared by adding 20 p i  of the 
standard stock solutions to 230 p i  of mouse plasma or 10% tissue 
homogenates to give final drug concentrations of between 0.025 and 
160 pg/ml in plasma and 40 pg/ml in tissues. Each concentration (n = 
13) was prepared as a single sample, except for the lowest (0.025
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p g /m l) ,  in term ediate  (10 pg/m l) and highest (160 or 40 p g / m l )  
concentrations which were prepared in triplicate.
2 . 2 . 3  E x tr a c t io n  e f f ic ien cy
Efficiency of the extration process for SR-4554 from plasma and 
tissues were evaluated using recovery standards prepared in 1 mM 
Tris-HCl buffer (pH 7.4). The recovery standards contained 1 p g /m l  
of the internal standard (Ro 07-0269). The recovery standards (0.025 
to 160 pg /m l for plasma or to 40 pg /m l for tissues) were also 
prepared as single samples except for the lowest (0.025 p g / m l ) ,  
intermediate (10 pg/ml) and highest (160 or 40 pg/m l) concentra tions 
which were prepared in triplicate. The overall extraction efficiency 
was calculated as the ratio of the slope of the p lasm a or tissue 
standard to recovery standard calibration curves.
2 . 2 . 4  Preparation of  quality control  (QC) sam ples
Quality control (QC) samples containing SR-4554 were prepared
in mouse plasm a as follows: QC1 blank; QC2 0.025 pg/m l; QC3 0.1
pg/ml; QC4 10 pg/ml; QC5 100 pg/ml; QC6 160 pg/ml. Aliquots (250 
pi) of the QC sample were stored at -70°C until analysis.
2 . 2 . 5  W ithin  and between day var iab i l i ty ,  f reeze /  
thaw stabil ity and long term stabil i ty  studies .
Six quality control samples at each concentration level were 
thawed and analysed together with the calibration standards on day 
1, to assess the within-assay (day) variability at the various levels. 
The between-day variability was evaluated on five separate occasions 
by assaying single QC samples from all the concentra tion  levels 
together with fresh calibration standards. W ithin-day and between 
day variability  were calculated as the percentage  coeffic ien t of 
variation (C.V) of the QC samples.
In addition, triplicates of freshly prepared QC samples, as well 
as, those subjected up to three cycles of freezing (-70°C) and thawing, 
were analysed to determine the ability of SR-4554 to withstand 
multiple cycles of freezing and thawing. The long-term stability of 
SR-4554 in mouse plasma was also assessed by analysing QC samples 
on day 1 and after storage for 32 days at -70°C.
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2 .2 .6  E x tra c tio n  of p lasm a  an d  tis su e  sam p les  a n d  
s t a n d a r d s
P l a s m a :  A liquots (250 p i)  of 1 mM T ris-H C l buffer (pH 8.5)
containing 1 pg/m l of the internal standard (Ro 07-0269) were added 
to plasm a samples or standards (250 p i) and vortexed. The buffered 
plasm a sam ples and standards were then applied to Bond E lut Ci 8 
cartridges (100 mg, 1 ml capacity; Varian, Harbor City, CA, USA), pre­
conditioned with 1 ml of methanol and 2 ml of 1 mM Tris-HCl buffer 
(pH 8.5). The samples were drawn through the cartridges under 
vacuum  using  a Vac E lu t SPS24 (V arian) system . P lasm a 
contaminants were eluted to waste with 1 ml of 1 mM Tris-HCl buffer 
(pH 8.5) and the colum ns dried for 5 min under vacuum . The 
analytes were then eluted with 1 ml of methanol-HCl (199:1).
The extracts were taken to dryness under vacuum  using a 
vo rtex -ev ap o ra to r (H aakebuchler In strum ents, Saddle B rook , NJ, 
USA), at a temperature of 50°C. The dried extracts were reconstituted 
in 250 p i of HPLC mobile phase, clarified by centrifugation to remove 
any contam inating silica resin (8 m in, 2500 x g ,  at 2 0 °C) and 
transferred into autosam pler glass inserts. A liquots (200 p i)  of these 
samples were then injected into the chrom atograph. All solvents used 
for the extraction of the plasma samples and standards were filtered 
(0.45 pm  Teflon PTFE-polypropylene filter m em branes) and degassed 
with helium .
T is s u e s :  As part of method developm ent, 30% w/v silver nitrate
( A g N 0 3 ;  1:10), ice cold methanol (1:1) and ice cold acetonitrile (1:1) 
w ere tested  as protein precipitants for SR-4554 con ta in ing  tissue 
hom ogenates. The precipitants were added to 250 p i of the tissue 
sam ples, contain ing  standards and 20 p i  of the in ternal standard 
so lu tion  (12.5 p g /m l). The sam ples w ere then vo rtexed  and 
centrifuged (2000 x g ) for 5 min. Aliquots (50 p i) of the supernatant 
obtained from these samples were then analysed by HPLC.
2 .2 .7  H P L C  m e th o d o lo g y
All ex tracts were analysed using a W alters chrom atographic 
system (M illipore, Milford, MA, USA) consisting of a W ISP M odel 712 
autosam pler, a Model 660 gradient controller with a quaternary HPLC 
pump, a M odel 991 photodiode-array detector and a NEC Pow erm ate
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SX/16 personal com puter running the W alters 991 photodiode array 
so ftw a re .
Separation of analytes were performed on a p -B ondapak C is (1 0  
p m , 300 x 3.9 mm) analy tical colum n (M illipo re) at am bien t 
te m p e ra tu re . T he a n a ly tic a l co lum n  w as p ro te c te d  from  
contam ination by a pellicular ODS pre-column (Anachem, Luton, UK). 
The m obile phase which com prised m ethano l-w ater (15:85), was 
filtered  through a 0.45 p m  T eflon  P T F E -p o ly p ro p y le n e  f i l te r  
m em brane, degassed with helium , and delivered isocratically  at a 
flow -rate of 2 m l/m in. Column effluents were m onitored by UV- 
photodiode-array detection at 324 nm and the peak area ratio of SR- 
4554 to internal standard (Ro 07-0269) used for conversion of the 
d e te c to r  resp o n se  to co n cen tra tio n  e s tim a te s . T he co lum n 
perfo rm ance  in the assay was de te rm ined  by m easu ring  the 
efficiency  or height equivalent to a theoretical p late (HTEP), the 
sym m etry factor (SF), and the resolu tion  (R) betw een drug and 
in te rnal standard using the standard equations below  (D avidson, 
1988):
HTEP = -------- -------- -
5.54(tR/W]/2)
^ _  2  (tRb tRa )
W a -W  b
where L,tR,W}/2,yx,A,tRb,tRa,Wa, and Wb are defined as length of column, 
retention time, peak width at half peak height, peak w idth at one- 
tw entieth  of the peak height, d istance betw een the perpendicu lar 
dropped from the peak maximum and the leading edge of the peak at 
one-tw entieth  of the peak height, retention tim e of second peak, 
retention time of the first peak, peak width of the first peak, and 
peak width of the second peak respectively (Davidson, 1988).
2 0
2 .2 .8  M ass s p e c tra l  (M S) an a ly s is
Prior to analysis by MS, plasm a sam ples containing SR-4554 
were separated on a column as above, and the peak corresponding to 
SR-4554 collected using a W alters fraction collector (M illipore). Both 
the SR-4554 fractions which were evaporated  to dryness under 
nitrogen gas, as well as authentic samples of SR-4554, were dissolved 
in a m inim um  am ount of dichlorom ethane-m ethanol m ixture (5:1). 
Aliquots (20 pi) were injected into a JEOL JMS-AX505HA (JEOL, Tokyo, 
Japan) MS in direct inlet mode. The mass spectrom eter was operated 
at an accelarating potential of 3 kV (voltage 200 eV) in the positive 
ion chem ical ionisation mode using methane gas.
2 .2 .9  S ta t i s t i c a l  a n a ly s is
The sta tistica l analysis of the results were generated using 
M initab Release 9 (M initab, State College, PA, USA) and M icrosoft 
Excel V ersion 4.0 (M icrosoft, Redmond, W A, USA). The assay 
precision was defined as the coefficient of variation C.V. (%) for each 
concentration level. This was calculated as the ratio of the standard 
deviation to the mean expressed as a percentage. The accuracy was 
defined as the mean % difference (% deviation) from  the given or 
nom inal concentration. The minimum quantifiable level (MQL) was 
defined  as the low est concentration  of analy te  w hich could  be 
accurately and reproducible m easured.
The follow ing acceptance criteria  were used to evaluate the
da ta :
1. p  -values for all statistical tests be < 0.05.
2. the within/betw een assay variability be w ithin 15%.
3. 75% of all QC samples analysed be within 15% of their
respective norm inal values.
4. the correlation coefficient (r) of calibration curves be > 0.98.
5. the C.V. for the lowest, intermediate and highest levels within
individual calibrations be within 15%.
2 . 3  RESULTS
2 .3 .1  C h r o m a t o g r a p h y
P la s m a :  Analysis of plasma samples and standards showed that the
assay w hich was developed in this thesis was su itab le  fo r the
detection and quantitation of SR-4554. A typical chrom atogram  of
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SR-4554 and internal standard is illustrated in Fig. 2.1. No drug- 
related m etabolites or interfering peaks were observed on analysis of 
the p lasm a sam ples and standards. The chrom atographic analysis 
was rapid allowing separation of SR-4554 and internal standard (Ro 
07-0269) w ithin 10 min. The retention times of these com pounds 
w ere 5.8 and 7.4 m in, respective ly , and the tw o peaks were 
com pletely resolved (resolution, R = 1.4). Typical column efficiencies 
(H ETP) were 0.28 mm and 0.14 mm for SR-4554 and in ternal 
standard (Ro 07-0269), respectively. In addition sym m etry factors 
were calculated to be 1.09 and 1.12, respectively. Both SR-4554 and 
the in te rn a l standard  (Ro 07-0269) had s im ila r U V -sp ec tra l 
properties with a Xmax (for both compounds) of 324 nm (Fig. 2.2). 
T is s u e s :  Sim ilar chromatograms as for plasma were obtained when
tissue sam ples were analysed. Fig. 2.3 shows the chrom atogram s 
ob tained  by ex tracting  10% tum our hom ogenates w ith  d iffe ren t 
precipitants. All precipitants showed good recovery (Table 2.1) and 
low background  interference. S ilver n itra te  p rec ip ita tio n  was,
however, twice as sensitive as the other two m ethods tested. The 
optimal volume of silver nitrate (30% w/v) used was 25 p i per 250 p i 
of tissue  hom ogenates (1 :10). F ig . 2.4 illu s tra te s  a typ ical 
ch rom atogram  of SR-4554 the ex tracted  from  liv e r and brain
hom ogenates using the conditions described in section 2.2.6. The
recovery of SR-4554 from these tissues is also presented in Table 2.1.
2 .3 .2  M ass s p e c tra l  (M S) an a ly s is
In addition to U V -spectra, the identity  of SR-4554 extracted
from  plasm a was also confirm ed by MS in positive ion chem ical 
ionisation mode (Fig. 2.5). As indicated in Fig. 2.5, the m ost intense 
m/z ratios were obtained from the protonated m olecular ion (M + 1) 
peak and another peak corresponding to (M - NO2). M ethane adducts 
such as (M + C2H 5) were also observed.
2 .3 .3  V a l i d a t i o n
The assay of SR-4554 in m ouse plasm a using solid phase
extraction  and HPLC was reproducible at all concentra tion  levels
(Table 2.2), with all C.V.’s within the accepted limit of 15%. The MQL 
was validated at 25 ng/ml (on-column concentration of 5 ng) with a 
C.V. of 6.0%.
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Fig. 2.1. A typical chrom atogram  obtained from a plasm a extract. 
A liquots (250 p i) of plasm a samples containing SR-4554 (4 p g /m l)  
were extracted with internal standard (I.S.; Ro 07-0269) using a Cig 
solid phase cartridge and analysed by HPLC as described in section 
2.2.7.
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Fig. 2.2. U V -spectra of SR-4554 and internal standard (Ro 07-0269) 
in HPLC m obile phase using photodiode array detection. Spiked 
plasm a sam ples of SR-4554 and internal standard were extracted, as 
described  in section 2.2.6, and the UV -spectra of the com pounds 
obtained using a W aters photodiode array detection. The ^ max for 
both com pounds was 324 nm.
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Fig. 2.3. Typical chrom atograms of SR-4554 (4 |ig /m l) and internal 
standard (I.S.) obtained from 0.1 M Tris-HCl buffer (pH 7.4) and 10% 
tum ours hom ogenates using different protein precipitation techniques 
as described  in section 2.2.6. The chrom atogram s represent (a) 
unextracted, (b) 30% w/v silver nitrate (1:10) extract, (c) m ethanol 
( 1:1) extract, and (d) acetonitrile ( 1:1) extract.
A b s o r b a n c e
(Arbi trary  uni t s )
S R - 4 5 5 4
S R - 4 5 5 4
J_L ± 1 . I
S R - 4 5 5 4
S R - 4 5 5 4
Table 2.1. Recovery of SR-4554 from  tissue hom ogenates 
using different clean-up techniques.
T issue P re c ip ita n t Mean Recovery (%) s.d.
T u m o u r M ethano l 90 .6 0 .2
T u m o u r A ceto n itrile 91 .9 0.3
T u m o u r Silver nitrate 97 .4 0 .2
L iv e r Silver nitrate 94.8 0 .2
B rain Silver nitrate 96 .0 0.1
The concen tra tion  of SR-4554 p resen t in each tissue  
hom ogenate was 4 pg/m l. Four determ inations were made 
for each tissue.
Fig. 2.4. Chromatograms of SR-4554 (4 pg/ml) and internal standard 
(I.S.) obtained by silver nitrate (30% w/v; 1:10) extraction of 10% 
liver (a), and brain (b) homogenates spiked with SR-4554.
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Fig. 2.5. Positive ion chemical ionisation spectrum of SR-4554. The 
spectrum was determ ined as described in section 2 .2 .8 , and shows the 
protonated m olecular ion peak (M + 1), as well as, o ther peaks 
corresponding to (M - NO2), and methane adduct (M + C2H 5).
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Table 2.2. Within and between day variability of the HPLC 
assay for SR-4554 at six different drug concentrations.
Within day variability
QC GIVEN CONC. CALCULATED CONC. (|ig/ml)
f us/ml) mean %C.V. %Deviation
1 Blank - - -
2 0.025 0.02 6.0 1.2
3 0.1 0.1 4.0 6.7
4 10 10.2 3.3 1.9
5 100 96.4 3.3 -3.6
6 160 148.9 1.5 -6.9
Between day variability
QC GIVEN CONC. CALCULATED CONC.^g/ml)
(fig/ml) mean %C.V. %Deviation
1 Blank - - -
2 0.025 0.02 11.9 -3.8
3 0.1 0.1 3.9 11.2
4 10 9.8 6.5 -2.9
5 100 97.1 6.3 -2.9
6 160 147.2 3.8 -8.0
Plasma samples were determined in each case as described 
in section 2.2.5.
W eighted calibration curves (weight = 1/y^) for SR-4554 were 
found to be linear over the concentration 0.025-160 tig/m l and had
near zero intercepts. For instance, the calibration curve for the peak 
area ratio  of SR-4554 to internal standard vs concentration of SR- 
4554 used in the determ ination of w ithin assay variability  had a
slope of 0.6 and an intercept of 0.013 (r = 0.99; s.d. = 0.03).
The recovery of SR-4554 from  mouse plasm a was determ ined
from  the slopes of the extracted standards vs recovery standards (Fig.
2.6). The mean recovery from four determ inations was found to be
81.1 ± 6.9% (C.V. = 8 .6%), whilst the recovery of the internal standard 
at a single concentration of 1 tig/ml was 80.6 ± 3.8 (C.V. = 4.7%).
Table 2.3 summarizes the freeze thaw and long term  stability of 
SR-4554 in mouse plasma. SR-4554 was stable up to three cycles of 
freezing and thawing as well as to storage at -70°C for 32 days.
2 .4  DISCUSSION
A rapid and sensitive HPLC method has been developed for the 
determ ination of SR-4554 in small volumes (250 p i) of mouse plasma 
and tissues. The method for extraction of plasm a employs a semi­
autom ated  so lid -phase  extraction  procedure fo llow ed by a fu lly  
autom ated HPLC assay. Extraction of tissues involved a sim ple 
pro tein  p rec ip ita tion  using silver n itrate w hich was found to be 
superior to ice cold methanol and acetonitrile in terms of sensitivity. 
A run time of 10 min for both plasm a and tissues allow several 
sam ples to be routinely analysed over a relatively  short period of 
tim e. Both SR-4554 and the internal standard (Ro 07-0269) had 
sim ilar UV -spectra, which made it possible to m onitor the elution of 
analytes at a single wavelength of 324 nm, representing the A,max of 
both com pounds. The sensitivity of the assay described here (25 
ng/ml for plasma and 100 ng/ml for tissues) is much better than that 
for m ost 2-nitroim idazoles reported to date (De Silva et a l ., 1970;
F lockhart et a l ., 1978a; W orkman et a l ., 1978). The assay is also 
highly specific and sufficiently reproducible for routine use. The 
specific ity  of the assay was confirm ed by U V -spectra  and m ass 
spectral analysis.
A lthough the parent drug was readily detected, it should be
noted that no m etabolites of SR-4554, be it degradation or bioreduced
products, were observed in plasma or tissue samples. A lthough this
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Fig. 2.6. Recovery of SR-4554 from mouse plasma. The regression 
lines rep re sen t unex tracted  and ex tracted  SR -4554 at d iffe ren t 
concentrations. The recovery or extraction efficiency was the ratio of 
the slopes of the extracted to unextrated regression lines.
C
oncentration 
of 
SR
4554 
(|ig/m
l)
SR4554/I.S. 
Peak area ratio
Table 2.3. Freeze-thaw and long-term stability of SR-4554 
in mouse plasma.
Mean conc. 
(ug/ml)
%Deviation %C.V.
Freeze-thaw stability
Fresh 10.3 2.8 1.4
Cycle 1 10.1 1.1 2.4
Cycle 2 10.3 2.7 1.6
Cycle 3 10.2 1.9 3.9
Long-term stability
Day 1 " 10.6 5.9 2.5
Dav 32 11.5 14.9 .. .1,9 _
Plasma samples were determined as in section 2.2.5.
assay is specific for an in tact n itro im idazo le  ch rom ophore, the 
analysis of samples at other wavelengths, and also with MS, did not 
give any indication of the presence of any SR-4554 m etabolites. 
There are, however, obvious lim itations to this assay. In particular, 
this technique will be unable to detect bioreduced m etabolites in free 
or bound form  (i.e. bound to m acrom olecules) due to loss of the 
characteristic UV-chromophore of the nitroim idazoles. The absence of 
degradation products, however, is an im portant property with respect 
to the use of SR-4554 as an MRS probe for tumour hypoxia, since the 
side chain containing the fluorine label is stable to in vivo  m etabolic 
processes other than nitroreduction.
SR-4554 and internal standard (Ro 07-0269), the only analytes 
observed by the HPLC m ethod developed in th is chap ter, were 
com pletely  resolved (R > 1.0). Due to slight peak tailing, however, 
peak areas instead of peak heights were used in the quantitation of 
the drug and internal standard peaks (Davidson, 1988). The recovery 
of SR-4554 from both plasma and tissues using this HPLC assay was 
found to be high and reproducible. In addition, the w ithin- and 
betw een day variability  of the assay, as w ell as the accuracy of 
determining SR-4554 were found to be within 15%. The results of the 
stability  studies also showed that, plasm a sam ples of SR-4554 were 
stable for up to three cycles of freezing and thawing, as w ell as to 
storage at -70°C for up to 32 days.
In an attem pt to develop a suitable rapid and sensitive method 
for the analysis of SR-4554 in mouse plasm a, other techniques were 
investigated. One such method, which involved a m ethanol extraction 
step and UV-HPLC analysis, offered good sample clean-up but had low 
sensitivity (MQL = 200 ng). In addition, an unsuccesful attem pt was 
made to develop an HPLC technique with fluorescent detection for SR- 
4554, inspite of its good fluorescent properties (^ ex c ita tio n  = 272 nm; 
^em iss io n  = 371, 546 nm). A solid phase extraction with UV detection 
was u ltim ately  em ployed with an increase in sensitiv ity . V arious 
sorbents such as C i8, Cs, propylsulfonic acid (PRS) and benzenesulfonic 
acid (SCX) were tested for their ability to retain and release the drug 
at various PH values in Tris-HCl buffer. The elution capabilities of 
other solvents such as methanol and acetonitrile were also tested. C is  
cartridges proved superior to other sorbents due to good sam ple 
re te n tio n , recovery  and low background  in te rfe re n ce , w ith o u t
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resorting to solvents which could affect the stability  o f the drug or 
sorbent. The reconstitution of the extract in HPLC m obile phase, prior 
to analysis by HPLC, allowed a high injection volum e to be used 
w ith o u t a s ig n if ic an t com prom ise  in the e ff ic ie n c y  o f the 
chrom atographic  separation.
The HPLC method developed in this chapter has been designed 
to be suitable for studying the pharm acokinetics of SR-4554 in mice 
(chapter 5). This HPLC assay can also been applied to the analysis of 
other 2 -nitroim idazole, either directly or with slight m odifications in 
m obile phase composition (chapter 5). Finally, it would be expected 
that this HPLC assay developed here would form  the basis for the 
analysis of SR-4554 during its anticipated c lin ical use as a non- 
invasive MRS probe for tumour hypoxia.
25
CHAPTER 3
Metabolism of 2-nitroimidazoles
3 .1  INTRODUCTION
As described in section 1.5, n itroreduction  is an im portan t 
m ech an ism  fo r the hypox ia  se lec tiv e  tum our re te n tio n  and 
cyto toxicity  of these nitroim idazoles. A wide variety of enzym es 
including NADPH: cytochrom e P450 reductase, NADPH: cytochrom e 
P450, xanthine oxidase, D T-diaphorase and aldehyde dehydrogenase 
can potentially act as nitroreductases, although many of these appear 
to have quite low substrate specificities for the reduction  o f 2 - 
n itro im idazo les (W orkm an, 1992). The m ajor m em brane-bound 
m icrosom al nitroreductases in liver are NADPH: cytochrom e P450 
reductase and NADPH: cytochrome P450 (Feller et al., 1971). These 
enzym es have been implicated in the m etabolism  of 2-nitroim idazoles 
in m urine tum ours and cell lines (Joseph et a l ., 1994; W alton & 
W orkm an, 1987). In their study, W alton and W orkman showed that 
the loss of benznidazole was dependent on NADPH: cytochrom e P450 
reduc tase  levels , w hile form ation of its am ine m etab o lite  was 
dependent on both NADPH: cytochrome P450 reductase and NADPH: 
cytochrom e P450 levels. Joseph et. al. (1994) on the other hand, 
transfected m onkey kidney cells with recom binant plasm ids in order 
to effect in tracellu lar overexpression of NADPH: cytochrom e P450 
reductase and DT-diaphorase. An increase (5-7 fold) in m etabolic 
b ind ing  of 2-ni.tjoipiidazoles was dem onstrated  in the NADPH: 
cytochrom e P450^1ine (80 fold increased activity), whereas the DT- 
diaphorase line only showed a small (1.5 fold) increase in m etabolic 
binding of 2 -nitroim idazoles, in spite of the (1000  fold) increased 
activity of DT-diaphorase in this line (Joseph et a l ., 1994). From  their 
data Joseph et al. (1994) also suggested that a tissue’s capacity  for 
binding 2 -nitroim idazole drug under hypoxia should be proportional 
to the square root of its in tracellu lar NADPH: cytochrom e P450 
reductase activity. Interestingly, both W alton (1987) & W orkm an 
and Joseph et al. (1994) showed that, xanthine oxidase was an 
ineffic ien t reductase for 2-nitroim idazole reduction. These studies 
have th e re fo re  d em o n stra ted  th a t N A D PH : cy to ch ro m e  P450
reductase is probably the m ost im portant reductive enzym e for 2 - 
nitroim idazoles, and that DT-diaphorase and xanthine oxidase do not
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play a major role in this reductive m etabolism. Using purified butter 
m ilk  xan th ine  ox idase , how ever, P rekeges et al. (1991) have 
dem onstrated the capability of this cytosolic nitroreductase to reduce 
the 2 -nitroim idazole fluorom isonidazole.
D ifferent m ethods have been used to characterise the reductive 
m etabo lism  of 2 -n itro im idazo les. In this regard , rad iochem ical 
m ethods have the ab ility  to m easure levels of 2 -n itro im idazo le  
adducts in the acid insoluble fraction of incubates (Joseph et a l ., 1994; 
M cmanus et al ., 1982). HPLC with UV-detection, as well as direct UV- 
spectrom etric m ethods can m easure either the loss o f parent drug 
(loss of the nitro  chrom ophore) or the form ation  o f the am ine 
m etab o lites  (P rekeges et a l ., 1991; W alton & W orkm an, 1987). 
Although loss of parent drug and adduct or amine form ation do not 
occur at sim ilar rates, both processes occur as a function of enzyme 
levels and oxygen conten t and can be used to charac terise  2 - 
nitroim idazoles equally well.
In th is ch ap te r the m etabo lism  of S R -4554  has been 
characterised  using m ouse liver m icrosom es, tum our hom ogenates 
and purified  ra t and human NADPH: cytochrom e P450 reductase 
enzyme. An HPLC method has been employed and loss of parent drug 
monitored. In addition, and for the first time, a high resolution 
NMR technique has been implemented to study m etabolite form ation 
in a series of 2-nitroim idazoles. Finally, the activity  of NADPH: 
cytochrom e P450 reductase enzyme in a panel of human and murine 
tum our xenografts has been determ ined in order to ascertain  the 
capability of these tumours to reduce 2-nitroim idazoles. The results 
of these studies are important to the interpretation of MRS studies in 
chapter 6 , where the oxygenation status of these same tumours have 
been evaluated using SR-4554.
3 .2  MATERIALS AND METHODS
3 .2 .1  C h e m ic a ls  a n d  re a g e n ts
The structures of the 2-nitro im idazoles used in this chapter 
in c lu d in g  S R -4 5 5 4 , C C I-103F , Ro 0 7 -2 0 4 4 , K U -2285  and
flu o ro m iso n id a z o le  (Ro 0 7 -0 7 4 1 ), a re  show n in F ig . 1.3. 
trifluoropropanal and fluorom isonidazole were obtained from  Roche 
products, W elwyn Garden City, Herts, UK. CCI-103F was obtained 
from  Dr. J. Raleigh, Cross Cancer Institute, Edm onton, Canada. KU-
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2285 was ob tained  from  Dr. S .-I. N ish im oto , D ep artm en t of 
H ydrocarbon C hem istry , K yoto U niversity , K yoto, Japan . The
com pounds w ere assessed for chrom atographic  pu rity  and used 
w ithou t fu rther purification . T hallium  ch lo ride  (T IC I3 . 4 H 2 0 ) , 
cytochrome c, bovine albumin and NADPH were obtained from  Sigma 
Chemical Co. (Dorset, UK). The Biorad protein assay kit was obtained 
from  BIORAD Laboratories (H ertfordshire, UK). Purified ra t and 
hum an NADPH: cytochrom e P450 reductase protein  were obtained
from  Prof. C.R. W olf (ICRF Laboratory of M olecular pharm acology, 
Dundee, UK). Zero grade N2 gas, as well as, various gas m ixtures of 
oxygen in N2 were obtained from Air Products Ltd., Glasgow, UK. All
other reagents were analytical or HPLC grade.
3 . 2 . 2  E xp er im enta l  anim als  and tum ou rs
Mice used in this chapter were obtained either from Harlan Olac 
L td., (Oxon, UK) or from the Departm ent of Experim ental C linical
Oncology, University of Aarhus, Aarhus, Denmark. Tum ours (Table 
3.1) were free from m ycoplasm a and grown subcutaneoiisly on the 
flank  of the various m ice. All human tum our xenografts were
passaged from  in vitro culture at a cell concentration of 10^ cells in 
0.1 m l. KHT tum ours were passaged as tum our p ieces of 
approxim ately 1 mm in diam eter. The rem aining m urine tum ours
w ere passaged  from  in vitro  culture at a cell concentra tion  of
approxim ately 2 x 10^ cells in 0.1 ml. Tumours ranged between 200 
and 500 mm^ at the time of the experiment. L iver m icrosom es and 
S9 were specifically prepared from male Balb/c mice.
3 . 2 . 3  Preparation of  mouse l iver microsomes,  S9 
frac t ion  and tumour samples
All tissues (livers and tumours) were excised rapidly and snap 
frozen prior to analysis. S9 fractions and m icrosom es were prepared 
according to the methods of Omura and Sato, 1964 (Omura & Sato, 
1964a). Briefly, tissues were homogenised in an equivalent volume of 
50 mM Tris-150 mM KC1-HC1 buffer, (pH 7.4). The homogenates were 
in itially  centrifuged (10,000 x g for 30 min) at 4°C to rem ove nuclei, 
m itochondria and cell debris. The supernatant obtain from  this initial 
centrifugation step was the S9 fraction. To obtain microsomes, the S9 
fraction, was further centrifuged at 100,000 x g for 1 hr (4°C). The
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pellet obtained by this process was resuspended and recentrifuged 
(100,000 x g for 1 hr) at 4°C. Samples were kept on ice throughout 
the experim ent in order to avoid lass of enzyme activity. The pellet 
obtained from this final centrifugation step, as well as the S9 fractions 
were stored at -70°C prior to use. Reconstituted m icrosom es, and S9 
fractions, could be stored at -70°C for up to 6 weeks without loss of 
activity. To study the in vitro m etabolism  of SR-4554 by tum our 
hom ogenates, SCCVII tumours were hom ogenised in an equal volume 
of 0.1 M Tris-HCl buffer (50% w/v) and the homogenate used directly 
w ithout fu rther treatm ent.
3 . 2 . 4  Prote in  and enzyme assay
The protein concentrations of microsomes and S9 fractions were 
assayed by a Biorad protein assay kit which m easures the absorbance 
at 595 nm of an acidic solution of Coomassie B lue-protein complex 
(B radford , 1976; Spector, 1978). B ovine album in was used as 
s ta n d a rd .
T issue  NADPH: cytochrom e P450 red u c tase  ac tiv ity  was
determ ined by m easuring the reduction of cytochrom e c at 550 nm 
(M asters et al., 1967). In addition, the NADPH: cytochrom e P450 
a c tiv ity  in liv e r  m icrosom es was d e te rm in ed  by d iffe ren c e
spectroscopy as described by Omura and Sato (Omura & Sato, 1964a;
Omura & Sato, 1964b).
3 . 2 . 5  Characteris t ics  o f  reductive  m etabo l ism  o f  SR-  
4 5 5 4
Incubation  m ixtures
SR-4554 (50 pM ) was metabolised in vitro (at 37°C) by 2 mg/ml 
m ouse liver m icrosom es in the presence of excess cofactor (5 mM 
NADPH) and under hypoxia (N2 gas) in a total volume of 3 ml. Each 
hypoxic incubation was preceded by pre-incubation of m icrosom es,
cofactor, and buffer (0.1 M Tris-HCl, pH 7.4) with N2 for 8 min. 
Inhibitory studies were carried out using 0.2 m g/m l TICI3 .4 H 2 O (an 
inhib itor of NADPH: cytochrome P450 reductase), carbon m onoxide
(an inhibitor of NADPH: cytochrome P450) and air.
The e ffe c t of m icrosom al p ro te in  co n ce n tra tio n  on the 
m etabolism  of SR-4554 (50 pM ) was studied at 0.2 to 8 m g/m l 
p ro tein . On the other hand, the effect of substra te  (SR -4554)
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concentration on m icrosomal metabolism was studied at a m icrosom al 
p ro te in  concen tra tion  of 2 m g/m l. In th is s tudy , substra te  
co n cen tra tio n s ranged betw een 0.05 and 4 mM . M icrosom al 
rpetabolism  of SR-4554 (50 pM ) was also perform ed with different 
gas mixtures of oxygen in N2 (20.9, 5, 1, 0.7, 0.4, 0.2, 0.1, 0.01, and 0% 
oxygen) to evaluate the oxygen dependence of m etabolism .
Purified  enzyme
Reduction of 50 pM  SR-4554 under hypoxia by both purified 
human and rat NADPH: cytochrome P450 reductase was carried out as 
above. In place of microsomal protein, however, 1.3 U/ml (1U = 1 
pm ol cytochrom e c reduced/m in/m g protein m easured at 37°C) of 
purified  ra t or human cytochrom e P450 reductase  and 5 m g/m l 
bovine albumin were used. This reaction was also carried out in the 
presence of 0.2 mg/ml TICI3 .4 H2 O.
Tum our homogenate
The reduction of 50 pM  SR-4554 by tum our hom ogenates was 
also investigated as above. As a typical exam ple, SCCVII tumours 
were used in order to show that tumours could reduce SR-4554. In 
this case, however, 50% w/v SCCVII tumour hom ogenate in 0.1 M 
Tris-H C l buffer (pH 7.4) was used as the enzym e source and as 
previously described by Walton & W orkman (1987). Specifically, 800 
p i of the tumour homogenate was used per 3 ml of the incubation 
m ixture. This reaction was also carried out in the presence of 0.2 
mg/ml TICI3 .4H 2O.
HPLC analysis
To assess the reductive metabolism (loss) of parent drug, 250 p i 
of the incubation mixture was withdrawn at 0, 3, 6, 9, 12 and 15 min 
into E ppendorf tubes containing the internal standard Ro 07-0269
(Fig. 1.3). The incubation samples were im m ediately extracted with
30% w/v silver nitrate (25 p i)  and kept on ice prior to analysis.
Aliquots (50 p i) of the samples were analysed by HPLC as previously 
described in section 2.2.7.
3 . 2 . 6  Identif icat ion o f  reductive  m etabol i tes  o f  2- 
nitroimidazoles by high resolution NM R
To evaluate the form ation of hypoxia dependent m etabolites,
SR-4554 (250 pM ) was incubated under hypoxia with excess cofactor 
(5 mM NADPH) and 2 mg/ml mouse liver m icrosom es as described
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above. At 5, 15, and 30 min, 0.7 ml of the incubation m ixtures were 
withdrawn and imm ediately kept on ice. Samples were spiked with 
125 pM  CCI-103F (Fig. 1.3; as an internal standard and chem ical shift 
reference), freeze-dried and reconstituted in 0.7 ml D 2 O for nuclear 
m agnetic resonance (NMR) analysis. High reso lu tion  1 9 p  NM R
analysis was carried out on a Bruker AM 200 (Aspect 3000), 200 MHz 
NM R system  using a total of 2048 scans and operating in 1 H
decoupled mode at 25°C. As part of the study, samples were also 
extracted with 30% w/v silver nitrate (1:10 v/v) or filtered through 
an ultrafiltration  m em brane with a cu t-off of approxim ately 30,000 
(Amicon Div., W.R. Grace & Co., Danvers, MA, USA) prior to freeze 
drying and analysis. Due to the better clean-up and hence higher 
ach iev ab le  co ncen tra tions of analy tes w ith the s ilv e r n itra te  
p rec ip ita tion , subsequent experim ents were carried  out using this
p recip ita tion  step.
The hypoxia dependent metabolism of a series of fluorinated 2- 
n itro im idazo les includ ing  C C I-103F, Ro 07-2044 , K U -2285 and
fluo rom ison idazo le  (Fig. 1.3), was also inv estig a ted  w ith  high 
resolution NMR. In each case samples were incubated with 2 mg/ml 
mouse liver microsom es and 5 mM NADPH for 30 min. In parallel 
stud ies, the sam e incubation  m ixtures w ere also  ex trac ted  and 
analysed by HPLC. -HPLC analysis of Trifluoropropanal, KU-2285 and 
fluorom isonidazole were similar to that described in section 2.2.7. On 
the other hand, CCI-103F was analysed using a m odification of the 
method described by W alton & Workman (1987) for benznidazole. In 
this latter m ethod, analytes were separated on a C is column with a 
m obile phase comprising of 25% acetonitrile/0.2 M glycine-HCl buffer 
(pH 2.5) and/5 mM octane sulphonic acid. The m obile phase was 
delivered at a flow rate of 3 ml/min and column effluents m onitored 
by UV-detection at 324 nm.
3 .2 .7  In  vivo  re d u c tiv e  m e ta b o lism  o f S R -4554  
an a ly sed  by h igh  re so lu tio n  N M R
EMT6 tumour bearing female Balb/c mice were injected i.p. with 
180 mg/kg (0.06 ml/g) of SR-4554 prepared in saline. L iver, brain 
and tum our samples were excised and snap frozen at 15 m in, 4 hr 
and 6 hr post-injection of SR-4554. Three mice per time point were 
used and 10 ml of pooled tum our hom ogenates (10% w /v) were
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ex trac ted  w ith 30% w/v A gN 0 3  (1:10 v/v), f reeze-dried  and
reconstituted in 0.7 ml D2 O. The samples were then analysed by
NMR (using 25,000 scans) to determine the presence and extent of 
hypoxia dependent metabolism in vivo.
3 . 2 . 8  S ta t i s t i c a l  ana lys is
The kinetic parameters, apparent Km and apparent Vm a x were 
g e n e ra te d  using  an enzym e k in e t ic  a p p lic a t io n  p ro g ram m e
(EnzymeKinetics, Version 1.11; Trinity Software, Campton, NH, USA). 
Modelling of rate of reduction vs oxygen tension was carried out using 
GraphPAD Inplot, Version 3.14 (GraphPAD Software Inc., San Diego, 
CA, USA). All other statistical parameters were generated using 
either Minitab Release 9 (Minitab, State College, PA, USA) or Microsoft
Excel, Version 4.0 (Microsoft, Redmond, WA, USA).
3 .3  RESULTS
3 . 3 . 1  E n zy m e  act iv i ty
The level of NADPH: cytochrome P450 in the liver microsomes 
as determined by difference spectroscopy was 1.03 ±  0.1 nmol/mg. 
The activity of NADPH: cytochrome P450 reductase in the microsomes 
and S9 fractions were measured by a UV spectrophotometrie method 
to be 231 ±  11 and 121 ±  26 nmol cytochrome c reduced/min/mg 
protein respectively (mean ±  s.d.; n = 3). NADPH: cytochrome P450 
reductase activity was also measured in S9 fractions of a panel of
human and murine tumour xenografts which were used in MRS
studies (section 6.2). Table 3.2 indicated, in general, that the activity 
of NADPH: cytochrome P450 reductase were low and only varied by 
about 3 fold between different tumour types. In terestingly , the 
levels also varied within tumour types as shown by the standard 
errors in the measurements.
3 . 3 . 2  C h ara c ter is t ic s  o f  red uct ive  m eta b o l i sm
SR-4554 was reduced by NADPH: cytochrome P450 and NADPH: 
cytochrome P450 reductase containing mouse liver microsomes under 
hypoxia. This was assessed by measuring parent drug loss with time 
by HPLC. Fig. 3.1 illustrates typical chromatograms obtained from the 
incubation of SR-4554 with mouse liver microsomes under hypoxic 
conditions. SR-4554 concentrations were calculated from peak area
3 2
Table 3.2. NADPH Cytochrome P450 reductase activities in a panel of 
murine and human tumour xenografts.
Tum our type NADPH cytochrome 
P450 reductase activity 
(n m o l /m in /m g )a
s.e.
M u rin e
EMT6 6.9^ 0.4
C3H-m am m ary carcinom a0 5.6 0.8
SCCVII 5.0 0.7
SCCVII0 4.9 0.8
RIF-1 4 .2 0.5
RIF-10 4.4 1.0
KHT 3.4 0.4
H u m a n
HN5 11.9 1.8
W IL 10.5 1.2
BE 6.6 1.3
HT-29 5.2 0 .2
a units of activity: nmol of cytochrome c reduced/min/mg protein. 
b Means and standard errors were calculated from four individual 
tumours per tumour type.
0 These tumours were obtained from the U niversity  of Aarhus, 
Aarhus, Denmark. All other tumours were grown at the department 
of Medical Oncology, Glasgow, UK.
Fig. 3.1. Typical HPLC chromatograms of extracts obtained from the 
hypoxic incubation of SR-4554 at zero time (a), and 15 min (b). The 
chrom atogram s illustrates the solvent front; SR-4554; the internal 
standard (I.S.; Ro 07-0269), and also demonstrates parent drug loss at 
the latter time point. The minor peak are contaminants from the 
microsom e-NADPH mixture.
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ratio of SR-4554 to internal standard Ro 07-0269. The rate of 
metabolism was obtained from the slope of SR-4554 concentration vs 
time plots which were linear within the time studied. This reductive 
process was almost completely inhibited in air, in the absence of 
cofactor (NADPH) and in the presence of TICI3 .4 H 2 O (an inhibitor of 
NADPH: cytochrome P450 reductase). In contrast, however, carbon 
monoxide (an inhibitor of NADPH: cytochrome P450) only caused a 
21% inhibition of microsomal metabolism (Table 3.3).
Linearity of SR-4554 reduction with time was also observed at 
different protein concentrations. The rate of reduction of SR-4554 as 
a function of microsomal protein concentration is illustrated in Fig. 
3.2a. No detectable reduction was observed at protein concentrations 
below 0.5 mg/ml. The rate of reduction with protein concentration 
was linear (r = 0.99) up to the highest protein concentration studied 
(8 mg/ml). The percentage of drug loss as a function of microsomal 
protein  concentra tion  is shown in Fig. 3.2b. At a substrate  
concentration of 50 pM, complete reduction occurred between 4 and 8 
m g/ml protein within 15 min. Even under these conditions, no 
metabolites of SR-4554 were identified on the chromatogram. Both 
non-linear regression and the Hanes-Woolf transformation were used 
to model the kinetics of microsomal reduction of SR-4554 (Fig. 3.3). 
The Km and Vm ax were determined as 590 pM  and 16 nmol SR-4554 
reduced/min/mg respectively ( r = 0.99).
The relationship between hypoxia dependent metabolism of SR- 
4554 and the oxygen content of incubation mixtures was investigated 
in order to assess the potential of this compound as a hypoxia probe. 
The results of this study is shown in Fig. 3.4. The slope of the linear 
portion of the curve was -1.1 ± 0.17 and the concentration of oxygen 
required to decrease the hypoxia dependent m etabolism  by 50% 
compared to nitrogen (half-maximum inhibition) was estimated to be 
0.48 ± 0.06%.
The charac teristics  of SR-4554 reduction  by m ouse  liver 
microsome suggested that NADPH: cytochrome P450 reductase was an 
important reductive enzyme for this compound. In order to confirm 
this observation, purified NADPH: cytochrome P450 reductase was 
used as the enzyme source to metabolise SR-4554. SR-4554 was as
expected, metabolised by both rat and human NADPH: cytochrome 
P450 reductase. Table 3.4 shows that the rat enzyme metabolised SR-
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Table 3.3. Characteristics of the metabolism of SR-4554 by mouse 
liver microsomes.
In c u b a t io n
Conditions
Rate of SR-4554
Reduction
(n m o l /m in /m g ) fl
%
In h ib .^
Complete systemc 1.12 ± 0.14^ 0
Complete system in the 
presence of TICI3 .4 H2O 0.15  ± 0.04 87
Complete system in the 
presence of Carbon monoxide 0 .88  ± 0.03 21
Complete system in the 
absence of NADPH 5 .2 e -3 ±  0.13 1 0 0
Oxic (Air)^ 5 .6 e -2 ±  0.10 95
a Units of rate: nmol of SR-4554 reduced/min/mg protein
b % inhibition was calculated as the difference between the rate of 
reduction under a particular condition and that of the complete 
system, expressed as a percentage.
c In the complete system, SR-4554 (50 p.M) was metabolised in the 
presence of 2 mg/ml microsomal protein and 5 mM NADPH in Tris- 
HCl buffer, under hypoxia (see section 3.2.5).
^  Mean rate of reaction ± s.d. (n = 3).
e This was similar to the complete system, except that metabolism 
was carried out in air.
Fig. 3.2. (a) The effect of microsomal protein concentration on the
rate of reduction of SR-4554 under hypoxia. The rate of reduction 
(nm ol SR -4554  reduced /m in /m g  pro te in ) was de te rm in ed  as 
described in section 3.2.5. (b) Relationship between the percentage
of SR-4554 reduced by hypoxic incubation for 15 min and microsomal 
protein concentration.
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Fig. 3.3. The kinetics of reduction metabolism of SR-4554 by mouse 
liver microsomes, showing the classical V vs [S] plot (a), and the 
corresponding Hanes Woolf plot (b). The units of V and [S] were nmol 
SR -4554 reduced /m in /m g  pro tein  and j i M  respectively. E ight 
concentrations of SR-4554 (each determined in duplicate) were used 
in the study. The apparent Km and apparent Vm a x were estimated as 
described in section 3.2.7.
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F ig . 3 .4 . The reduc tion  rate of SR-4554 (nm ol SR -4554 
reduced/m in /m g pro tein) by mouse liver m icrosom es at various 
oxygen concentrations. The concentration of oxygen which produces 
half-maximal inhibition was estimated to be 0.48%.
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Table 3.4. Reduction of SR-4554 by purified rat and human NADPH 
cytochrome P450 reductase.
Enzyme Rate of SR-4554 reduction
(nmol/min/mg)a
Rat
NADPH cytochrome P450 reductase 17.8 ± 0.9b
Human
NADPH cytochrome P450 reductase 5.0 ± 1.0
Incubation mixtures contained 1.3 U/ml of each enzyme. 
a Units of rate: nmol of SR-4554 reduced/min/mg protein 
k Data represent mean reduction rates± s.d. (n = 4).
4554 at a higher rate than the human enzyme, suggesting inter- 
species variation. Importantly, the reduction of SR-4554 by both the 
rat and human enzymes was completely inhibited by TICI3 .4 H 2 O. In 
add ition  to m etabolism  by m icrosom es and pu rif ied  NADPH: 
cytochrome P450 reductase, SR-4554 was also metabolised by SCCVII 
tumour homogenate at a rate of 1.2 ± 0.4 nmol/min/ml (n = 3). The 
reduction was, however, not completely inhibited by TICI3 .4 H 2 O (rate 
= 0.5 ± 0.2 nmol/min/ml; n = 3).
3 . 3 . 3  Id en t i f i c a t io n  o f  red uc t ive  m eta b o l i t e s
An attempt was made to evaluate the exact nature of the MR- 
visible metabolites. Preliminary in vitro  studies with m icrosomes 
using NMR showed the presence of three SR-4554 metabolite
peaks at 10.3, 16.2 and 22.7 Hz downfield from the parent drug peak 
(Fig. 3.5). These peaks could also be m etabolite(s) in different 
chemical shift environments. The same peaks were also found to be 
p resen t in the supernatant of silver nitrate prec ip ita tes and in 
u ltrafiltrates obtained by passing incubation m ixtures through an 
ultrafiltration membrane (cut-off 30,000), but not in the resuspended 
pellet of silver nitrate precipitates. The formation of reductive 
metabolites of SR-4554 and corresponding loss of parent compound as 
determined by high resolution 19p NMR is illustrated in Fig. 3.6. The 
figure also shows that the formation of these reductive metabolite(s) 
is inhibited in air.
The microsomal reduction of other fluorinated 2-nitroimidazoles 
was also characterised by NMR. Figures 3.7, 3.8, 3.9 and 3.10 
show NMR spectra of extracts obtained from  30 min hypoxic 
incubation of CCI-103F, Ro 07-2044, KU-2285 and fluoromisonidazole 
respectively. In most cases, the peaks representing fluorinated 2- 
n itro im id azo le  m etabo lites  were sh ifted  to h igher f req uencies  
(downfield). HPLC analysis confirmed that the parent (fluorinated 2- 
nitroimidazole) compound was in all cases, reduced by more than half 
of the original concentration following hypoxic incubation for 30 min. 
The NMR spectral characteristics, however, differed markedly. For 
instance no differences in chemical shift was observed following 
hypoxic incubation of CCI-103F (octanol/water partition coefficient = 
20), whereas all the o ther com pounds show ed chem ical shift 
d ifferences. SR-4554 and Ro 07-2044 (octano l/w a ter  partition
34
Fig.  3.5. Reductive  m etabolism  of SR-4554 by m ouse liver
microsomes. The figure shows a high resolution NMR spectrum of a 
microsomal extract, obtained 30 min after the incubation of SR-4554 
under hypoxia. The spectrum represents original SR-4554 (vertical 
arrow) and its hypoxic metabolites.
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Fig. 3.6. Hypoxia-dependent metabolism of SR-4554. (a), (b) and (c)
rep resen t the t im e-dependen t reductive m etabolism  of SR-4554 
under hypoxia at 5, 15 and 30 min respectively. The spectra show 
that loss of parent drug was associated with the form ation of 
metabolites. (d) and (e), on the other hand, represent incubation of 
SR-4554 in air at 5 and 30 min respectively. Reduction of SR-4554 
was inhibited under these conditions. CCI-103F was used as the 
internal standard in these experiments.
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Fig. 3.7. Reductive m etabolism  of CCI-103F by m ouse liver 
microsomes. The figure shows a high resolution NMR spectrum of a 
microsomal extract, obtained 30 min after the incubation of CCI-103F 
under hypoxia. The spectrum represents original CCI-103F (vertical 
arrow) and its hypoxic metabolites. No chemical shift was observed 
between CCI-103F and its metabolite(s), although HPLC analysis of the 
same incubation mixture indicated loss of parent drug.
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Fig. 3.8. Reductive m etabolism  of Ro 07-2044 by mouse liver 
microsomes. The figure shows a high resolution NMR spectrum of a 
microsomal extract, obtained 30 min after the incubation of Ro 07- 
2044 under hypoxia. The spectrum represents original Ro 07-2044 
(vertical arrow) and its hypoxic metabolites.
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Fig . 3 .9 . R eductive  m etabolism  of KU-2285 by m ouse liver
microsomes. The figure shows a high resolution NMR spectrum of a 
microsomal extract, obtained 30 min after the incubation of KU-2285 
under hypoxia. The spectrum represents original KU-2285 (vertical 
arrow) and its hypoxic metabolites.
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Fig. 3.10. Reductive metabolism of fluoromisonidazole (Ro 07-0741) 
by mouse liver microsomes. The figure shows a high resolution NMR 
spectra of a microsomal extract, obtained 30 min after the incubation 
of f luorom isonidazo le  under hypoxia. The spectrum  represents
o r ig in a l  f lu o ro m iso n id azo le  (vertica l arrow) and its hypoxic  
m e tab o li te s .
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coeffic ien ts  of 0.64 and 3.35 respectively) showed in term ediate  
chemical shift differences of between 0.05 to 0.8 ppm. The two 
compounds with lowest partition coefficients, fluoromisonidazole and 
KU-2285 (0.41 and 0.25 respectively) showed higher chemical shift 
differences (up to 1.5 ppm) between metabolite peaks and original 
drug peaks. Interestingly, these same compounds have their fluorine 
atoms closer to the site of nitroreduction.
3 . 3 . 4  In  vivo r e d u c t iv e  m e ta b o l ism  o f  SR -4554
Two of the three NMR metabolites observed with microsomes 
were also identified in vivo in silver nitrate extracts of EMT6 tumours 
excised after SR-4554 administration to tumour bearing mice (Fig. 
3.11). This figure shows that in v ivo , parent drug levels are high at 
the early time point (15 min post-injection), and gradually converted 
into metabolites (2 and 4 hr). At 6 hr post-injection, only bioreduced 
metabolites remained. The low levels of the m etabolite  at 6 hr 
suggested that the bioreduced metabolite was also eliminated, albeit 
at a slower rate. These same peaks were also observed in liver but 
not brain (Fig. 3.12). Urine samples obtained from  non-tum our 
bearing mice over 24 hr showed the presence of other metabolites
(Fig. 3.13). The urinary fluorine spectrum was, however, dominated
by unchanged SR-4554 suggesting that this is the major elimination 
route for the compound.
3 .4  DISCUSSION
The m etabolism  of 2-nitroimidazoles has been shown to be 
mainly dependent on oxygen tension and enzyme content (Franko e t  
al., 1987; Joseph et al., 1994; Koch et al., 1984; Walton & Workman, 
1987). In this chapter, the characteristics  of this enzym atic  
b io reductive  m etabolism  of the hypoxia  probe SR -4554, w ere
investigated. Loss of parent drug, as determined by HPLC with UV 
detection, was used as a measure of SR-4554 nitroreduction. It 
should be noted that no metabolite was observed by this HPLC 
method even at the highest protein concentration of SR-4554. Walton 
and W orkm an , how ever, de tec ted  the am ine m e ta b o l i te  o f 
benznidazole using a similar technique (Walton & W orkman, 1987). 
In this case, the additional chromophore introduced by the aromatic
ring in the N -l  side chain of benznidazole (see Fig. 1.3) was
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Fig. 3.11. SR-4554 (vertical arrow) and its metabolites in EMT6
tumours excised from drug treated mice at (a) 15 min, (b) 2 hr, (c) 4 
hr, and (d) 6 hr post-injection. Drug injection, sample preparation and 
NMR analysis were carried out as described in section 3.2.6.
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Fig. 3.12. SR-4554 (vertical arrow) and its metabolites in liver (a)
and (b), and brain (c) and (d), of Balb/c mice. SR-4554 was present in 
both liver and brain at the early time point (15 min) and eliminated 
by 6 hr. Liver samples contained high levels of metabolites even at 
15 min, whereas no metabolites were observed in brain sample.

Fig. 3.13 SR-4554 (vertical arrow) and its metabolites in non­
tumour bearing mouse urine collected over 24 hr. The original plot 
shows that parent drug was the major metabolite in urine. The sub­
plot represents an expansion of the smaller peaks in the spectrum.
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responsible for the UV detection ability at the lower ^ m a x  of the 
amine metabolite (Walton & Workman, 1987).
SR-4554 metabolism was found to be dependent on two major 
enzym es, NA DPH: cy tochrom e P450 red u c tase  and NA DPH:
cytochrome P450. Inhibition of NADPH: cytochrome P450 reductase 
activity by its chemical inhibitor T 1C 13.4H 20, a lm ost com plete ly  
suppressed the reduction of SR-4554. This suggests that NADPH:
cytochrome P450 reductase may be involved in the early steps of the 
reductive process (see Fig. 1.4). The lower efficiency of inhibition of 
the reduction process by carbon monoxide (an inhibitor of NADPH: 
cytochrome P450) suggests that NADPH: cytochrome P450, on the 
other hand, is not a major nitroreductase in the early steps of the 
reductive  process. Interestingly, NADPH: cytochrom e P450 was 
shown to be only important in the latter steps of benznidazole 
nitroreduction resulting in the formation of the amine m etabolite  
(Walton & Workman, 1987). The importance of NADPH: cytochrome 
P450 in the reductive metabolism of SR-4554 was confirm ed by
metabolism with rat and human NADPH: cytochrome P450 reductases. 
Since the rat enzyme was more efficient in reducing SR-4554 than the 
hum an equivalent, this lim ited study suggests that in te rspecies  
variations are likely, and should be considered in the future clinical 
development of the compound. The possibility that reductases other 
than NADPH: cytochrome P450 reductase may be involved in the 
metabolism of the drug was suggested by experiments with SCCVII 
tumour homogenates. In this case, TICI3 .4 H 2 O did not completely 
inhibit the reductive process.
SR-4554 reduction was also found to be dependent on both 
pro tein  and substrate concentration. The linearity  of SR-4554 
reduc tion  with m icrosom al protein  concen tra tion  suggests  that 
d ifferences in enzyme concentrations of the order used in this
experim ent should produce marked differences in reduction rates. 
The substrate dependence of reduction was characterised  by an 
apparen t Km (590 pM ) and apparent V m a x  (16 nmol SR-4554 
red u c e d /m in /m g  p ro te in )  ind ica ting  re la t iv e ly  h igh  su b s tra te  
specificity for the enzymes involved in the reduction process. It 
would be in teresting  to investigate  w hether the high substate
specificity will translate into a high rate for the hypoxia-dependent
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binding kinetics of SR-4554 to macromolecules. This study will 
become possible when radiolabelled SR-4554 becomes available.
SR-4554 metabolism was also shown to be dependent on oxygen 
tension. The reductive process was completely inhibited in air (20.9% 
oxygen) and partially inhibited by increasing levels of oxygen in 
nitrogen. The oxygen concentration which produced 50% inhibition of 
SR-4554 reductionbetween nitrogen and air (0.48%) was similar to 
that previously reported for other 2-nitroimidazole binding such as 
misonidazole and desmethylmisonidazole (Franko, 1986; Franko et al. , 
1987; Joseph et al., 1994; Koch et al., 1984). This observation is 
interesting, since the effect of oxygen tension on the in vitro  reduction 
rates of 2-nitroimidazoles (i.e. loss of parent drug) per se has not been 
re p o r te d .
Due to the importance of NADPH: cytochrome P450 reductase in 
the reduction of SR-4554, this enzyme was profiled in a panel of 
m urine and human tumour xenografts used in section 6.2, to 
in ves tiga te  w hether enzym e activ ity  in these  tum ours would 
significantly affect the absolute retention of SR-4554 in its use as a 
hypoxia probe. The activity of NADPH: cytochrome P450 reductase in 
these tumours ranged between 3.4 and 11.9 nmol cytochrom e c 
reduced/m in/m g protein. Interestingly, both between and within 
tumour type variations were observed. The activities of NADPH: 
cytochrome P450 reductase observed in these tumours were found to 
be similar to those previously reported for untransformed cell lines 
(Fitzsim m ons et al., 1995; Joseph et al., 1994) and biopsy samples of 
gliom as (Rampling et al., 1994). As demonstrated in this chapter, 
these activities were not much less than that of liver S9 fractions (10- 
30 fold) or microsomes (20-60 fold). At similar oxygen tensions, 
tumour cells would be expected to metabolise SR-4554 at different 
rates, and at a much lower rate than that of the model system (liver 
microsomes) used in this chapter. According to Joseph et al., the 
ability of tissues to bind 2-nitroimidazoles would be a function of the 
square root of their reductase content (Joseph et a l., 1994). The 
enzym e profiling studies in this chapter, therefore, ind icate  that 
NADPH: cytochrome P450 reductase activities in the panel of tumours 
used here, and in future chapters, will be unlikely to markedly affect 
the reduction and hence selective retention of the nitroimidazole, and
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that oxygen tension per se would be the most important determinant 
of selective 2-nitroimidazole retention.
Although no metabolites of SR-4554 were detectable by HPLC, 
these were seen in high resolution 1 9 p  NMR studies. Hypoxic 
reduction of SR-4554 was characterised by three peaks in microsomal 
incubation mixtures. These metabolites were also found to have low 
molecular weight (less than that of plasma proteins; 30,000). Similar 
metabolites were observed in vivo in mouse liver, EMT6 tumours and 
mouse urine collected over 24 hr, but not in mouse brain which also 
had low levels of the parent drug. Although original SR-4554 was the 
m ain com pound present in urine, low concen tra tions  o f  other 
metabolites not previously present in microsomes were also observed. 
It was noted that the appearance of metabolites was very rapid in 
m ouse liver compared to tumours suggesting a higher reductive 
capacity due to the high levels of reductive enzymes. Although the 
exact nature of these metabolites were not fully elucidated, they are 
likely to be bound to low molecular weight molecules. Firstly, and as 
p rev iously  d iscussed , the higher p roportion  of 2 -n itro im idazo le  
adducts are represented by those bound to RNA and glutathione both 
of which are low molecular weight compounds (Chapman et a l ., 1990; 
Koch, 1990). Secondly, the ability of in vivo MRS to give sharp peaks 
(W orkman et al., 1992), indicates that low molecular weight adducts 
may play a major part in 2-nitroimidazole binding. Since the parent 
d rug  was c leared  fas ter  than the m e tab o li te ,  the red u c tive  
metabolism could be used to selectively measure hypoxia. This NMR 
m ethod would, therefore, complement radio labelled  studies which 
measure adduct formation in the acid insoluble fraction.
A high resolution NMR method was also used to identify the 
charac teris tics  of reductive m etabolism  of o ther f luorina ted  2- 
nitroimidazole. The five 2-nitroimidazoles, SR-4554, CCI-103F, Ro 07- 
2044, KU-2285 and fluoromisonidazole were characterised according 
to their NMR spectra. The chemical shifts observed in this series are 
are characteristic  of the intracellular and/or transm em brane shifts 
previously reported in NMR literature (Keniry et al., 1986; London, 
1994; Xu et al., 1993). Initially it was hypothesised that differences 
in 'through-bond' distances between the fluorine atoms and the site of 
nitroreduction could give differences in chemical shifts. Contrary to 
this notion, however, it was demonstrated that partition coefficient
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rather than 'through-bond' distance per se was of greater importance 
in the limited series investigated. This lipophilicity effect could be 
due to the presence of different drug metabolites or metabolite(s) in 
d ifferent compartments or chemical shift environm ents. Although
other analogues would be required to test this hypothesis fully, it
should be noted that only chemical shifts of up to 1.5 ppm were 
observed. This study, therefore, suggests that side chain fluorine
atoms may not produce resolved MRS spectra of parent and reduced 
metabolite at current clinically relevant magnetic field strengths, and 
that this effect may only lead to spectral broadening in in vivo  MRS 
s tud ies .
Studies in this chapter have characterised the enzymology and 
bioreductive activation of SR-4554. As a consequence, the data
produced in this chapter will form the basis experiments in future 
chapters of this thesis, as well as in the clinical development of SR- 
4 5 5 4 .
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CHAPTER 4
Localisation of SR-4554 in multicellular 
spheroids as measured by electron energy 
loss spectroscopic imaging 
4 .1  INTRODUCTION
4 . 1 . 1  S u b ce l lu lar  loca l i sa t ion  o f  2 -n i t r o im id a z o le s
N itro im idazo les , including m isonidazo le , have been under
evaluation as potential diagnostic probes for hypoxic cells. This is due 
to the specific reductive m etabolism  of the drugs to reactive 
metabolites which bind to macromolecules within hypoxic cells (see 
section 1.5.2 and Fig. 1.4). The characteristic of covalent binding of 2- 
nitroimidazoles has been evaluated in various cell lines and tumours, 
and although the exact nature of the metabolites is unknown, various 
candidates have been implicated in this process (Chapman et a l., 
1983; Chapman et a l., 1990; Miller et aL, 1982). These candidates 
include glutathione, ribonucleoproteins and lipoproteins. For instance 
previous subcellular fractionation studies in EMT6 cells with 1 4 q  
m isonidazole indicated that 23 and 77% of the total activity was 
associated  with the acid-insoluble and the acid-soluble  fractions 
respectively (Miller et a l., 1982). Further, the acid-insoluble fraction 
was distributed amongst RNA (17%), DNA (1%), lipid (4%), and protein
(1%) (M iller et a l ., 1982). In another study, the involvem ent of
intracellular enzymes in the activation process was implicated, since 
the tem perature dependence for this process showed an activation 
energy  of 33.5 kcal/m ol (Chapman et a l ., 1983). This latter 
investigation  demonstrated that the binding rate of m isonidazole  
within hypoxic cells was at least 50 times greater than that observed 
within aerobic cells. The data also suggested that the activation sites 
m ay be lipid-associated, thus favouring the bioreduction of more 
lipophilic compounds. Various techniques such as autoradiography,
imm unohistochem istry  and flow cytometry have been employed to
localise 2-nitroimidazoles in spheroids and tumour biopsies (Garrecht 
& Chapman, 1983; Hodgkiss et a l., 1994; Lord et a l., 1993; Raleigh e t  
a l ., 1991b). These studies have shown that 2-nitroimidazoles label
hypoxic cells within tumours and are, therefore, particularly suitable
as markers. In this regard, electron energy loss spectroscopy (EELS) 
has been investigated in this thesis as a method for localising 2-
4 0
nitroimidazole in spheroids. This technique is described in section 
4.1.2.
4 . 1 . 2  Electron energy loss spectroscopy (EELS) and 
e lectron spectroscopic  im aging  (ESI)
Electron energy loss spectroscopic analysis (EELS) and electron 
spectroscopic imaging (ESI) are emerging techniques for in situ  
exam ination of compounds in cells and tissues. A lthough the 
technique has been used frequently on biological samples, it has only 
recently been applied to anticancer drug localisation (Huxham et a l. , 
1993; Huxham et a l., 1992). The technique is capable of relating 
spa tia l  chem ica l com position  of b io log ica l  sys tem s to cell 
ultrastructure and also of providing relative concentrations of specific 
elements within unstained areas of the cells on a nanometer scale.
EELS re lies  upon the m easu rem en t of e lec tron  energy  
distribution of transmitted electrons that have lost energy following 
interaction with a specimen in vacuo  . Specifically at high voltage 
(80-100 kV), the incident electron beam directed at a specimen 
produces both elastically and inelastically scattered electrons (Fig. 
4.1). Elastically scattered electrons result from the interaction of the 
inc iden t e lectron beam  with positively  charged nuclei in the 
specimen. This leads to a significant change in direction of the 
emergent electrons but with no change in energy. Such electrons can 
therefore be excluded by the insertion of an objective aperture in the 
microscope. In contrast, inelastically scattered electrons result when 
the incident electron beam interacts with electrons in the specimen. 
This leads to a slight change in energy but little or no change in 
direction of the resultant emergent beam. Such energy loss provides 
valuable information since it is characteristic of the element, electron 
orbital and shell with which the incident beam interacts. Using an 
energy filtering transm ission electron m icroscope (EFTEM ), the 
emergent electrons can be analysed according to the intensity of their 
energy loss to give an energy loss spectrum (Fig. 4.2) or alternatively 
can be used for the production of an electron spectroscopic image 
(ESI). These filtered electron spectroscopic or image sequences 
contain information about the element-specific energy loss population 
(equivalent to energy loss edge) superimposed on the non-specific 
energy loss population (equivalent to background). By varying
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Fig. 4.1. Elastically  (a) and inelastically (b) scattered electrons 
produced by the interaction of the incident electron beam  with 
specim en nuclei and e lectrons respectively. Exclusion  of the 
elastica lly  scattered (zero-loss) electrons allows the energy loss 
spectrum or image of a particular atomic species in the specimen to 
be produced.
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Fig. 4.2. (a) Typical energy loss spectrum showing a continuously
decreasing background and an elemental edge, (b) The spectra in (a) 
after undergoing a background removal process to reveal the true 
elem ental contribution. (Produced by A.D. Johnson, Division of 
Molecular and Cellular Biology, University of Glasgow).
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precisely the source of high energy voltage whilst m aintaining the 
m irror voltage constant, the different regions of the energy loss 
spectrum are scanned selectively and the specimen imaged at these 
values. Data are processed mathematically to obtain edge intensity
information which relates directly to the elemental concentration of 
the specimen. Comparing the intensity of two elements, as performed 
here, can thus disclose semi-quantitative elemental information on a 
local (nm) scale.
In this chapter, EELS was used to study the localisation of SR- 
4554 within A2780 human ovarian m ulticellu lar spheroids. The 
A2780 spheroid model was chosen because it provides the co­
existence of both aerobic and hypoxic cells under normal aerobic cell
culture conditions, allowing manipulations of both types of cells to be 
carried out simultaneously. Moreover, EELS has previously  been 
applied  to the localisa tion of f luorine-contain ing  drugs in this
spheroid model (Huxham et al.y 1993; Huxham et a l.y 1992).
Together with the bioreductive m etabolism  studies reported 
here, the present localisation studies will help in our understanding of 
the characteristics of metabolism induced binding of SR-4554 and of 
2-nitroimidazoles in general.
4 . 2 MATERIALS AND METHODS
4 . 2 . 1  Chem icals  and reagents
Human ovarian cancer cells A2780 were obtained from Dr. R.F. 
Ozols (NCI, Bethesda, MD, USA). The cells were cultured in a medium 
consisting of RPMI (Life Technology, Paisley, Scotland) supplemented 
with 10% foetal calf serum (Globepharm, Esher, Sussex, England), and 
0.001% (w/v) insulin (Lewes, Sussex, England). The 2-nitroimidazoles 
used in this chapter have been previously described (Fig. 1.3).
4 . 2 . 2  Reductive metabolism of SR-4554 by A 2780 cells
A2780 cells were cultured as monolayers and grown to near 
confluence. The cells were then trypsinized, and plated at a
concentration of 5 x 10^ cells/ml in 5 ml. Cells were then allowed to 
adhere to the flasks and the medium replaced with one containing 10 
and 20 pM  SR-4554. The flasks were then incubated for various 
lengths of time up to 3 hr under hypoxic (98% nitrogen, and 2% CO2) 
or aerobic (2% CO2, and 20% oxygen in nitrogen) conditions. Drug
4 2
containing media obtained at 0, 0.5, 1, 2, and 3 hr were then analysed 
by HPLC (see chapter 2).
Aliquots (250 pi) of the incubation media were spiked with 20 
p i  of an internal standard (8 pg/m l Ro 07-0269) and the mixture 
extracted with 25 p i  of 30% w/w silver nitrate solution. Samples 
were vortexed, centrifuged (at 1000 x g ) for 10 min, and the
supernatants analysed by HPLC (see chapter 2). Calibration standards 
(0.35 to 35.46 pM) were prepared in RPMI medium and also analysed 
by HPLC. The concentrations of parent drug in the incubation samples
were determined and plotted against time. Rates of reduction were
estim ated from the initial slope of the concentration of SR-4554 
versus time curve which was linear within the time period studied.
4 . 2 . 3  P reparat ion  o f  A2780 m u l t ice l lu la r  sp h ero id s
Human ovarian A2780 cells were plated (in RPMI medium) at a 
concentration of 2 x 10^ cells/50 ml and incubated in stirrer flasks at 
3 7 ° C  to form spheroids. After 3.5 days in culture, spheroids of
approximately 0.8 to 1.4 mm in diameter were obtained for use in the 
EELS experiment.
4 . 2 . 4  Incubation of  A2780 spheroids with SR -4554
A 2780 sphero ids were incuba ted  w ith  cu ltu re  m ed ium  
containing a non-toxic concentration of 1 mM SR-4554 at 37°C for 3 
hr. Incubations were carried out under normal aerobic cell culture 
conditions. Half of the spheroids were then transferred onto ice to 
stop further reaction. The other half were washed with fresh culture 
m ed ium  and 'chased ' at 37°C for 2 hr under norm al aerobic 
conditions. These were also transferred onto ice to stop further 
reac tion .
4 . 2 . 5  E lectron  energy loss spec troscop ic  analys is
For analytical electron microscopy, all spheroids were briefly 
washed in phosphate buffered saline (PBS), and chemically fixed (on 
ice) with 1% glutaraldehyde in PBS for 1.5 hr. The spheroids were 
dehydrated in a series of alcohols for embedding at low temperature 
in Lowicryl K4M, a nitrogen-free hydrophilic m ethacrylate  resin, 
without the use of heavy metal stains to avoid electron scattering. 
U ltra-thin sections were mounted onto 700 mesh copper grids for
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electron spectroscopic analysis using a Zeiss TEM902 microscope (Karl 
Zeiss Oberkochen Ltd, Overkochen, Germany) operating at 80 kV and 
12,000 times magnification. The microscope was fitted with an 
electron energy filter for analysis of the local electron associated with 
fluorine (K-edge onset at A E = 688 eV) and nitrogen (K-edge onset at 
A E = 405 eV). This novel technique has a resolution of about 2 nm 
and an energy resolution of about 5 eV for sections of resin 
embedded cells, and a theoretical detection limit of fluorine of about 
500 atoms (Huxham et al., 1992; Johnson et al., 1995).
Energy filtered image sequences were recorded between A E = 
650-750 eV for fluorine and between A E 350-450 eV for nitrogen, 
changing only the (measurable) video camera (Dage SIT, Michigan, 
MN, USA) kV setting between each sequence pair to accommodate the 
change in energy loss intensity relative to the dynamic range of the 
v ideo  cam era. Com parisons betw een defined  reg ions  w ithin  
peripheral (outer) and cells approximately 150-160 pm  from the edge 
of the spheroid (inner cells) were made using in-house software. 
Energy loss contribution of both fluorine and nitrogen were measured 
following background modelling for each pixel in m edian filtered 
energy loss image sequence. This was accomplished using the least 
mean square determination of the param eters which describe the 
energy loss curve (De Bruijn et al., 1993; Johnson et al., 1995). 
Cum ulative background-stripped grey level values from 12 image 
sequences over a 30 eV portion of the post-ionization edge for 
fluorine and nitrogen were used to calculate elemental ratios. In this 
way, variations in the density of cellu lar m aterial betw een one 
domain and another could be normalised as a function of the nitrogen 
content for each region of interest, to produce local semi-quantitative 
elemental maps. Data were also expressed as average grey level 
value representing energy loss for fluorine as a function of section 
area for each pixel.
4 . 2 . 6  S ta t i s t i c a l  ana lys is
Statistical parameters were generated using Minitab Release 9 
(Minitab, State College, PA, USA) or M icrosoft Exel, Version 4.0 
(M icrosoft, Redmond, WA, USA). The M ann-W hitney  test of 
significance was employed to assess differential subcellular binding. 
A 95% confidence level was used.
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4 .3  RESULTS
4 . 3 . 1  Metabolism of SR-4554 by A2780 cells
SR-4554 was reduced by A2780 cells in culture under hypoxic 
conditions. This was assessed by chromatographic analysis of parent 
drug metabolised by the cells in culture. Fig. 4.3 shows a typical 
chromatogram of a hypoxic compared to an aerobic incubation sample 
also containing the internal standard (Ro 07-0269). No UV absorbing 
metabolites were observed. The rates of reduction of SR-4554 by 
A2780 cells under aerobic and hypoxic culture conditions are shown 
in Table 4.1. These data, obtained at 37°C, demonstrate the selective 
reduction of SR-4554 under hypoxia in contrast to normal aerobic 
conditions. As expected, the reduction rates increased at a higher 
substrate concentration.
4 . 3 . 2  Growth character is t ics  of  A2780  sp hero id s
Initially, the cells aggregate but after 3.5 days in culture, they 
form tight proliferating spheroids as demonstrated by the presence of 
mitotic bodies indicating dividing cells. Under these conditions the
large spheroids develop a region of hypoxia between the outer and
the inner necrotic core. For this study, the most outer cell layer of the 
spheroid were taken as being aerobic, whereas cells in the inner 
region of the spheroid at approxim ately 150-160 p m  from  the 
surface, but separate from any necrotic core, were selected as hypoxic 
as shown by Miller et al. (1989) using EMT6 spheroids. A2780 
spheroids are similar to EMT6 spheroids in that both form  tight 
spheroid  structures. In this regard, spheroid m odels showing 
differences in oxygen levels and binding of 2-nitro im idazoles has 
previously been established (Franko et al., 1987; Franko et a l., 1992).
4 . 3 . 3  Sub-cellular localisation of SR-4554 in A2780
s p h e r o i d s
EELS analysis of spheroids incubated with SR-4554 enabled the 
localisation of fluorine atoms in subcellular components within the
spheroid. Fig. 4.4 shows an unstained, energy f ilte red  image
(reversed contrast) of A2780 cells from a spheroid after culture in 
SR-4554 containing medium, recorded at A E = 150 eV. By means of 
spectroscopic  imaging, m ost in tracellu lar structures of unstained
45
Fig. 4.3. Typical HPLC plot of SR-4554 after incubation with A2780 
cells for 30 min under (a) Aerobic and (b) Hypoxic conditions. From 
left to right the three peaks illustrated indicate the solvent front, SR- 
4554 and internal standard (I.S.; Ro 07-0269) respectively.
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Fig. 4.4. Energy filtered image of a portion of a heavy metal free 
A2780 cell within SR-4554 treated multicellular spheroids after a 
’chase1 culture, recorded at A E = 150 eV, showing enhanced contrast 
in phosphorus-rich regions. The image shows a well defined nuclear 
region (N), nucleolus (Nclo), nuclear membrane (NM), vessicle (V), 
p la sm a  m em b rane  (PM ), m itochondria  (M) and cy top lasm ic  
polyribosomes (CR). Bar = 700 nm.
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m ateria l,  o therw ise  d ifficu lt to see w ithout f i lte r ing , could be 
identified for analysis. Using our in-house image analysis software,
reg ions of in terest (ROI) for each electron spectroscopic  image 
sequence (ESIS) were defined simply by drawing on the reference
image on the display screen. The same ROI was used for analysis of 
both nitrogen and fluorine ESIS sequences. The energy loss for 
n itro g en  and f luo rine  were then de te rm ined  by p lo tting  the
cum ula tive  grey level value for the ROI for each ESIS. A
represen ta tive  pro jec ted  distribution of fluorine (green) within a 
section of the inner region of the spheroid after the 'chase' process is 
shown in Fig. 4.5. This represents residual bound drug in the cell.
4 . 3 . 4  S em i-q u a n t i ta t iv e  loca l isa t ion  o f  SR -454  in 
A 2 7 8 0  sp h e r o id s
An analysis of cytoplasmic domains (which includes cytoplasm, 
m itochondria , vesicle n ^ - 1 i  plasma m em brane regions) of
c<*-11p - * * 4 6) suggests that the drug was
la b le  4 .2  dem onstra tes that the drug d is tr ibu tion  presen t 
within the cells from both the inner and outer regions of 'chased' 
spheroids was not uniform. Relative to the intrinsic nitrogen content 
of specific  in tracellu lar  regions, which takes into account local 
variations of biological material, the amount of drug within the inner 
cells was found to be com paratively  high at the periphery  of 
intracellular vesicles, within the cytoplasm, in the nucleus and at its 
periphery. In contrast, the amount of drug was comparatively low 
within m itochondria  and at the plasma membrane. M ann-W hitney
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m ateria l, otherwise d ifficu lt to see w ithout fi lte ring , could  be 
identified for analysis. Using our in-house image analysis software, 
reg ions of interest (ROI) for each electron spectroscopic  image 
sequence (ESIS) were defined simply by drawing on the reference 
image on the display screen. The same ROI was used for analysis of 
both nitrogen and fluorine ESIS sequences. The energy loss for 
n itrogen  and fluorine were then de term ined  by p lo tt in g  the 
cum ulative  grey level value for the ROI for each ESIS. A 
representa tive  projected distribution o f  fluorine (green) w ith in  a 
section of the inner region of the spheroid after the 'chase' process is 
shown in Fig. 4.5. This represents residual bound drug in the cell.
4 . 3 . 4  Sem i-quantitat ive  loca l isa t ion  o f  SR-454 in 
A 2 7 8 0  sp h e ro id s
An analysis of cytoplasmic domains (which includes cytoplasm, 
m itochondria, vesicle periphery and plasma mem brane regions) of 
cells within A2780 spheroids (Fig. 4.6) suggests that the drug was 
distributed into cells across the whole spheroid after a 3 hr culture. 
Following chemical fixation of these spheroids, only m arginally less 
drug was bound to intracellular components within cells of the inner 
region of the spheroid as compared to the equivalent components of 
cells in the outer region. More importantly, an eight fold higher level 
of drug was present within the cytoplasmic domains of these inner 
cells after 'chasing' with drug-free media, as most of the drug which 
was present in the outer cells had diffused away following the 'chase' 
process. This selective retention of drug by the inner cells is 
indicative of increased bioactivation within the inner cells of the 
sph ero id s .
Table 4.2 dem onstrates that the drug d is tr ibu tion  p resen t 
within the cells from both the inner and outer regions of 'chased' 
spheroids was not uniform. Relative to the intrinsic nitrogen content 
of specific intracellular regions, which takes into account local 
variations of biological material, the amount of drug within the inner 
cells was found to be com paratively  high at the periphery  of 
intracellular vesicles, within the cytoplasm, in the nucleus and at its 
periphery. In contrast, the amount of drug was comparatively low 
within mitochondria and at the plasma membrane. M ann-W hitney
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Fig. 4.5. (a) Reference image of a section from an inner A2780 cell
within SR-4554 treated multicellular spheroids after a 'chase' culture, 
recorded A E = 150 eV. The image shows the plasma membrane 
(PM), vesicles (V), cytoplasm (C), nuclear membrane (NM), nucleus 
and nucleolus (Nclo). (b) The same image upon which the projected 
fluorine distribution is superimposed (green). The green binary 
fluorine map simply shows regions in which fluorine was found to be 
present (i.e. a stripped grey level value above background). TIFF 
images were reproduced on a Kodak Colourease™  printer (field width 
= 5 (iM).

O
uter 
cells 
Inner 
cells
Mean Relative F/N Ratio
Fig. 4.6. Histograms showing the mean ± standard deviation of 
f luorine /n itrogen  (F/N) elem ental ratios for cytoplasm ic dom ains 
(which inc ludes cytoplasm , m itochondria , vesicle periphery  and 
plasma membrane regions) from the outer and inner cells of A2780 
multicellular spheroids cultured for 3 hr (dark hatch) in SR-4554 and 
after a 2 hr 'chase' (light hatch) in drug-free media.
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4.2. 
The 
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average 
fluorine 
and 
fluorine/nitrogen 
elem
ental 
ratios 
for 
six 
intracellular 
dom
ains 
of 
both 
outer 
and 
inner 
cells 
from 
A2780 
m
ulticellular 
spheroids 
follow
ing 
a 
'chase' 
culture 
with 
SR
-4554.
test revealed that there were statistically significant differences (p <
0.05) when the following comparisons were made:
Outer cells F/N ratio:
a. cytoplasm vs nuclear periphery and nucleus.
Inner cells F/pixel:
a. mitochondria vs nucleus and nuclear periphery.
b. nuclear periphery vs cytoplasm, vesicle periphery and plasma 
m e m b ra n e .
Inner cells F/N:
a. vesicle periphery vs mitochondria and plasma membrane
b. mitochondria vs nucleus, nuclear periphery and cytoplasm.
Although the nitrogen atoms in the drug will contribute to the 
total nitrogen intensity signal of the EELS technique, by far the 
greater contribution will come from the biological macromolecules of 
the cell to which the drug is localised. When simply expressed in 
terms of the average amount of fluorine per unit area of cell section, 
the data suggested that there was a relative accumulation of fluorine 
at the nuclear periphery and in the nucleus com pared to other 
regions, more representative of the projected fluorine distribution 
shown in Fig. 4.5. In addition, it was observed that across all 
domains, there was less drug (3-10 fold) localised within the outer 
(aerobic) cells compared to the inner (hypoxic) cells.
4 .4  DISCUSSION
The localisation of 2-nitroimidazoles following reduction by 
tumour cells is important in our understanding of the use of these 
compounds as hypoxic probes. The aim of this study was to study the 
uptake, subcellular localisation, and hypoxia selective retention of SR- 
4554 within A2780 spheroids. The human ovarian A2780 cell line 
was used in this study since this cell line has been previously well 
ch a rac te r ised  (Tsuruo et a l ., 1986), and has also been shown to 
express NADPH: cytochrome P450 reductase, an im portant enzyme 
involved  in the reductive m etabolism  of 2 -n itro im idazo les  (see 
chapter 3), by enzyme assay and PCR analysis (data not shown). This 
cell line was also considered likely to develop a hypoxic region in 
spheroids over the size range used and was, therefore, used in the 
reductive drug localisation studies.
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SR-4554 was m etabolised by A2780 cells in culture under 
hypoxia, albeit at a slower rate than in mouse liver microsomes. This 
may be due to the higher enzyme levels in m icrosomes compared 
A2780 cells. This hypoxia mediated m etabolism  was selectively 
inhibited in the presence of air. This is due to the reversal of 2- 
nitroimidazole reduction by oxygen, as previously demonstrated with 
SR-4554 in chapter 3, as well as with other analogues such as 
m isonidazole, desmethylmisonidazole and benznidazole (Chapman e t  
a l ., 1983; Joseph et al., 1994; Walton & Workman, 1987).
The use of the novel EELS technique permitted the localisation 
of the SR-4554 within human ovarian carcinoma spheroids. It should 
be noted that the EELS technique measures fluorine atoms within SR- 
4554 and will therefore not differentiate between original parent 
drug and (bound or unbound) metabolites In cultures not subjected 
to ’chasing', no significant differential was observed between cells of 
the inner and outer regions of the spheroid. This presumably is due 
to the presence of both original parent drug and bound drug. The 
m ethod of 'chasing' in drug-free media to d ifferen tia te  between 
bound and unbound drug was, therefore, employed to allow the 
assessment and localisation of bound metabolites.
Interestingly, the results obtained in our study using spheroids 
and EELS were in accordance with the metabolism-induced binding of 
2-nitroim idazoles to macromolecules as previously dem onstrated by 
other methods with limited spatial resolution such as autoradiography 
and immunohistochemistry (Lord et al ., 1993; Miller et al., 1982). In 
contrast to these other methods, the EELS technique also allows the 
ability to measure drug binding in relation to the density of other 
local m acrom olecu lar com ponents. A lthough some non-specific  
binding occured in the cells of the outer (aerobic) region of the 
spheroids, levels of fluorine in the cytoplasm of cells from the inner 
(hypoxic) regions were at least eight fold higher. This differential is 
the more likely to occur in an in vivo situation where elimination 
processes will result in the removal of unbound drug compared to the 
bound metabolite. Importantly, the localisation characteristics shown 
in this study are very relevant to the use of this novel fluorinated 
compound as a non-invasive marker of tumour hypoxia in the clinic. 
The presence of three magnetically equivalent fluorine atoms in the 
s truc tu re  o f the com pound, which rem ains in tac t on enzym e
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reduction , is im portant in terms of its de tection  by m agnetic  
resonance techniques, as well as EELS.
Further studies using EELS enabled the more detailed analysis 
of the subcellular localisation of SR-4554 within cells in the outer and 
inner regions of the spheroid. In this study, the mitochondria and 
plasma membrane did not appear to bind significant amounts of drug. 
Of interest, however, were the high levels of SR-4554 localised to the 
nuclear periphery, nucleus and cytoplasm within the inner hypoxic 
cells. These data are in agreement with previously published studies 
using subcellular fractionation of cells labelled with 1 4 c  misonidazole, 
considering that the molecular components in these regions consist 
mainly of RNA, DNA, lipids and proteins (Chapman et al., 1990; Miller 
et a l ., 1982). In addition, the distribution of 2-nitroim idazoles to 
cytoplasm , nuclear and perinuclear regions were also mentioned by 
Cline et a l  (1994) who used antibodies, which were raised against the 
hexafluo rina ted  2 -n itro im idazole  C C I-103F /C C I-103F  adducts , in 
order to follow the distribution of hypoxia and/or reductive enzymes 
within cells of canine tumours. In contrast, and as expected, there 
was less drug localised by EELS within all the domains in the outer 
cells.
The in it ia l  steps in the red u c tiv e  m e tab o lism  of 2- 
nitroimidazoles are mainly catalysed by NADPH: cytochrome P450 
reductase and to a lesser extent by NADPH: cytochrome P450, both of 
which are found in the endoplasmic reticulum (Mcmanus et a l ., 1982; 
W alton & Workman, 1987). The subcellular distribution of SR-4554 
demonstrated in these studies, was consistent with the view that the 
reactive intermediate is short lived and binds to m acrom olecules 
within the vicinity of the metabolism site or to nucleophiles such as 
RNA close to these sites. Importantly, the evidence would suggest 
that the reactive metabolites do not diffuse far from their sites of 
activation, a fact which has previously been suggested by Franko & 
Koch (1984) from  their experim ents with m ison idazo le . This 
characteristic is also relevant to the design of bioreductive drugs, 
based on 2-nitroimidazoles, which will target the nucleus of the cell to 
deliver radioisotopes or alkylating moieties.
Currently, SR-4554 is undergoing pre-clinical development prior 
to scheduled clinical trials as a probe for investigating  tumour 
hypoxia by non-invasive MRS. Important to the direction of these
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studies, the observations made in this chapter are useful in the 
interpretation of data from non-invasive MRS studies. In addition, 
the EELS technique itself can also be used to study the distribution of 
hypoxic regions within tumours labelled in vivo with SR-4554 even 
though this will involve invasive (biopsy) procedures. As a semi- 
quantitative technique, however, it offers the potential of measuring 
hypoxia on a cell to cell basis at a molecular level with good resolution 
compared to antibody techniques and also the investigation of drug- 
cellular macromolecule interactions without the use of radioisotopes.
5 0
CHAPTER 5
Toxicity and pharmacokinetics of SR-4554 in mice
5 .1  INTRODUCTION
Pharmacokinetics is defined as the study and characterisation of 
the time course of drug absorption, d istribution m etabolism  and 
excretion. The two processes of m etabolism  and excretion  are 
referred to as elimination. Both pre-clinical pharmacokinetic studies 
and toxicity profiles provide useful data to enable the establishment 
of a safe human dose, as well as the intensity and time course of 
therapeutic effect.
The litera ture  on the pharm acokinetics of n itro im idazoles , 
particularly those in use as radiosensitizers, is very large (see review 
by W orkm an, 1983b). This is due to the m ajor influence of 
pharmacokinetics on the activity and toxicity of these agents. In 
general there are two m ajor p roperties  which are considered  
im portan t in the design of 2-nitro im idazoles. These are their 
re d u c tio n  p o ten t ia l  and l ip o p h il ic i ty  (o c ta n o l/w a te r  p a r t i t io n  
coeffic ien t; P0ct) (Adams et al.y 1979; Brown & W orkm an, 1980; 
Workman & Brown, 1981). The reduction potential of N -l substituted 
2-nitroimidazoles, which relates to the rate of metabolic reduction 
and adduct formation, varies only slightly from one 2-nitroimidazole to 
another (Adams et a l ., 1979; Workman & Brown, 1981). In contrast, 
however, the lipophilicity and hence tissue penetration particularly  
into the nervous system of 2-nitroimidazoles vary very widely. This 
property of the compounds is very important with regard not only to 
their toxicity, but also to their pharmacokinetics and distribution to 
reductive sites (White et al., 1982; White & Workman, 1980; White e t  
a l ., 1980; Workman, 1979; Workman, 1982).
The dose limiting toxicity of the prototype 2-nitroim idazole, 
m ison id azo le , is neuro tox ic ity  p resen ted  m ain ly  as p e r iphe ra l  
neuropathy and also central effects such as ototoxicity (Urtasun et al., 
1978). It has been demonstrated in mice that for a series of 2- 
nitroimidazoles with varying N-l substituents, the more lipophilic 2- 
nitroimidazoles are more toxic than misonidazole, whereas the more 
h y d r o p h i l i c  2 -n i t r o im id a z o le s ,  such  as e t a n id a z o le  and  
desm ethylm isonidazole, are less toxic (Workman & Brown, 1981). 
This is also exem plified  by the fact that e tan idazo le  can be
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adm in is te red  at the equ iva len t o f three tim es the dose  of 
m ison idazo le  in man to give the same degree of periphera l 
neuropathy as misonidazole (Coleman et al., 1986). Experiments 
conducted in mice and dogs have shown that exclusion of the more 
hydrophilic 2-nitroimidazoles from the brain and nervous system but 
not from  tumours, as well as their increased plasma clearance is 
responsib le  for the d irect corre la tion  betw een l ip o h il ic i ty  and 
neurotoxicity (White et al., 1982; White & Workman, 1980; White e t  
al., 1980; Workman & Brown, 1981).
The mechanism of nitroimidazole neurotoxicity is still a subject 
o f  c o n t in u in g  r e s e a rc h .  R e s u l ts  o b ta in e d  u s in g  r a t  
phaeochromocytoma and mouse neuroblastoma cell lines suggest that 
nitroim idazoles cause the disruption and degeneration of dendritic 
projections (Stevenson et al., 1989). The identity of the proximal toxic 
species is, however, still a matter of controversy. The presence of 
reactive metabolites of misonidazole in the urine of patients treated 
with misonidazole, led Varghese & Whitmore (1984a) to suggest that 
n itro reduction  products such as the hydroxylam ine species and 
glyoxal (see Fig. 1.4 and 1.5), may be involved in neurotoxicity.
Generally, metabolism is the major elimination m echanism  for 
lipophilic nitroimidazoles whereas renal clearance predom inates for 
m ore hydrophilic  analogues and m etabolites (W orkm an, 1983b; 
Workman & Brown, 1981). It is therefore not unexpected to find that 
m isonidazole exhibits non-linear elimination kinetics, whereas more 
hydrophilic analogues such as desmethylmisonidazole exhibits linear 
kinetics (W orkman, 1980). In spite of these differences, tumour 
concentrations of 2-nitroimidazoles appear not to vary markedly. For 
instance, the tum our concentrations of neutra l (un-ion ised) N -l 
substituted 2-nitroimidazoles consistently averages around 70-100% 
of circulating concentration (Brown & W orkman, 1980; W orkman, 
1983b; Workman & Brown, 1981).
The structural features of SR-4554 as a potential MRS hypoxia 
probe are unique, in that apart from  the p resence  o f  three 
m agnetically equivalent fluorine atoms, the compound has also been 
designed to include an amide side chain similar to etanidazole. This 
feature was incorporated with the expectation that it would reduce 
nervous tissue penetration and exposure in a similar way to that seen 
with etanidazole, thereby reducing toxicity. This chapter therefore
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looks at the toxicity (or tolerability) and the pharmacokinetics of SR- 
4554 in mice to assess the effect of the trifluoromethyl (lipophilic) 
and amide (hydrophilic) functions. These studies would also aid in 
modelling MRS/MRI protocols for SR-4554 in animals and in man.
5 .2  MATERIALS AND METHODS
5 . 2 . 1  C hem icals  and reagents
SR-4554 and etanidazole  (SR-2508) were syn thesized  and 
supplied by SRI international, Menlo Park, CA, USA. Misonidazole (Ro 
07-0582), desm ethylm isonidazole (Ro 05-9963), f luorom isonidazole  
(Ro 07-0741), Ro 07-2044, e thylm isonidazole (Ro 07-0913), and 
chloromisonidazole (Ro 07-0269) were obtained from Roche products, 
Welwyn Garden City, Herts, UK. CCI-103F was obtained from Dr J. 
Raleigh, Cross Cancer Institute, Edmonton, Canada. The structures of 
these compounds are shown in Fig. 1.3. The com pounds were 
assessed  for chrom atographic  purity  and used w ithou t fu rther 
purification. All other reagents and chemicals used were of analytical 
or HPLC grade.
For the preparation of dose solutions used in this chapter, SR- 
4554 was weighed and dissolved in warm (50°C) saline to a final 
concentration of between 2.7 and 6.5 mg/ml. In all studies, dose 
solutions were prepared just  before use. Quality control of dose 
solutions was carried out by taking samples from dose solutions 
before and after the experiments and freezing them at -70°C. The 
exact concentrations of the dose solutions were then verified by direct 
HPLC analysis.
5 . 2 . 2  E xp er im en ta l  an im als  and tum ou r  im p la n ta t io n
Female Balb/c mice (6-9 weeks old) were obtained from Harlan 
Olac Ltd., UK and were allowed laboratory chow and water ad libitum. 
The mouse mammary tumour line EMT6 was obtained from Dr P.R. 
Twentym an (MRC Clinical Oncology and R adio therapeutics unit, 
Cambridge, UK) and cultured as a monolayer according to the methods 
of Twentym ann et al. (1986). The cells were trypsinized, washed 
with culture medium, and resuspended in phosphate buffered saline 
(PBS) ju s t  before use. Fem ale Balb/c m ice were inoculated  
in traderm ally  in the right flank with 10^ cells in 0.1 ml PBS. 
Tumours were used when they reached between 100 and 200 mm^.
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5 . 2 . 3  Parti t ion  coeff ic ient  o f  SR-4554
The partition coefficient of SR-4554, together with misonidazole 
and e ta n id a zo le ,  were d e te rm ined  sp e c t ro p h o to m e tr ic a l ly  as 
previously described by Yang et al. (1995) in order to establish the 
relative affinity for lipid vs aqueous environments prior to toxicity 
and pharmacokinetic studies. Partition coefficients were determined 
at room temperature by shaking solutions of the various compounds 
(0.1, 0.2, and 0.5 mM) in 50 ml 1-octanol with 150 ml distilled water 
for 3 min. The phases were separated by centrifugation (2000 x  g 
for 30 min) and the partition coefficients were determined from the 
amount of compound remaining in the aqueous phase (concentration 
in non-aqueous phase by difference). Sample blanks were prepared
by using the same volumes of 1-octanol and distilled water as test
samples. The spectrophotometric assay was carried out at 324 nm in
a L am b d a  2 sp e c tro p h o to m e te r  (P e rk in -E lm e r ,  U e b e r l in g e n ,  
Germany). Partition coefficient of each compound was determined in 
triplicate and the mean and standard deviations calculated.
As an alternative  means of com paring the l ipoph ilic  vs
hydrophilic character of 2-nitroimidazoles, the retardation of a series 
of 2 -n itro im idazo les  (SR-4554, m isonidazo le  ch lo rom ison idazo le , 
e tanidazole, desm ethylmisonidazole, ethylm isonidazole, Ro 07-2044, 
fluoromisonidazole and CCI-103F) on a Cis column were evaluated. 
All samples (10 |ig/ml) except CCI-103F were analysed individually 
and then together using the same conditions as described in section 
2.2.7. To allow comparison with the other 2-nitroimidazoles, CCI- 
103F (10 pg/ml) was analysed together with chloromisonidazole (Ro 
07-0269) using a mobile phase consisting of 25% acetonitrile, 5 mM 
octane sulphonic acid and 0.2 M glycine/HCl buffer (pH 2.5). The 
mobile phase was delivered isocratically at a flow rate of 3 ml/min 
and analytes monitored by UV photodiode detection at 324 nm. The 
ratio of the time the analyte spends in the stationary phase to the 
time in the mobile phase, expressed as the capacity factor (k) for the 
various 2-nitroimidazoles was calculated using the equation below 
(Davidson, 1988):
k  =  ( t R - t o ) / t o
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where tR and to are the retention and void times respectively.
5 . 2 . 4  T o x ic i ty  s tudies
Initially this study was designed to establish the lethal dose 
which would kill 50% (LD50) or 10% (LD10) of mice. Due to the limited 
solubility of SR-4554 in saline (maximum solubility in saline = 6.5 
m g/m l), however, only a limited study could be carried out to 
determine the tolerability of SR-4554 at selected doses. SR-4554 was 
adm inistered  in four different schedules to non-tum our bearing 
Balb/c mice. In the first schedule, SR-4554 (3.82 m g/m l) was 
administered as a short (30 sec) i.v. infusion through the tail vein at a 
dose of 191 mg/kg (0.05 ml/g). In the second schedule, SR-4554 
(3.82 mg/ml) was administered i.p. at a dose of 382 mg/kg (0.1 ml/g). 
In the third and fourth schedules, SR-4554 (6.5 mg/ml; maximum 
solubility) was administered i.p. at a dose of 650 mg/kg (0.1 ml/g) 
and 1300 mg/kg (two dose of 0.1 ml/g separated by 30 min) 
re sp ec t iv e ly .
With each dose schedule two mice were treated with drug and 
two mice received an equivalent volume of 0.9% saline. Mice were
weighed and observed immediately after treatm ent and then daily 
for 23 days.
5 . 2 . 5  P lasm a and t issue p h a rm a co k in et ic  stud ies
To study the plasma and tissue pharmacokinetics of SR-4554 in 
mice, the drug solution (2.7 mg/ml) was administered as a single i.p. 
injection of 162 mg/kg body weight (0.06 ml/g) to mice bearing the 
EM T6 tumour. Control mice received 0.9% saline alone. Mice were 
sacrificed at 5, 10, 15, 30, 45, 60, 90, 120, 240, and 360 min following 
i.p. injection of the drug. Three mice per time point were used and 
w hole b lood was rem oved under e ther anaesthes ia  by cardiac 
p u n c tu re  in to  herparin ised  tubes. P lasm a was o b ta ined  by 
centrifugation (3000 x  g for 5 min). Tumour, liver, and brain tissue 
were excised from each mouse into pre-weighed plastic vials. All 
samples were immediately frozen using solid CO2 and stored at -70°C 
prior to analysis.
To allow comparison of pharm acokinetic  studies with MR- 
experiments, the plasma and tumour pharm acokinetics of SR-4554 
were repeated at 180 mg/kg (3 mg/ml; 0.06 ml/g). In these studies,
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livers and brains were also excised and frozen at 5, 45, 120 and 360 
min. In addition to this, a limited sampling (3 mice per time point at 
5, 120 and 360 min) plasma pharmacokinetic study was carried out at
a dose of 337 mg/kg (5.62 mg/ml; 0.06 ml/g) in EMT6 tumour
bearing female Balb/c mice to enable a dose response model for SR- 
4554 to be established.
Prior to the determination of SR-4554 concentration in plasma 
samples, the samples were thawed and aliquots (250 p i)  extracted 
together with a fresh calibration standard. Sam ples were then 
analysed by HPLC as previously described (section 2.2.6 and 2.2.7). 
Tissue samples were also thawed and homogenized (10%) in 0.1 M 
Tris-HCl buffer. Aliquots (250 jil) of the samples and fresh calibration 
standards prepared in untreated tissue homogenates were extracted 
and analysed by HPLC as previously described (section 2.2.6 and 
2.2.7). All samples from mice were analysed individually to enable 
the assessment of variability.
5 . 2 . 6  B i o a v a i l a b i l i ty  s tu d ie s
In order to assess the bioavailability of SR-4554 and to allow 
comparison with other 2-nitroimidazoles such as m isonidazole and 
etanidazole, the drug was administered to non-tumour bearing female
Balb/c mice at a dose of 90 mg/kg body weight via the i.v. (tail vein),
i.p. and p.o. (oral) routes. This lower dose was chosen due to 
solubility and volume constraints with the formulation and route of 
administration of the compound. Again three mice per time point 
were used and the drug was administered as 0.02 ml/g body weight 
(4.5 mg/ml) for i.p. and i.v. routes and 0.0138 ml/g body weight (6.5 
m g/m l) for the oral route. Plasma samples were collected and 
prepared as above prior to analysis.
5 . 2 . 7  E l im in a t io n  o f  SR -4554
To assess the route and extent of drug elimination, SR-4554 was 
injected as a single i.p. dose of 180 mg/kg (3 mg/ml; 0.06 ml/g) to 
n o n - tu m o u r  bear ing  fem ale  B a lb /c  m ice . F o l lo w in g  the 
administration of SR-4554, mice were housed in m etabolic  cages 
(Metabowl Mark III; Jencons Scientific Ltd, Leighton Buzzard, UK) for 
24 hr. They were allowed laboratory chow and water ad  libitum  
during this period. The total urinary volume over 24 hr was
5 6
measured and aliquots stored at -70°C prior to analysis. Faecal pellets 
obtained from the same mice were weighed and stored at the same 
t e m p e ra tu re .
For the analysis of SR-4554 concentration, urine samples were 
thawed and diluted (125 fold) in 0.1 M Tris-HCl buffer (pH 7.4). The 
samples were then clarified by centrifugation (3000 x  g ) for 10 min 
and aliquots (50 p i)  of the supernatant analysed directly by HPLC. 
Faecal pellets from individual mice were thawed and prepared as 10% 
homogenates in 0.1 M Tris-HCl buffer (pH 7.4) followed by agitation 
on a shaker for 2 hr. The samples were then extracted with an equal 
volume of methanol and centrifuged (3000 x  g)  for 10 min. Aliquots 
(50 pi) of the extracts were subsequently analysed by HPLC.
5 . 2 . 8  P h a r m a c o k i n e t i c  a n a ly s e s
Pharm acokinetic  param eters were determ ined by fitting  the 
data using a computer generated iterative least square regression 
p rogram m e with appropria te  w eighting  fu nc tions  (A D A PT II) 
(D ’Argenio & Schumitzky, 1979). Following i.v. administration, drug 
concentrations fitted a two compartment (bi-exponential) open model 
(D’Argenio & Schumitzky, 1979):
Ct =[D(a - Kpc)/Vdl(a - p)]<? ’at + [D(Kpc - p )/Vdl(a - P)]e -P*
All other data fitted a one compartment (m ono-exponential) open 
m odel:
Ct = [FDKa/Vd(Ka-Ke)] (e -Ket. e -Kat)
where Ct is the plasma or tissue concentration at time t, D is the dose 
administered, F is the fraction of dose absorbed, Vd and Vdl are the 
volume of d istribution  and volume of the cen tra l com partm ent 
respectively, the constants Ka, Ke, Kpc, a  and p are absorption rate 
constant, elimination rate constant, peripheral to central compartment 
m icroconstan t,  d istr ibu tion  rate constan t and the term ina l rate 
constant respectively. The half life (tl/2), clearance (CL) and central 
to peripheral m icroconstant Kcp were also estim ated using these 
m odels.
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The area under the concentration time curve (AUC) was derived 
using the trapezoidal rule (Curvfit: L. Hart Institute  of Cancer
Research, Sutton, Surrey, UK) and extrapolated to infinity using the 
elimination rate constant:
A U C (tiast- °°) = Qast/P
where Ciast is the final concentration of SR-4554 measured at time 
t iast- The bioavailability F, from an extravascular (ex) dose was 
determined as follows:
F = AUC(ex) x Dose(i.v>)/AUC(i.v.) x Dose(ex)
T he o p t im a l  sam p ling  t im es u sed  fo r  the  p la sm a
pharm acokinetic  study were generated using ADAPT. Bayesian 
parameter estimates of Vd, Ke, and Ka were also derived using ADAPT. 
The coefficient of variation in the model param eter estim ates was 
fixed at 50%. The model dependent AUC in this case was derived as 
follows:
AUC(o-oo) = Dose/CL
The amount of SR-4554 excreted unchanged in the urine was 
calculated as a percentage of the dose administered to each mouse.
5 . 2 . 9  P la s m a  p r o te in  b in d in g  s tu d ie s
The in vitro mouse and human plasma protein binding of SR- 
4554 was studied by centrifugal ultrafiltration, using two different
protocols. In the first protocol, fresh female Balb/c mouse plasma and 
human plasma (from healthy volunteers) were spiked with stock 
solutions of SR-4554 (2 mg/ml) in 0.1 M Tris-HCl buffer (pH 7.4) to 
give 1, 50 and 150 pg/ml at room temperature (25°C). To assess non­
specific binding, SR-4554 standards were prepared at the same 
concentrations in buffer.
P lasm a pro tein  binding was m easured  using an Am icon
m icropartition system, MPS1 (Amicon Div., W .R. Grace and Co,
Danvers, MA, USA) with a cut-off of 30,000. For the separation of 
free and protein bound microsolute, all samples were centrifuged
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using fixed angle rotor (3000 x  g for 15 min) at 20°C. The samples 
were then directly analysed by HPLC (section 2.2.7). The percentage 
of protein bound SR-4554 was assessed by comparing the peak area 
of the plasma peak to that of unfiltered standard. Correction for non­
specific binding was made by comparing filtered and un-filtered 
standards. Four samples were determined at each concentration.
To allow comparison with other 2-nitroimidazoles, in the second 
protocol, the procedure was repeated for SR-4554 and misonidazole at 
30 |ig /m l. The method was, however, m odified to include the 
incubation of samples in a water bath at 37°C for 1 hr prior to 
ultrafiltration (Workman & Brown, 1981).
5 .3  RESULTS
5 . 3 . 1  P ar t i t io n  c o e f f ic ien t  stud ies
The partition coefficients (Poet) of SR-4554, misonidazole (Ro 07- 
0 5 2 8 )  and  e t a n id a z o le  (S R -2 5 0 8 )  as d e te r m in e d  by 
spectrophotometric assay (mean ± s.d.) were 0.65 ± 0.10, 0.41 ± 0.10, 
0.048 ± 0.01 respectively.
The chromatographic retardation of a series of 2-nitroimidazoles 
on a C i8 column is illustrated in Fig. 5.1. Fig. 5.2 shows that a plot of 
log k vs log P (the latter derived from both this study and from 
literature values (Brown & Workman, 1980; Raleigh et a l .y 1991a; 
Rauth et a l ., 1978)) was linear, i.e. the higher the partition coefficient 
(Poet), the higher the capacity factor (k) or retardation. Importantly, 
however, even though P oct of SR-4554 was higher than that of 
misonidazole, the k (or log k) of SR-4554 was actually lower than that 
of misonidazole (Ro 07-0582).
5 . 3 . 2  T o x ic i ty  s tudies
The pilot dose ranging studies of SR-4554 in non-tum our 
bearing mice showed than SR-4554 was non-toxic up to a dose of 
1300 mg/kg (Fig. 5.3). No deaths or significant change in body weight 
(as a percentage of day 1) were observed in both drug treated mice 
and saline controls at the four selected doses (Mann Whitney test; 95 
confidence level). In addition, no visual changes (neurological, 
gastro in tes tina l,  perform ance status, hair charac te ris tics , feeding 
status, lacrymation, urine colouration) or abnormal anatomical status 
at day 23 were observed.
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Fig. 5.1. HPLC retardation of a series of 2-nitroimidazoles (10 |j,g/ml) 
on a C i 8 column. Analytes were eluted with either 15% methanol- 
water (top chromatogram) or 25% acetonitrile-5 mM octane sulphonic 
acid-0.2 M glycine/HCl buffer (pH 2.5) (bottom chromatogram), and 
monitored by UV detection at 324 nm.
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Fig. 5.3. Pilot toxicity studies with SR-4554. Non-tumour bearing 
female Balb/c mice were injected with saline or SR-4554 and their 
body weight monitored daily. The mean body weight as a percentage 
of day 1 from two mice per dose level (191 mg/kg i.v.; 382, 650, 1300 
mg/kg i.p.) are presented.
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5 . 3 . 3  P h a r m a c o k i n e t i c  s tu d i e s
The pharmacokinetics and tissue distribution properties of SR- 
4554 were examined in the mouse. Plasma, tumour, liver, brain, 
urine and faecal samples were extracted and analysed by HPLC. Fig
5.4 shows typical chromatograms of extracts obtained  from  the 
plasma of control and drug treated mice. No UV-visible metabolites 
were observed on the analysis of all samples analysed by HPLC.
The plasma pharmacokinetics of SR-4554 in tum our bearing 
female Balb/c mice at a dose of 162 mg/kg fitted a one compartment 
open model (Fig. 5.5; Table 5.1). The drug was rapidly absorbed with 
a tmax and Cmax of 15 min and 93 pg/ml respectively. SR-4554 was 
eliminated thereafter with plasma drug levels near the MQL at 6 hr 
post-injection. The biodistribution of SR-4554 at the same dose in 
tumour, liver and brain is illustrated in Fig. 5.6. The drug- 
concentration vs time profile also fitted a one com partm ent open 
model. SR-4554 was eliminated from these tissues by 4 hr post­
injection. The pharmacokinetic parameters obtained from  this study 
are presented in Table 5.1. The table shows that SR-4554 was rapidly 
absorbed into the liver ( t max = 10 min; C m ax = 46 pg /m l), but less 
rapidly into tumour (tmax = 30 min; Cmax = 64 pg/ml) and brain ( tmax =  
45 min; Cmax = 6 pg/ml). Relevant to the potential toxicity of SR-4554, 
the level of drug in the brain remained generally low. Tissue to 
plasma ratios are illustrated in Fig. 5.7. Expectedly, the exposure of 
the drug to brain tissue ( A U C )  was also low compared to that of 
plasma, tumour and liver. Tissue to plasma exposure ratios over the 
entire time course were calculated from the AUCs, and were found to 
be 0.84, 0 .35, and 0.07 for tumour, l iver and brain  tissues 
respectively. The ratio A U C b r a in / A U C tum0ur which serves as a measure 
of the relationship between toxicity and MR detection sensitivity of 
the drug was determined to be very low (0.08), indicating a low CNS 
level relative to tumour.
The plasma and tissue pharmacokinetics of SR-4554 at 180 and 
337 mg/kg showed similar profiles as above. The pharmacokinetic 
parameters generated using ADAPT are presented in Table 5.2. The 
AUCs at the above doses together with that at 90 mg/kg (see section 
5.3.4) were used to derive the relationship between SR-4554 dose
6 0
Fig. 5.4. Typical chromatograms of plasma extracts obtained from 
(a) control, and (b) SR-4554 treated mice. Plasma samples were 
extracted using a C is  solid-phase cartridge and analysed by HPLC as 
described in chapter 2.
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Fig. 5.5. Plasma pharmacokinetics of SR-4554 at 162 mg/kg body 
weight in EMT6 tumour bearing female Balb/c mice. Three mice were 
used at each time point and the data was modelled using ADAPT as 
described in section 5.2.8.
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Fig. 5.6. Biodistribution of SR-4554 (162 mg/kg) in tumour ( □  ), 
liver (O ) and brain (A) of tumour bearing mice. The tissues were 
prepared as 10% homogenates in buffer prior to analysis by HPLC. 
Mean values from three mice per time point are presented.
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Fig. 5.7. Tissue to plasma ratio of SR-4554 as a function of time 
following a 162 mg/kg i.p. injection.
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and AUC (Fig.5.8). SR-4554 showed linear pharmacokinetics from 90
mg/kg up to 337 mg/kg body weight.
5 . 3 . 4  B io a v a i la b i l i t y  s tu d ies
The b io av a ilab il i ty  of SR -4554 by d if fe re n t  rou tes  of 
adm inistration was studied in non-tumour bearing fem ale  Balb/c 
mice at a dose of 90 mg/kg. The plasma drug-concentration vs time 
profiles for i.v., i.p., and p.o. routes are shown in Fig. 5.9. 
Pharm aco k ine tic  param eters  generated  from  these  m odels  are 
presented in Table 5.3. Administration of SR-4554 by the i.v. route 
gave very high peak plasma levels (Fig. 5.9) comparable to the i.p. 
administration at 162 mg/kg and fitted a two com partm ent open 
model. The i.p. and p.o. routes, however, fitted a one compartment 
open model and gave lower peak plasma concentrations compared to 
the i.v. route. The bioavailability of SR-4554 from the i.p. and p.o. 
routes was calculated to be 100% and 96% respectively.
5 . 3 . 5  E l im ination of  SR-4554
Analysis of faecal pellets from non-tumour bearing mice treated 
with 180 m g/kg of SR-4554 showed no drug or U V -visib le  
metabolites. SR-4554 was, however, excreted in the urine. Table 5.4 
shows that between 53 and 76% (mean ± s.d. of 68 ± 8%; n = 7) of SR- 
4554 was excreted unchanged in urine collected over 24 hr. Absence 
of radiolabelled SR-4554 precluded a definitive mass balance study 
being performed.
5 . 3 . 6  P lasm a prote in  binding studies
The binding of SR-4554 to plasma proteins was found to be low 
(Table 5.5). Plasma protein binding of SR-4554 and misonidazole 
were found to be higher in mouse compared to human plasma. In 
particular, human plasma protein binding was less than 5% in all 
cases. The results also indicate that at 30 pg/ml, SR-4554 was bound 
to a lesser extent compared to misonidazole. Plasma binding of SR- 
4554 was also higher at 1 |ig/ml compared to 50 and 150 p g /m l .
5 .4  DISCUSSION
SR-4554 was rationally designed to have both low toxicity and 
high sensitivity for detection by MRS. Of particu lar note, the
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Fig. 5.8. Linear relationship between i.p. dose of SR-4554 injected 
and the corresponding area under the concentration vs time curve 
AUC in female Balb/c mice (r = 0.99). All AUC's were obtained using 
the Trapezoidal rule except for the highest dose which was calculated 
from the ratio of dose to clearance.
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Fig . 5 .9 . Intravenous (i.v.; □  ), intraperitoneal ( i .p . ;0 )  and oral 
(p.o.;A) plasma pharmacokinetics of SR-4554 (at 90 mg/kg) in female 
Balb/c mice. Mean values from three mice per time point are 
presented. The bioavailabilities following i.p. and p.o. routes were 
calculated from the AUC of these curves.
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Table 5.4 Urinary excretion of SR-4554 in non-tumour 
bearing female Balb/c mice.
M ouse Total SR-4554 Dose 
(m g)
Total SR4554 
excreted (mg)
F(unc) 
(%)
1 3.6 2.6 73 .8
2 3.3 2.4 71 .6
3 3.5 1.8 52 .6
4 4.3 2 .6 61 .6
5 4 .0 3.0 76.1
6 4 .0 2.9 73 .4
7 4.1 2.6 64 .2
Results from 2 independent studies. The average amount of SR- 
4554 excreted unchanged in the urine ± s.d. was 68 ± 8 %.
F(unc) is the fraction of SR-4554 excreted unchanged in the urine 
as a percentage of the amount injected.
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compound was designed to contain an amide side chain similar to 
etanidazole. It was anticipated that the hydrophilic character and 
hydrogen bonding capability introduced by the amide and hydroxyl 
functions should discourage penetration into the nervous system and 
reduce the risk of neurotoxicity. However, the Poct value of SR-4554 
determined in this chapter (0.65), as well as that reported by SRI 
International who supplied the compound (0.63), were found to be 
higher than that of both etanidazole (0.048) and misonidazole (0.41) 
(reported in this study and elsewhere (Brown & W orkm an, 1980; 
Rauth et a l ., 1978)). Thus in apparent contrast to the design 
specifications, these predictions of overall lipophilic character would 
suggest that SR-4554 can penetrate the nervous system, if anything, 
to a greater extent than either misonidazole or etanidazole. In 
contrast to the prediction from the Poct measurements, however, the 
retardation (k) of SR-4554 was lower than that of misonidazole on a 
C ig/methanol-water system. The interpretation of this latter finding 
is that SR-4554 may actually exhibit less lipophilic character than 
misonidazole, contradicting the Poct data.
Dose ranging studies with SR-4554 showed that SR-4554 was 
non-toxic up to a dose of 1300 mg/kg. Further studies to determine 
the true LD50 or L D 10 of this compound in saline may be limited by its 
low solubility (maximum solubility in saline = 6.5 mg/ml), and future 
experiments would need to explore ways of increasing the solubility 
of the drug to enable the administration of higher doses. Despite the 
absence of toxicity, the doses used in these studies are relatively high 
and readily facilitates the detection of SR-4554 in both plasma and 
tissue by HPLC and 19p MRS (see chapter 6).
Using an HPLC assay developed in this thesis (section 2.2.6 and 
2.2.7), plasma and tissue samples obtained from both tumour and 
non-tumour bearing mice treated with SR-4554 were analysed. No 
m etabolites were observed when both plasm a and tissue samples 
were analysed by this method. The detection of metabolites by NMR 
(see chapter 3) but not HPLC therefore illustrates the limitation of the 
UV detection technique, a situation which may be addressed when 
radio-labelled SR-4554 becomes available. It is unlikely that this 
HPLC assay will detect bioreduced metabolites, since such metabolites 
would have lost the nitro moiety responsible for the characteristic UV 
a b so rp t io n  p ro p e r t ie s  o f  2 -n i tro im id a z o le s .  C o m p a re d  to
6 2
misonidazole, however, the data indicate the relative stability of the 
amide group of SR-4554 (Flockhart et al., 1978b; W orkman et a l ., 
1978). This is important to the development of SR-4554 as a probe 
for tumour hypoxia by MRS since it is important that fluorine atoms 
are retained.
The plasma and tumour pharm acokinetics of SR-4554 were 
found to deviate from the trend shown by most 2-nitroimidazoles in 
comparison to their lipophilicities as measured by Poct (Brown & 
W orkman, 1980; Workman, 1982; W orkman & Brown, 1981). For 
instance, compared with misonidazole (Table 5.6), SR-4554 has a 
shorter plasma half-life and lower AUC at similar doses in spite of its 
higher Poct. Tumour SR-4554 concentrations generally followed that 
of plasma giving tumour to plasma ratios which increased with time 
until approximately 30 min post injection and varied less markedly 
afterwards. The tumour to plasma ratios of SR-4554 (between 30 and 
120 min post injection) were found to vary between 0.86 and 1.27. 
In general, most 2-nitroimidazoles have a tumour to plasma ratio at 
these time points of between 0.7 and 100 (Brown & Workman, 1980; 
Workman, 1982; Workman & Brown, 1981). The data obtained with 
SR-4554 (Fig. 5.7) is therefore consistent with previous studies. 
Following i.p. injection, the drug was also absorbed quickly into the 
liver but cleared rapidly suggesting a high metabolic activity in the 
liver. This may be explained at least in part by the high levels of 
reductive enzymes and consequent bioreductive m etabolism  of SR- 
4554 by liver as described in chapter 3.
The m ost unexpec ted  and in te res tin g  p ro p e r ty  of this 
compound, however, was the low brain levels and the consequent low 
brain to plasma and brain to tumour ratios observed. Brown & 
W orkman (1980) have previously showed that 2-nitroimidazoles with 
a Poct of greater than 0.41 have a brain to p lasm a ratio  of 
approximately 0.9 to 1.0. The very low brain to plasma ratio of SR- 
4554 observed in this study is therefore characteristic of the more 
hydrophilic 2-nitroimidazoles such as etanidazole (P0ct = 0.048). This 
unique property may be due to the additional hydrophilic character 
and hydrogen bonding capability of the amide group in SR-4554. The 
fact that hydrogen bonding may play a role is supported by the HPLC 
re ta rda tion  (k) studies which indicated tha t SR -4554 is more 
hydrophilic than m isonidazole. Additional supportive evidence is
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prov ided  by m olecu lar m odels of SR-4554, m ison idazo le  and 
etanidazole (Appendix B). The similarity of SR-4554 to etanidazole, 
but not lipid-soluble structures such as in misonidazole, implies that 
stabilisation of the acetamide side chain in SR-4554 by hydrogen 
bonding, may result in its slower uptake across lipophilic blood brain 
barrier compared to misonidazole (Dabrow et a l ., 1993; W orkman, 
1982). For instance, Dabrow et al. (1993) reported the presence of 
in term olecular hydrogen bonding between the amide nitrogen and 
the terminal hydroxyl group, as well as between the carboxy group 
and the terminal hydroxyl group in etanidazole. In contrast, no 
hydrogen bonding was seen with misonidazole (Dabrow et al ., 1993).
Although a correlation between brain to p lasm a ratio  and 
toxicity of some fluorinated 2-nitroimidazoles have been previously 
reported (Kagiya et al., 1992), the authors in this study attributed this 
trend to the introduction of the fluorine group. This is an unlikely 
explanation, however, since the fluorinated 2-nitroim idazoles which 
showed low brain to plasma ratios in that particular study also had 
amide side chains. In addition to these studies, physiological models 
(based on permeability rate-limited distribution of drug into brain) 
correctly  pred ic t m isonidazole brain concentra tions and gives a 
reasonable fit to etanidazole brain data, but not to that of SR-4554 
(unpublished report, Zeneca Pharmaceuticals, Macclesfield, UK). These 
discrepancies suggest that P oct is not a good model for predicting 
brain penetration of SR-4554. The inability  of P oct to predict 
compound entry into brain has also been observed in a series of 
centrally  acting H2 receptor histamine antagonists (Young et al.,
1988). To shed further light on this, it would be interesting to use
other model solvent systems such as propylene glycol dipelargonate 
(PGDP) due to the differing balance of p ro ton  donor/accep to r 
properties which these alternative solvents show (Leahy et al., 1989).
B io av a ilab il i ty  studies ind icated  that SR -4554 is a lm ost
com plete ly  absorbed following i.p. and oral adm in istra tion . In 
addition, the absence of any significant variation in absorption rate
co n s tan t  (Ka) at high doses of SR-4554, suggests that the high 
bioavailability may still be the case for SR-4554 at higher doses. 
Previous studies with a series of 2-nitroimidazoles (P0ct = 0.01-1.0) in 
dogs showed that whereas lipophilic 2-nitroim idazoles tend to be 
rapidly and completely absorbed following oral administration, the
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hydrophilic analogues including etanidazole in general display lower 
bioavailability (White et al.y 1980). The data obtained with SR-4554 
in this chapter, therefore compares well with that of o ther 2- 
nitroimidazoles with similar lipophilicities confirming the observation 
that absorption of 2-nitroimidazoles from an extravascular dose is 
largely a function of lipophilicity, i.e. Poct is a good indicator for 
nitroimidazole bioavailability. The reason why Poct appears to predict 
well for the oral bioavailability of SR-4554 but poorly for the uptake 
into brain is not clear. This unusual balance of properties is, however, 
favourable with respect to the potential clinical use of the compound 
as an MRS hypoxia probe.
Another property of SR-4554 which could not be predicted by 
P oct is urinary excretion. A high percentage of the administered dose 
of SR-4554 was excreted unchanged in the urine (68 ± 8%). This 
together with the absence of metabolites such as glucuronides is a 
property characteristic of more hydrophilic 2-nitroimidazoles such as 
etanidazole (Workman & Brown, 1981). Thus in this respect, the 
urinary excretion is more in keeping with the low brain levels than 
the high oral bioavailability.
SR-4554 does not bind extensively to plasma proteins. The
studies showed that the binding of SR-4554 and m isonidazole to 
mouse plasma were' low at biologically relevant concentrations and 
temperatures (5.3 and 19.9% respectively). As expected, binding to 
human plasma was significantly less than to mouse plasma (Mann
Whitney 95% confidence level), e.g. 1.5 and 2.3% at 37°C for SR-4554 
and m iso n id azo le  resp ec tiv e ly . The low er b in d in g  of 2- 
n itro im idazoles of varying lipophilicities to human, com pared to 
mouse, plasma has previously been reported (W orkman & Brown,
1981). Importantly, this may be relevant in helping to predict human 
doses of SR-4554 from mouse data. Based on the results in this
chapter, however, it can be inferred that although, protein binding is 
of minor significance in determining the biological properties of SR- 
4554, it could not be predicted from Poct.
SR-4554 was designed to have low toxicity by increasing its 
hydrophilic character. It has been shown in this chapter that the 
reduction in brain drug levels is greater than could be predicted by 
pre-existing trends. In this particular respect and in terms of its high 
oral bioavailability, linear kinetics, relatively short plasma half-life,
65
high urinary excretion and lower protein binding, SR-4554 is ideal for 
MRS/MRI studies in animal and human tumours.
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CHAPTER 6
I n  v i v o  magnetic resonance spectroscopy and 
imaging of SR-4554
6 .1  INTRODUCTION
As described in sections 1.4 and 1.5, by means of a variety of 
detection techniques, 2-nitroimidazole probes can be em ployed to 
measure hypoxia within tumours on a cell to cell basis and when 
labelled appropriately can allow non-invasive detection to be carried 
out. For instance, the labelling of 2-nitroimidazoles with the naturally 
occurring, stable isotope of fluorine (1 ^F) enables the detection of the 
compounds by magnetic resonance spectroscopy (MRS) and imaging 
(MRI) techniques. This detection technique for tumour hypoxia has 
been encouraged by the availability and use of MR facilities in many 
hospitals throughout Europe and America. is suitable for MRS
and MRI studies because it has a spin of j  , low background signal in
v iv o , high natural abundance (100%), and a relatively high sensitivity 
for detection (0.83 relative to protons).
As mentioned in sections 1.4 and 1.5, 2-nitro im idazoles are 
red u c ed  by c e l lu la r  red u c tases  under h y p o x ia  to rea c t iv e  
in te rm e d ia te s  w hich fo rm  adducts w ith c e l lu la r  com po nen ts  
(Chapman et a l ., 1983; Urtasun et al., 1986b; W alton & W orkman, 
1987). Since the adducts are cleared at a slower rate compared to the 
original 2-nitroimidazole, it was envisaged that the degree of hypoxia 
in tumours could be assessed by the injection of 2-nitroim idazole 
probes followed by m easurem ent of residual (m etabolised) probe 
after the 'washout' of the original compound (Chapman, 1984). The 
low concentration of bound adducts generated in tumours, however, 
means that generally only probes with multiple fluorine substitution 
or which can be given in relatively high doses (in the order of 0.1 
m m ol/kg /m agnetica lly  equivalent fluorine atom) are su itable  for 
M RS/M RI studies (Workman et al., 1992). Other important design 
criteria  for these probes include their chem ical/biological stability 
(o ther than b ioreduction), pharm acok inetic /tox ic ity  considera tions 
(see chapter 5), and oxygen dependence of binding. In addition to 
these considerations, the signal attenuation due to m acrom olecular 
binding and its influence on the stoichiometry of the retention of
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these com pounds is relevant to the quantitation  of hypoxia  in 
tu m o u rs .
Pioneering research in the use of MRS as a detection
technique, has employed the 2-nitroimidazole probes Ro -07-0741 
and CCI-103F (Fig. 1.3). For instance, using 19p MRS as a detection 
technique, the selective retention of the fluorinated 2-nitroimidazole 
probes, Ro 07-0741 and CCI-103F in mouse tum ours with high 
radiobiological hypoxic fraction (EMT6 and KHT) has been reported 
(M axwell et al., 1988). In the same study, less dramatic residual 19p 
signals were observed from RIF-1 tumours, a tumour model with low 
hypoxic fraction. By means of a i H / l ^ F  technique, Jin e t  al. (1990) 
confirm ed the selective retention of CCI-103F in m ouse tumours 
compared to normal tissues. This study also showed that the both the 
half-life of CCI-103F, as well as the amount retained after 4 hr in 
tum ours were higher in hypoxic SCCVII tumours than in RIF-1 
tumours. Other workers have reported the selective retention of CCI- 
103F in rat Dunning R3327 prostate adenocarcinomas and Walker- 
256 carcinosarcom as (Kwock et al ., 1992; Raleigh et a l ., 1991a). 
Parallel studies using CCI-103F immunostaining in Dunning prostate 
adenocarcinomas showed that the distribution of residual CCI-103F 
adducts correlated with the expected oxygen concentration gradients 
within the tumour (Kwock et al ., 1992).
Although Ro 07-0741 and CCI-103F have provided useful data 
in this field, the two compounds are not ideal as MRS markers for 
tumour hypoxia. Due to the presence of one 1 9 p  atom per drug 
molecule, high in vivo concentrations of Ro 07-0741 are required to 
enable its detection by MRS. CCI-103F, on the other hand, shows high 
sensitiv ity  for detection by MRS due to the p resence  of six 
m agnetically  equivalent 19p atoms. Initial comparative studies with 
com pound in EMT6 tumour bearing mice, however, revealed 
extensive loss of the fluorine label (Raleigh et a l ., 1986). The 
com pound has also been reported to have a high octanol/w ater 
partition coefficient of 20 (Raleigh et al., 1986), thus making it a 
potentially toxic compound.
With regard to the technical aspects of MRS detection, it is 
worth noting that, most of the methods reported so far for the study 
of selective retention of fluorinated 2-nitroimidazoles are based on 
relative 1 9 p  probe levels rather than absolute concentrations of the
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1 9 f  probes (Kwock et al ., 1992; Maxwell et al., 1988). This is due to 
the intrinsic difficulty in defining parameters such as the observation 
volume, magnetic field inhomogeneities and coil loading. Initial 
studies by Thulborn and Ackerman (1983), however, showed that by 
means of multi-tuned circuits, it was possible to obtain absolute 
metabolite concentration by using signal from water as an internal
intensity reference standard. This method relies on the mapping of 
the sample volumes of two (or more) nuclides when saturation effects 
are set equal, so as to define, in effect, the observation volume of in  
vivo  MRS experiments. Under these conditions, if the concentration of 
one of the nuclides is constant (e.g., in water is ~ 111 M), the ratio
of the signal intensities observed for the two nuclides (e.g., X -n u c l id e  
in drug to signal in water) provides a measure of the concentration 
of X-nuclide which is independent of the sample volume for a given 
coil. The dynamic range and spectral resolution limitations associated 
with lH  MRS at high static magnetic fields, however, led to the use of 
2 H as an internal intensity reference standard (Evelhoch et al., 1989; 
Shungu et al., 1992; Song et al., 1992). On the other hand, the 2 H 
nucleus has a relatively low sensitivity and a potential for line 
broadening due to quadrupolar relaxation. The relatively short T i 
relaxation times, however, allow for some recovery in the effective
sensitivity achievable per unit time since more rapid data averaging 
can be performed. This concept has been implemented in the non- 
invasive  m easurem ent of both the trideuterom ethyl analogue of 
m ison idazo le  (Evelhoch et al., 1989) and phosphorus m etabolites 
(Shungu et al., 1992; Song et al., 1992) in v ivo . In the study by
Evelhoch et al. (1989) this non-invasive technique was validated by
comparison with scintillation counting of misonidazole.
These factors have prompted the design of superior fluorinated 
2-nitroimidazole probes, as well as the application of the absolute
quantitation technique, for detecting and quantifying tumour hypoxia. 
Thus SR-4554 was rationally designed to have low toxicity (chapter 5) 
and enhanced sensitivity for non-invasive detection by MRS/MRI. It 
was also envisaged that this compound would have lower non-specific 
binding compared to misonidazole-based analogues (Koch, 1990; Koch 
et al., 1993). In this chapter a model based on the pharmacokinetics 
of unchanged drug (section 5.3.3), as well as the form ation of 
hypoxia-dependent adducts, is employed to quantify hypoxia present
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within tumours by MRS (Fig. 6.1). With regard to the technical 
aspects of the work, the concept of multi-tuned circuits has, for the 
first time, been extended to allow for the quantitation of signals
levels from SR-4554 in phantom studies, and in vivo  in mouse 
tumours. Due to the absence of an in vivo internal reference standard 
for fluorine, suitable external reference standards have been used to 
enable signal quantitation. The development of MRI techniques to 
visualise drug distribution and sites of bioreduction has also been 
investigated with SR-4554.
6 .2  MATERIALS AND METHODS
6 . 2 . 1  Chem icals  and reagents
The fluorinated 2-nitroimidazoles used in this chap ter have 
already been described (Fig. 1.3; section 5.2.1). Hypnorm (10 mg/ml 
fluanisone; 0.315 mg/ml fentanyl citrate) was obtained from Janssen 
Pharmaceutical Ltd., Oxford, UK. Hypnovel (5 mg/ml medazolam) was 
obtained from  Roche Products Ltd., W elwyn, UK. H ydralazine 
hydrochloride was obtained from Sigma, St. Louis, MO, USA. All other 
reagents were analytical or HPLC grade.
6 . 2 . 2  Exper im enta l  animals and tum ou r  m odels
The mice used in this chapter were obtained from Harlan Olac 
Ltd., Oxon, UK, and the Department of Experimental Clinical Oncology, 
University of Aarhus, Denmark. All mice weighed between 18 and 26 
g at the time of the experiments. Nude mice were specifically kept 
under pathogen-free conditions. Tumours used in this study were
grown subcutaneously as described in section 3.2.2 (Table 3.1), on the
flank of the various mice, except for the C3H mammary tumour, 
which was either grown on the flank or foot. Tumours ranged
between 200 and 600 mm3 at the time of experiment, except in 
studies to investigate the effect of tumour mass on l ^ F  retention (up 
to 1500 m m3).
6 . 2 . 3  Development of an MRS method for the absolute
quantitation of  I ^ F  levels
In order to obtain the absolute concentration of 1 si gnal  
levels following SR-4554 treatment in mice, a m ulti-tuned circuit
technique was developed and evaluated in vitro  in 1.6 cm diameter
7 0
Fig. 6.1. A model for studying hypoxia in tumours using 19p  MRS. 
The continuous line represent the absorption and d isposition of 
original drug, whilst the broken line represent total drug, a, b, c, d, 
and e represent increasing retention of reductive metabolite within 
the tumour.
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spherical glass phantoms. SR-4554 was accurately weighed and
dissolved in 0.1 M NaCl to give a concentration of 4 mM. Other
concentrations (2, 1, 0.5, 0.25, 0.152, and 0.0625) were prepared by 
serial dilution in 0.1 M NaCl. The concentrations of these standard 
solutions were determined by MRS in triplicate using a double tuned
(1 9 f /2 h ) circuit. Sample solutions were secured on a surface coil (1.7
cm diameter) in a 4.7 T MR-spectrometer (SISCO; Freemont, USA). A 
( -3 0  jil)  re ference  bulb contain ing  the ex ternal s tandards 5- 
Fluorotryptophan (5-FTP; Sigma, Dorset, UK) and Acetic acid-d (AcOH- 
d; Sigma) in DMSO was attached to the coil on the opposite side of the 
sample. ’Shimming’ was performed on the proton resonance of water 
using the same transm itter/receiver coil. Typical line widths of 
between 10 and 25 Hz were obtained. The spectrometer was tuned to 
fluorine and signals from SR-4554 (in glass phantom) and 5-FTP 
(in the reference bulb) measured using 64 transients (scans) acquired 
at a pulse repetition time of 7.5 sec. Without changing the position of 
the phantom , the spectrometer was tuned to deuterium  and 
spectra from water (HOD; internal standard in phantom) and acetic 
a c id -d  (AcOH-d; in a reference bulb) obtained using 128 transients 
acquired at a pulse repetition time of 3 sec. To ensure equal flip 
angles for 19p  and ^ h , a calibrated 90° pulse width (with respect to 
the phantom) was used in each case for spectroscopic measurements. 
The internal standard (HOD), and the external standards - 5FTP and 
A c O H - d  - were used for the absolute quantitation of SR-4554 
concentrations according to the equation 6.1 below:
[SR  — 4554 ] {m M ) =  S ^ 3* - 455* x  AcOH F  equation 6.1.
S i s  - F T P  S I hod
where S I  s r - 4 5 5 4  > S I s f t p  » S I  A c O H - d  , and S I h o d  are the integrated 
signal intensities of SR-4554, 5FTP, AcOH-d and HOD respectively and 
F  is a factor that depends on the concentration of internal and 
external standards as well as the number of fluorine atoms per drug 
molecule (F  = 0.15 mM for SR-4554 in phantoms). The longitudinal 
re laxa tion  constan t ( T i )  was determined by means of an auto­
p rogram m e using an inversion  recovery  sequence. For the 
determ ination of T i , 2 mM SR-4554 solutions were used and the 
spectral acquisitions were 'interleaved'.
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6 . 2 . 4  D r u g  a d m i n i s t r a t i o n
Unless otherwise stated, SR-4554 (3 mg/ml in 0.9% saline) was 
administered as a single i.p. injection of 180 mg/kg body weight. In 
some experim ents, hydralazine (5 mg/m l in 0.9%  saline) was 
administered as a single i.v. injection of 5 mg/kg via the tail vein 1 hr 
prior to the administration of SR-4554.
Mice were anaesthetised in all cases with a combination of 
Hypnorm, Hypnovel and water in the ratios of 1:1:2 (0.01 ml/g i.p.), 
except in direct p 0 2  measurements to investigate the effect of SR- 
4554 and anaesthesia on 19p  retention, which were carried out on 
conscious mice. In imaging experiments where mice were studied 
continuously for long periods of time, an i.p. line was set up and 
anaesthesia maintained at a dose of 0.0025 m l/g/hr beginning 2 hr 
after induction.
6 . 2 . 5  In  vivo M RS pro toco l
SR-4554 was injected into mice and anaesthes ia  induced 
between 8 and 20 min post-injection. A naesthetised mice were 
secured horizontally with the tissue of interest (tumour, brain or 
thigh) resting on a surface coil (1.0 or 1.7 cm diameter, 1 9 p / 2 j j  
double-tuned coil) in a 4.7 or 7.0 T in vivo  M R spec trom eter . 
'Shim m ing' and pulse acquisition were carried out as previously 
described (see section 6.2.3). Typical proton linewidths of between 
50 to 80 Hz were obtained. 19p signals from SR-4554 (in the tumour) 
and 5-FTP (in the reference bulb) were measured at 45 min and 6 hr 
post-injection of SR-4554. The absolute quantitation of 1 9 p  signal 
levels (due to drug and hypoxic m etabolites) was achieved by 
in tegra ting  spectra from HOD (in tumour) and A cO H -d  (in
reference bulb) and comparing 19p and signal intensities. In this 
case in tissues, however, a correction to the equation 6.1 for the water 
weight per gram of tissue (0.82) and the assumption that tissue water 
has a density of 1 g/ml were made (Evelhoch et a l ., 1989). Based on 
these criteria, F  was calculated to be 0.12 pm ol/g tissue wet weight. 
Mice were kept warm throughout the studies. T i  values were 
de te rm ined  in vivo  in a RIF-1 tumour model using an inversion 
recovery sequence with the spectral acquisitions 'interleaved'.
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6 . 2 . 6  Retention of  \n tumours
To compare the in vivo  re tention of three fluo rina ted  2- 
nitroimidazoles, SR-4554, fluoromisonidazole (Ro 07-0741), and CCI- 
103F, the compounds were administered concurrently in a ’cocktail', 
as a single i.p. injection to SCCVII tumour bearing mice. The doses 
(based  on f luorine  sensitiv ity ) of the in d iv id ua l  com pounds 
administered in the ’cocktail’ were respectively 0.32, 1.0, and 0.125 
mmol/kg. 1 9 p  ancj 2 j j  MR spectra were determined repeatedly  in 
tumours up to 24 hr post-injection of the compounds.
In all other MRS studies, SR-4554 was administered at a dose of 
180 mg/kg to tumour bearing mice and MR-spectra were obtained at 
both 45 min and 6 hr post-injection. 19p signal levels were calculated 
for each tumour at 45 min and 6 hr using equation 6.1 above (section
6.2.3 and 6.2.5). The retention index was defined as the ratio of 
1 9 f  signal levels determined by MRS at 6 hr relative to 45 min. In 
addition to 19p  retention index determination, RIF-1 tumours were 
a lso  ex c ised  im m ed ia te ly  afte r  MRS s tu d ies  and o r ig in a l  
(unm etabolised) SR-4554 concentrations determ ined by HPLC (see 
section 2.2) in order to evaluate the contribution of original SR-4554 
to the MR signal at 6 hr post-injection. The l ^ F  retention index was 
determined for murine (RIF-1, KHT, SCCVII, EMT6) and human (BE, 
HT-29, WIL, HN5) tumour xenografts with varying degrees of hypoxia 
to evaluate the ability of MRS to m easure tum our hypoxia.
Subsequently  the re la tionship  between re ten tion  index and
tum our mass was studied in RIF-1 tumours to assess w hether 
increased tumour mass correlates with increased hypoxia. In this 
study mouse tumours were excised whole and weighed immediately 
after each MRS measurement.
To evaluate whether tumour bioenergetics could account for the 
differences in the observed 1 9 p  retention, 3 1 p  spectra of KHT 
tumours were obtained in-between the two 19p  MRS m easurem ents 
by means of an image selected in vivo spectroscopy (ISIS) sequence 
(Ordidge et a l ., 1986). Localised spectra were obtained from a 1 cm^ 
voxel, using a 500 psec adiabatic sincos pulse. Three arrays of 160 
transients each were obtained at a pulse repetition time of 3 sec. 
Summed spectra were used to investigate the correlation between 
tum our b ioenergetics and * 9 p  retention. The tumour pH was
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determined from the a-nucleotide triphosphate (a-N T P ) and inorganic 
phosphate (Pi) resonances as previously described (Howe et a l ., 1993).
6 . 2 . 7  Corre la t ion  between retention index and the 
oxygenation  status of  mouse  tum ours
The oxygen tension (p 0 2 )  of mouse tumours was determined 
using a fine needle oxygen electrode (Eppendorf, Hamburg, Germany). 
Between 4 and 7 parallel tracks were made in each tumour. For each 
track, the electrode was inserted up to a depth of 1 mm into the 
tumour and moved automatically through the tissue in forward (0.7 
mm increm ents) and backward (0.3 mm) steps p rio r  to each 
measurement. A total of 50 to 100 measurements were made within 
each tumour. Initially, this technique was em ployed to assess 
whether SR-4554 and anaesthesia individually or combined, had any 
effect on tumour oxygenation. In this study, p 0 2  measurements were 
performed in C3H mammary tumours 1 hr after SR-4554 injection 
and 40 min after anaesthesia. For comparisons between p 0 2  and 
retention index, however, MRS signals were determined as previously 
described in section 6.2.5. Electrode measurements within the same 
tumours were carried out at 3 hr after SR-4554 injection, i.e. between 
the two MRS measurements.
6 . 2 . 8  Effect o f  agents that modulate  tumour blood  
flow and/or oxygenation on the 19jr retention  
i n d e x
Three modulators including hydralazine, carbogen and carbon 
monoxide were used in this study. RIF-1 tumour bearing mice were 
treated with 5 mg/kg of hydralazine 1 hr before the administration of 
SR-4554 and the tumour retention index  de te rm ined  and
compared to that in untreated RIF-1 tumour bearing mice. In another
experiment, C3H mammary (flank) tumour bearing C D Fi mice were 
made to breath either air, carbogen (95% 0 2 + 5 %  C 0 2 )  or carbon 
monoxide gas mixture (660 ppm CO + 20.99% 0 2  in N2). Carbogen and 
carbon monoxide gas mixtures were delivered through a nozzle at a 
rate of 2.5 L/min (Nordsmark et al ., 1995). Mice were allowed to 
breath carbogen for a total of 82 min starting at 8 min after SR-4554 
in jection. A lternative ly , mice were a llow ed to b reath  carbon 
monoxide for a total of 60 min starting at 25 min after SR-4554
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trea tm ent. To enable  a com parison  betw een  the change in 
oxygenation and corresponding 19p retention index to be assessed, 
the pC>2 of C3H mammary tumours in mice from the same batch (as 
used for the MRS studies) were also assessed in parallel studies using 
an oxygen needle electrode (Eppendorf) as described in section 6.2.8. 
The m ean p 0 2  was determined for untreated contro ls  and gas 
breathing mice.
6 . 2 . 9  In  vivo M R I p ro toco l
Both 1- and 2-dimensional chemical shift imaging (1-D and 2-D 
CSI) techniques were used to visualise the distribution of l ^ F  across 
the tumour region in a RIF-1 tumour bearing mouse. A 
surface coil (1 cm diameter) was used and data were acquired using a 
p e lD  and SISCO csi3D pulse sequences for 1-D and 2-D imaging 
respectively. A sincos pulse with a pulse width of 2000 p. sec was 
employed in these studies. In 1-D experiments, 8 transients for each 
phase encoding increment were acquired with a spectral width of 18 
kHz and an acquisition time of 0.128 sec. Mouse tumours hung into 
the surface coil and a ’zxy' orientation was used. In 2-D experiments, 
32 x 32 increments were used and the data interpolated to a 256 x 
256 matrix size.
The application  of whole body MRI to study drug
d is t r ib u t io n  and lo ca lisa t io n  of b io re d u c tiv e ly  a c t iv a te d  2- 
nitroim idazoles was investigated using a 4 cm diam eter i H / l ^ F  
Hemholtz transmitter/receiver coil. RIF-1 and SCCVII tumour bearing 
C3H mice were treated with SR-4554 at doses of 180 mg/kg and 360 
m g/kg (0.06 ml/g) respectively. In each case the mice were 
anaesthetised, and placed horizontally in the coil. An i.p. line was 
surgically placed in the peritoneum of the mice to enable anaesthesia 
to be maintained (see section 6.2.4). A 'shorte' pulse sequence (i.e. a 
spin echo pulse sequence optimised for short echo times) was used for 
both l H  and imaging. The proton sequence consisted of a
multislice 1000 psec gauss pulse, a relaxation delay of 1.0 sec, 64 
repetitions, 32 phase encoding increments, and an echo time of 3.2 
msec. The pulses were calibrated and data  acquired with the 
frequency set on-resonance according to the nucleus o f  interest. 
Proton images consisted of 3.6 mm slices while 1 9 p  images were 
acquired from a slice thickness of approximately 4 times that of
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protons. The fields of view in both cases were set equal to 8 and 5 cm 
in the readout and phase encoding directions respectively. In order 
to assess the relationship between 19p  sensitivity and echo time, a 
whole body T2 relaxation of 19p was determined using the Hemholtz 
coil.
6 .3  RESULTS
6 . 3 . 1  MRS studies
Fluorine and deuterium signals were obtained in vitro  and in  
v iv o .  Fig. 6.2 show typical fluorine and deuterium spectra obtained 
from a RIF-1 tumour. Even with the low number of transients used, 
resolution of tissue and reference signals was possible in both cases. 
Such spectra were used in the quantitation of signal levels from
drug and bioreduced metabolites in tissues. Validation of this method 
in a glass 'phantom ' was carried out by com paring  SR-4554 
concentra tions obtained from the MRS study and corresponding  
nominal concentrations (Fig. 6.3). Regression analysis of data showed 
that the calibration curve was linear over the range 0.125 to 4 mM (r 
= 0.99; slope = 1.02). The limit of detection was 0.125 mM (> 3 noise)
with a standard deviation of 0.03 (n = 3). The in vitro  (2 mM SR-
4554 in 100 mM NaCl) and in vivo (180 mg/kg SR-4554 in RIF-1 
tumour) T i  values of the and compounds as determined by an 
inversion recovery sequence are presented in Table 6.1. The results 
show lower T i  values for SR-4554 and HOD in vivo. As expected, the
T i of external reference standards were similar in both in vitro  and
in vivo protocols.
6 . 3 . 2  Retention of  signals in mouse tumours
Initial experiments to compare the retention of the fluorinated 
2-nitroimidazoles SR-4554, fluoromisonidazole (Ro 07-0741) and CCI- 
103F in SCCVII tumours, indicated that the three com pounds 
exhibited similar retention profiles in vivo (Fig. 6.4). The 19p  signal 
levels of the three compounds within the same tumour were higher at
4.7 hr compared to those at 35 min. Subsequently, the signal levels 
decreased until the last time point at 24.0 hr post-injection.
In Table 6.2, 19p signal levels have been computed for tumour 
(RIF-1) and brain (head region) of C3H mice from MRS and HPLC 
measurements. The MRS data in this case indicated biodistribution of
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Fig . 6.2. Typical fluorine (a) and deuterium (b) spectra obtained 
from a RIF-1 tumour (and reference bulb) after the injection of 180 
mg/kg of SR-4554. The spectra were acquired by means of a double­
tuned ( 1 9 f / 2 h )  circuit using 64 and 128 transient (7.5 and 3 sec 
pulse repetition times) for fluorine and deuterium respectively.
(a) 19 F Spectra
-I-
60 50 40 30 10 -2020 03 -10 ppm
(b) 2H Spectra
AcOH- d
HOD
Fig. 6.3. Quantitation of SR-4554 in 100 mM saline solution using a 
double tuned ( l^ F /^ H )  MRS circuit at 4.7 Tesla. The graph shows the 
mean and corresponding standard deviations (error bars) of replicates 
(n = 3). The error bars were too small to be observed. MRS 
concentrations were calculated by comparison of 19p and spectral 
in tensities obtained from  SR-4554, and natural abundance deuterium  
(in glass phantom ), and 5-fluorotryptophan and acetic ac id -d  (in 
reference bulb). The correlation coefficient and gradient of the 
calibration curve was 0.99 and 1.02 respectively.
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Table 6.1. T i values of flu o rin a ted  and d eu te ra ted
com pounds m easu red  in both  in v itro  and in v ivo  
experim ents by means of an inversion recovery sequence.
C om pound T i (sec)
In vitro In vivo
SR -4554 1.52 ± 0.12 0.66 ± 0.19
HOD 0.45 ± 0.08 0.24 ± 0.03
5-FTP 0.73 ± 0.17 0.59 ± 0.13
AcOH-J 0.06 ± 0.002 0.04 ± 0.002
Values represent mean T i ± s.e. determined using an auto­
p ro g ram m e.
HOD, 5FTP, and AcOH-d  are natural abundance deuterium  in 
water, 5-fluorotryptohan and Acetic acid-d respectively .
Fig. 6 .4 . Typical spectra obtained from  a tum our (SCCVII)
bearing m ouse after the co-injection of fluorom isonidazole (Ro 07- 
0741) (1 m m ol/kg), SR-4554 (0.32 mmol/kg) and CCI-103F (0.125 
m mol/kg). The spectra were acquired at 35 min (a), 4.68 hr (b) and 
24 hr (c) post-injection. In (a) and (b), 64 transients (at 7.5 sec pulse 
repe tition  tim e) were used, w hilst 128 transients were used for 
spectral acquisition in (c).
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6.2. 
Retention 
of 
19p 
signals 
from 
SR-4554 
in 
RIF-1 
tum
ours.
SR-4554 to tumour and brain region (45 min), although in all cases, 
the concentrations of total drug in tumours were higher than in the 
brain. The parent compound (SR-4554) was cleared from  tumours by 
6 hr post-injection as indicated by the HPLC m easurements.
The 1 9 p  retention indices of a variety of hum an and m urine 
tum our xenografts with d ifferent reported hypoxic frac tions were 
m easured following the injection of SR-4554 (180 m g/kg) in order to 
assess the ability of 19p MRS to detect tumour hypoxia. The results of 
this study in eight tum our types are p resented  in Fig. 6.5 and 
rep re sen ts  the m ean and corresponding  95% con fidence  levels 
(analysis of variance of transformed data) of 1 9 p  re ten tion  indices 
obtained from  4 to 13 mice per tumour type. The data showed that 
w ithin each tum our type, there was a marked individual variation in
retention index. When pooled together, however, the mean 19p
retention  index for each murine tumour type, in general, correlated 
well w ith the reported radiobiological hypoxic fraction (Table 6.3). 
For instance, a more hypoxic tumour such as EMT6 gave a higher (not 
statistically  significant) mean 19p retention index com pared to RIF-1, 
a less hypoxic tum our. Apart from  the W IL tum ours, the other 
hum an xenografts showed less retention of 1 9 p  com pared to the 
m urine tum ours with HT-29 giving the low est m ean 1 9 p  reten tion  
index. In W IL tumours, however, a high variation in 1 9 p  reten tion  
index was observed with maximum and m inim um  1 9 p  re ten tion  
indices of 2.1 and 0.0 respectively.
In RIF-1 tum ours, the 1 9 p  reten tion  index co rre la ted  w ith 
tumour mass as illustrated in Fig.6.6. A correlation coefficient of 0.83 
was obtained from  regression analysis of the data. The absence of 
any co rre la tion  betw een 1 9 p  retention index and tum our m ass or 
volume in KHT tumours, for example, prompted studies to investigate 
w hether this effect was due to differences in bioenergetic status using 
3 1 p  MRS. Fig. 6.7 illustrates a typical 3 1 p  spectrum  obtained from a 
KHT tum our. No correlations were, however, observed betw een 31p  
param eters such as Pi/PCr, Pi/Total NTPs, PM E/Total NTPs or pHi and 
l ^ F  retention index (n = 6). The pHi of the KHT tum ours varied 
between 6.98 and 7.41.
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Fig. 6.5. The retention of 19p  signals from SR-4554 in m urine and 
human xenografts. The graph shows mean 19p retention indices and 
associated  95% confidence in tervals calculated  on the basis of 
transform ed data (i.e. square root of individual 19p retention indices) 
and then transform ed back to original scale. Tukey HSD m ultiple 
comparison test showed that the data were significant (p < 0.05) for 
EMT6 vs HT-29 and SCCVII vs HT-29. The p-values for KHT vs HT-29 
and RIF-1 vs HT-29 were both = 0.08.
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T able 6.3. Hypoxic fraction of solid tum ours as m easured by 
radiobiological assays.
TUMOUR HYPOXIC FRACTION (%) REFERENCES
RIF-1 1.6 (1.1 - 2.1) (Brown et al., 1980)
4.7 (3.3 - 6.6) (Shibam oto et al., 1986)
1.0 (MRCRU, Lab data, 1994)
EMT6 50 (31 - 80) (Guichard et al., 1977)
21 (8.8 - 49) (Guichard et al., 1977)
20 (13 - 31) (Rockwell, 1981)
56 (38 - 82) (Rockwell, 1981)
14 (9.9 - 19) (Shibamoto et al., 1986)
SCCVII 8.5 (6.9 - 11) (Shibamoto et al., 1986)
8.4 (6.6 -12) (Shibamoto et al., 1986)
25 (MRCRU, Lab. data, 1994)
KHT 15 (8.2 - 28) (Van Putten & Kallman, 
1 9 6 8 )
12 (8.6 - 18) (Hill, 1980)
39 (30 - 52) (Hill, 1980)
10 (MRCRU, Lab. data, 1994)
H T -29 17 (9.2 - 31) (Leith et al., 1991)
12 (Guichard et al., 1983)
MRCRU: MRC Radiobiology Unit, Didcot, UK.
Tumour sizes ranged between 5 and 20 mm diameter or 0.5 and 2 g.
Fig. 6.6. Relationship between 19p retention index and tumour mass 
in RIF-1 tum ours. Each point represents a single tum our. The 
correlation coefficient of the regression line was 0.83.
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Fig. 6.7. A localised 31 p spectra obtained from a KHT tum our by 
m eans of an ISIS sequence. The spectra  shows the various 
phosphorus m etabolites including phosphom onoester (PM E), inorganic 
phosphate (Pi), phosphodiester (PDE), phosphocreatine (PCr), and a - ,  
p - ,  and y -n u c le o tid e  tr ip h o sp h a te s  ( a - ,  p , and y-N T P 's). The 
in tracellular pH (pHi) was calculated from the difference between the 
Pi and a-N T P  peaks.
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6 . 3 . 3  C orre la tion  betw een  retention index and the
oxygenation  status o f  m ouse tum ours
To investigate whether the MR protocol used in this thesis could 
affect the phenomenon of interest (i.e. influence tum our oxygenation), 
tum our p 0 2  m easurem ents in SR-4554 treated  vs un trea ted  and 
anaesthetised  vs unanaesthetised  mice were obtained (T able 6.4). 
S tatistical analysis of the data (Kruskal-W allis test; 95% confidence 
level) showed no significant differences between means and % of p 0 2  
values < 5 and 10 mmHg. Significant differences w ere, however, 
observed upon comparison of medians and % of p 0 2  values < 2.5 
mmHg (Kruskal-W allis test; 95% confidence level). Further analysis of 
the data (medians and % p 0 2  values < 2 . 5  mmHg) showed that a small 
bu t s ig n ifican t increase  was produced  by S R -4554  and the 
com bination  of SR-4554 and anaesthetic (m edian pC>2 of 3 and 1 
mmHg respectively).
Three tum our m odels (two sites) were characterised according 
to their retention index and p 0 2 . The relationship between 19p 
retention index and pC>2 param eters including m edian p 0 2 , and % of 
pC>2 values < 2.5, 5, or 10 mmHg are illustrated in Fig. 6.8. No strong 
correlation was found between the p 0 2  parameters and retention
index for each tumour type alone or for all tum our types combined. 
The v a riab ility  betw een these two techn iques was p a rticu la rly  
evident at high oxygenation or low retention indices. Although
the d ifferen t tum our types showed rela tively  d ifferen t trends, in 
general, high 19p retention indices were associated with low m edian 
pC>2 and high % of pC>2 values < 2.5, 5 or 10 mmHg. In particular 19p 
retention index of greater than 0.5 corresponded to m edian p 0 2  of 
less than 2.5 mmHg (9 out of 10 tumours) and % of p 0 2  values < 5 
mmHg of greater than 60% (10 out of 10 tumours).
6 . 3 . 4  Effect o f  agents that m odulate tum our blood  
flow and/or oxygenation on the l ^ F  retention  
i n d e x
The com puted 1 9 p  retention indices follow ing a ltera tions in 
tum our m icroenvironm ent are presented in Table 6.5. A dm inistration 
of hydralazine at a dose of 5 mg/kg caused greater than two fold 
increase in 1 9 p  reten tion  index of RIF-1 tum ours com pared  to 
untreated controls. Analysis of three hydralazine treated tum ours by
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Fig . 6 .8 . R ela tionsh ip  between l ^ F  retention index and p 0 2  
param eters: (a) m edian pC>2, (b) % p02  values < 2.5 mmHg, (c) % of 
p 0 2  values < 5 mmHg, and (d) % of p02  values < 10 mmHg.
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F ig . 6 .8 . R ela tionsh ip  betw een 1 9 p  retention  index and pC>2 
param eters: (a) m edian pC>2, (b) % p02  values < 2.5 mmHg, (c) % of 
pC>2 values < 5 mmHg, and (d) % of p02  values < 1 0  mmHg.
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HPLC showed that significant amounts of original drug were present
(0.07 ± 0.02 jLimol/g tissue). Fig. 6.9 shows typical 1 9 p  tum our
spectra obtained from control and carbogen breathing m ice at 45 min 
and 6 hr post-in jection . Carbogen breathing decreased  the 1 9 p  
retention index in C3H mammary tumours by six fold com pared to 
untreated controls (Table 6.5). Oxygen tension (p 0 2 )  m easurem ents 
in another set of mice from the same batch showed that this decrease 
in retention index was associated with an increase in mean p 0 2  of
about 9 mmHg (Table 6.5). Surprisingly, how ever, even though
carbon monoxide breathing caused a decrease in mean p 0 2  of about 
13 mmHg, the corresponding 1 9 p  retention  index com pared  to 
controls, was lower rather than higher.
6 .3 .5  M R I s tu d ie s
In Fig. 6.10a, the 1-D chemical shift image of SR-4554 in a RIF-1 
tum our, as well as that of the reference tube containing 5-FTP is 
shown. The use of an adiabatic pulse enabled two regions of SR-4554 
dependent 19p signal to be obtained. These regions corresponded to 
the tumour and bladder regions. The image also shows a signal from 
the reference tube at the relative resonance frequency of 5-FTP. Fig. 
6.10b illustrates a 2-D chemical shift image carried out in the same 
m anner as the 1-D experim ent but w ithout the reference bulb. The 
image in the two phase encoding axes confirms the observation in Fig. 
6 .10a .
The application of whole body 19p MRI to the imaging of drug
biodistribution was also investigated in C3H m ice bearing either the
RIF-1 and SCCVII tumours. In each case a image of the mouse was
obtained prior to the 19p  image to enable the visualisation of mouse
anatomy and also to aid in the subsequent slice selection used for the 
1 9 p imaging. Examples of lH  spin echo im ages from  the SCCVII 
tum our bearing mouse are illustrated in Fig.6.11. The three images 
represent the top, middle and bottom 3.6 mm slices along the length 
of the mouse. The bladder is easily seen in the bottom slice while the 
tumour is seen in all slices. Fig. 6.12a shows a ^ F  image (9 hr after 
SR-4554 injection) superimposed on the corresponding image of a 
SCCVII tumour bearing C3H mouse. The figure shows that residual 
1 9 f  signal was present in the bladder and tum our and to a lesser 
extent in the liver region. A similar image in a RIF-1 tum our bearing
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Fig. 6.9. Typical tumour 19p spectra obtained from control [(a) and
(b)] and carbogen breathing [(c) and (d)] CDFi mice at 45 min [(a) and
(c)] and 6 hr [(b) and (d)] after the injection of SR-4554. Whereas the 
l^ F  signal is retained in control tumours, it is almost completely lost 
in carbogen breathing mice. The spectra also shows the reference 
standard  5 -flu o ro try p to p h an .
S R -4554
-  ti
5-FT P CO
Nl'RO
L
Fig. 6.10. (a) A typical 1-D CSI of SR-4554 (3 hr post-injection) in
RIF-1 tumour showing drug signals from tumour and bladder regions. 
The im age also  show s signals from the reference standard  5- 
fluorotryptophan. (b) A 2-D CSI of the same tumour (4 hr post 
in jection) w ithout the reference standard showing a sim ilar drug 
localisation profile as in (a). The image in the two phase encoding 
axes is presented in (b).
S R -4554
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Fig. 6.11. The lH  spin echo images obtained from a tumour (SCCVII) 
bearing mouse. The 3 images represent the top (a), middle (b), and 
bottom  (c) 3.6 mm slices along the length of the mouse.
( a )
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Fig. 6.12. (a) A  Spjn echo image (green contours) superim posed 
on the corresponding lH  image of a tumour (SCCVII) bearing C3H 
mouse. The image was obtained with a 4 cm Hemholtz coil at 9 hr 
after the adm inistration of 360 mg/kg SR-4554. (b) A sim ilar image
in a tum our (RIF-1) bearing C3H mouse obtained at 5 hr after the 
adm inistration of 180 mg/kg SR-4554. The image in both cases show 
localisa tion  of 1 9 p  in the tumour (T), bladder (B), and liver (L) 
regions. M otion artefacts in the phase encoding direction may account 
for the ’sm earing’ observed.
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m ouse (5 hr after SR-4554 injection) is presented in Fig. 6.12b. 
S im ila r studies in other tum our bearing m ice show ed that the 
distribution was not always the same as in Fig. 6.12. In some cases 
l ^ F  signal was not present in the tumour region 4 hr post-injection of 
SR-4554 whereas in one case retention was found in the kidneys. It 
should be noted that these are T 2-w eighted  im ages, and that the 
actual distribution in a particular organ may not be apparent. In 
addition, the sensitivity of was not high enough to allow tissue 
heterogeneity to be studied by this technique. A typical T2 curve 
obtained from  a RIF-1 tumour bearing mouse (3 hr post-in jection) 
using the Hemholtz coil fitted a bi-exponential m odel with a short T2 
com ponent of 4.6 ms and a long component of 141 msec is shown in 
Fig. 6.13.
6 .4  DISCUSSION
The development of improved and clinically relevant techniques 
for the detection and quantitation of hypoxia in tum ours is im portant 
to the design of appropriate  therapeutic  m odalities fo r hypoxic 
tumours. This led to the design and synthesis of SR-4554 which was 
envisaged to be less toxic, more stable, and m ore sensitive  for 
detection by MRS and MRI techniques. The pre-clinical developm ent 
of SR-4554 as an M RS/M RI probe for tum our hypoxia has been 
presented in this chapter.
As part of the study and for the first tim e, a sim ple l ^ F /^ H  
m ethod for the absolute in vivo quantitition of was im plem ented. 
This was based on a m odification of the m ulti-tuned MRS technique 
first described by Thulborn & Ackerman (1983). N aturally abundant 
deuterium  in tissue water was used as in ternal standard, w hilst a 
co m b in a tio n  of 5 -fluo ro tryp tophan  and ace tic  a c id -d  served as 
external standards for the quantitation of drug levels. The external 
s tandards also served as chem ical sh ift re fe rences , as w ell as 
e lim inating errors due to coil loading and tuning. As previously 
suggested by Thulborn and Ackerman (Thulborn & Ackerm an, 1983), 
this technique allows m etabolite concentrations to be determ ined and 
is valid for inhomogeneous B i as produced by surface coils at higher 
frequencies. Using the 1 9 f /2 h  technique, nom inal concentrations of 
SR-4554 correlated with MRS concentrations over the range 0.125 to 
4 mM (r = 0.99). A reasonable limit of detection was obtained (0.125
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Fig. 6.13. A T2 curve obtained from a RIF-1 tumour bearing mouse 
at 3 hr after the in jection of 180 mg/kg SR-4554. Spectra were 
acquired using a 4 cm  Hem holtz coil and the data fitted  a b i­
exponential m odel with a short T2 component of 4.6 msec and a long 
T2 component of 141 msec.
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mM) due to the presence of three equivalent fluorine atom s per drug 
m olecule. This m ethod is therefore more sensitive than the method 
describ ed  by E v e lh o ch  et. al. (1989) u sing  tr id e u te ro m e th y l 
m isonidazole (which had a limit of detection of 0.5 mM). It is worth 
noting that water w eight per gram tum our m ay vary slightly  from  
one tumour to the other, even with tumours of sim ilar histologies. It 
is envisaged therefore that the exact tumour concentrations may vary 
slightly. However, a com parison of tumour concentrations at different 
times (45 min and 6 hr) corrects for these probable d ifferences, as 
well as possible variations in SR-4554 delivery.
Due to the m ore  effective re laxation  o f spins by tissue 
com ponents, T i values for drug and HOD were found to be lower in  
v ivo . The in vitro  vs in  vivo T \  data reported here are also similar to 
those obtained by Evellhoch et al. (1989). For each nuclide, therefore, 
spectra were acquired a t  > 5 times the T i value of the species with 
the higher T i to avoid any saturation effects.
The fluorinated hiypoxia probes SR-4554, fluorom isonidazole (Ro 
07-0741) and C C I-103F showed sim ilar tum our reten tion  profiles. 
A lthough any possible interactions between the three com pounds are 
unknown, the data suggested that at the doses used, the compounds 
will probably be sim ilar in assessing tum our oxygenation. In itial 
studies in C3H mice bearing the RIF-1 tumour suggested that the 
signal from SR-4554 w as selectively retained in tumours com pared to 
brain. It could be assum ed that the retention of high concentrations 
of fluorinated  probe ;at 6 hr, despite the m uch low er (20 fold) 
concentration of o rig inal drug detected by HPLC at 7 hr, represents 
one or more nitroreduiced m etabolites. This is in agreem ent with 
previous high resolutiom NMR studies with excised tum ours (chapter 
3). By comparing braim concentrations of SR-4554 by MRS to similar 
co n cen tra tio n s  d e te rm in ed  in p h arm acok ine tic  ex p erim en ts  (see 
section 5.3.3) it was observed that the MRS m easurem ents were 
slightly higher than exipected. In view of the fact that bioreduced 
drug is absent from  tlhe brain (see section 3 .3.2), this observation 
could only be explained by a possible signal contam ination from skin 
(Cobb et a l., 1990) and other structures within the head region, using 
the surface coil, rather ithan from the brain per se.
The 1 9 p signal levels from  SR-4554 w ere norm alised  for 
delivery and expressed as the ratio of integrated signal at 6 hr to that
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at 45 min post injection to give the 19p retention index. The selection 
of these time points was based on studies in this chapter, as well as 
previous pharm acokinetic studies (section 5.3.3) which showed that at 
a dose of 180 mg/kg, original drug (SR-4554) peaks at 45 min post 
injection w ithin tumours and is com pletely elim inated at 6 hr post­
injection. The retention index was subsequently determ ined for a 
num ber of m urine and human tum our xenografts. W hen taken 
ind iv idually , the 1 9 p  retention index w ithin tum ours of the same 
origin and histological classification varied m arkedly. For instance, 
the W IL tumour showed a marked variation in 19p  retention index. 
In vitro  this cell line exists as a mixed population of anaplastic and 
d ifferentiated cells. The marked variation in 1 9 p  reten tion  index 
cou ld  th e re fo re  be ex p la ined  by the h e te ro g en e o u s  grow th  
characteristics of this tumour. The mean 1 9 p  retention indices for 
m urine tum ours correlated with the reported rad iobio logical hypoxic 
fraction. A comparison could not be made in the case of the human 
xenografts, due to lack of radiobiological hypoxic fraction data in most 
of the tumours. Radiobiological hypoxic fraction data, however, are 
usually  based on the best statistical fit and m ay not necessarily  
re flec t the variab ility  in the data. For instance, based on the 
scattering of their data, Guichard et. al. (1983) reported  in their 
studies with HT-29 that a 0% hypoxic fraction was ju st as statistically 
acceptable for this tumour model as the best fit of 12%. In addition, 
RIF-1 tumours which have a reported radiobiological hypoxic fraction 
of 1% showed a mean 1 9 p  retention index of 0.5. A dditional 
supporting evidence for the high retention index obtained for RIF-1 
tumours can obtained from studies in this chapter. For instance, 19p 
retention index vs p 0 2  m easurem ents, dem onstrated that this high 
retention  was associated w ith an equally high % p 0 2  values < 5 
mmHg of 83.7 ± 5.1, thus justifying the l ^ F  retention index obtained. 
A m ajor assum ption of the MRS studies discussed here, is that the 
ac tiv ities of reductases in these tum ours are non-lim iting . As 
d iscussed  in chapter 3, this assum ption m ay be ju s tif ied , since 
differences in NADPH cytochrome P450 reductase activities between 
the tumour types used in this study are small (up to 3 fold), and may 
not sign ifican tly  affect the absolute reduction  rate  and selective 
retention of SR-4554 within these tumours.
82
In RIF-1 tum ours, the re ten tion  index  increased  w ith
increasing  tum our m ass suggesting increased  hypoxia  in b igger 
tumours. Similar results have been reported by Kwock et al. (1992) 
using 19p MRS and immunostaining. In their study, only the less well 
vascularised and more hypoxic Dunning rat prostate adenocarcinom a 
with diam eters > 3 cm had detectable 19p  signals (from  CCI-103F) 
after 24 hr, and also stained im m unohistochem ically  in locations 
w ithout obvious necrosis. C orrelations betw een tum our size and 
hypoxia have also been reported in RIF-1, KHT, hum an ovarian 
carcinom a MLS, SCCVII, FSall, and the radiosensitive M eth-A mouse 
tum our using bioenergetic status param eters determ ined by 3 1 p  MRS 
(Fu et al., 1990; Koutcher et al., 1990; Okunieff et a l., 1986; Rofstad e t 
a l ., 1989). No correlation between 3 1 p  param eters and retention
index (of SR-4554 in this chapter) was, however, observed in KHT 
tumours (n = 6) suggesting that bioenergetic status of the tum our may 
not necessarily  co rre la te  to the labelling  o f hypoxic  cells by 
fluorinated  2-n itro im idazo les. This is not unexpected , since 2- 
nitroim idazoles label only hypoxic cells, w hilst a com ponent of the 
signals from  31 p experim ents (especially  Pi) may also be due to 
necrosis (Tozer & Griffiths, 1992).
O xygen  ten s io n  ( p 0 2 )  m easurem ents in d ica ted  th a t the 
anaesthetic  used (H ypnorm -H ypnovel-w ater) d id  not sign ifican tly  
alter tumour oxygenation. In contrast, SR-4554 and the com bination 
of SR-4554 and anaesthetic produced a significant increase in tumour 
oxygenation when m edians or % p 0 2  values < 2.5 mmHg were 
com pared  (K ruskal-W allis  test; 95% con fidence  lev e l) . This 
observation is contrary to the decrease in tum our blood flow (and 
h e n ce  o x y g e n a tio n )  p ro d u ced  by a n o th e r  2 -n itro im id a z o le  
pim onidazole at pharmacological doses (Chaplin, 1991). It is unknown 
whether this effect of SR-4554 at low (< 2.5 mmHg) p 0 2  readings is 
due to a d irec t in terference of the com pound w ith  the oxygen 
electrode e.g. by an electrochem ical m echanism. Provided the same 
protocol is used in all cases, however, this increase in oxygenation 
p roduced  by the com bination  w ill not be expec ted  to a ffect 
m easurem ent of tum our oxygenation by SR-4554. In addition, no 
significant differences (Kruskal-W allis; 95% confidence level) in 19p 
re ten tion  were observed betw een tum ours w hich had the ir p 0 2  
m easured  and those w hich did not, ind ica ting  th a t the p 0 2
83
m easurem ents did not significantly affect the retention of SR-4554 
(data  not shown). To determ ine the re la tionsh ip  betw een 1 9 p  
retention indices and p 0 2  in mouse tumours, three different tumour 
m odels (two sites) were used in the study to allow for variability in 
oxygenation status. No precise correlations were observed when the 
two techniques were compared. The inability  to observe a strong 
correlation, from  the relatively small group of anim als used in the 
study, is not altogether surprising. It can be im agined that pC>2 
m easurem ents using oxygen electrodes can give low pC>2 values 
resu lting  from  regions w ithin the tum our not con ta in ing  viable 
hypoxic cells, such as necrotic regions. The data, however, indicated 
that substantial retention of 19p  signal was associated with a high 
level of tumour hypoxia (low tumour oxygenation). Previous studies 
in C3H mammary foot tumours suggested that when m edian p 0 2  was 
less than 2.5 mmHg and the % of p 0 2  ^ 5 mmHg was 60%, the 
equivalent clonogenic hypoxic fraction was 10% (N ordsm ark et a l., 
1995). It can therefore be predicted that substantial retention of 19p  
will be evident in tumours with a radiobiological hypoxic fraction of > 
10%. In general, the studies in this chapter have also dem onstrated 
the ability of 19p MRS to detect tumour oxygenation at critical levels 
that have been reported to lim it radiocurability  of hum an tum ours 
(i.e. 26% of tumour cells with p 0 2  < 8 mmHg) (Gatenby et al., 1988).
It is conceivable from the above discussions that determ ination 
of changes in oxygenation as measured by 19p  MRS m ay be more 
sensitive  than absolu te  hypoxic frac tion . C hanges in  tum our 
o x y g en atio n  resu ltin g  from  the ad m in istra tio n  o f h y d ra laz in e , 
carbogen and carbon m onoxide were investigated in RIF-1 and C3H 
m am m ary tum ours using 1 9 p  MRS. It was dem onstrated that the 
m ean 1 9 p  retention index increased tw o-fold in response to the 
ad m in istra tio n  of 5 m g/kg hydralazine  com pared  to un trea ted  
controls. Hydralazine decreases tumour blood flow and subsequently 
decreases tum our oxygenation (Honess & B leehen, 1992). D irect 
m easurem ent of this reduction in tum our perfusion has also been 
reported in RIF-1 (Bhujwaller et al., 1990), C3H m am m ary carcinom a 
(Horsman et al., 1989), KHT (Honess & Bleehen, 1991), SCCVII (Trotter 
et a l., 1989), F S all (Kalmus et a l., 1990), and Lewis lung tumours 
(Chaplin, 1988; Chaplin & Acker, 1987). Honess & Bleehen (1992) 
reported that at 5 mg/kg hydralazine decreased the perfusion of KHT
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tumours to 35% (Honess & Bleehen, 1992). This same dose was also 
show n to reduce liver and kidney perfusion  to 64 and 73% 
respectively. Based on their data, Honess &Bleehen (1992) suggested 
th a t there  may be an im pairm ent in the m etab o lism  and/or 
elim ination of drugs which are m etabolised or elim inated by these 
organs following the administration of hydralazine. This may explain 
the presence of original drug in hydralazine treated RIF-1 tumours at 
7 hr post-injection of SR-4554 (this chapter). The levels of original 
drug presen t in the tum ours, however, could not account for the 
enhanced signal obtained, suggesting that the effect is m ainly due to 
hypoxia. In addition, 19p levels within hydralazine treated  tumours 
were high even at 45 min indicating that the reduced perfusion does 
not impede delivery of SR-4554 to the tumour.
On the other hand, carbogen breathing drastically increased the 
oxygenation of C3H mammary tumours as indicated by both 1 9 p  
retention index and p 0 2  (Eppendorf m easurem ents). This effect of 
carbogen on tum ours has also been previously  investiga ted  with 
oxygen electrodes and 31p  MRS (Nordsmark et a l., 1995), as well as 
lH  functional imaging (Robinson et a l., 1994). Surprisingly, however, 
the re la tio n sh ip  betw een 1 9 p  retention index and p 0 2  in mice 
breath ing  carbon m onoxide was contrary  to the expected  result. 
Carbon m onoxide decreases tumour oxygenation by two m echanism s, 
(a) a decrease in the oxygen carrying capacity of blood and, (b) a 
reduction in tumour blood flow (Grau et a l., 1994). Data from this 
chapter, and as reported by others (Nordsmark et al., 1995), indicated 
that pC>2 values in C3H mammary tum ours decreased dram atically  
when mice breathed carbon monoxide gas. The l ^ F  retention index in 
these tum ours, however, were low (instead of high) com pared to 
control m ice, in spite of high 1 9 p  signals at 45 m in suggesting 
unim peded delivery. H irst et al. (1985) showed that acute hypoxia 
induced by reduced haem atocrit was associated w ith an increase in 
1 4 c  labelled m isonidazole binding. This response was subsequently 
shown to be accompanied by compensatory m echanism s w hich act to 
increase cardiac output and maintain the supply of oxygen to tissues 
(Sensky et al., 1994). Such an effect is unlikely to be observed in the 
1 4 c  m isonidazole model used by Hirst et al. since the oxygen carrying 
capacity of blood will remain low throughout the m easurem ent period 
(H irst et al., 1985). In the carbon monoxide m odel, how ever, such
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com pensatory  effects could occur due to reoxygenation  and may 
account for the unexpectedly low retention index observed. In
addition, the decreased retention index may be attributed in part
to the partial inhibition of SR-4554 bioreduction produced by the 
inhibitory effect of carbon monoxide on the NADPH: cytochrome P450 
enzyme (section 3.3.1) and possibly other haem containing reductases. 
Using 31p  MRS, tumour bioenergetics were also shown (Nordsmark e t 
a l ., 1995) to be unaffected by carbon monoxide breathing (660 ppm) 
in spite of the high degree of radiobiological hypoxia induced by this 
protocol. It was suggested that this unusual 31 p M RS behaviour 
produced by carbon monoxide may be due to the continued supply of 
g lucose and other nutrients to the tum our m aking such tum ours 
resistant to a decrease in oxygen content (Nordsmark et a l., 1995).
By means of 19p MRI, SR-4554 was dem onstrated to localise in 
bladder, tumour and liver of mice after 5 hr post-injection. This is in 
accordance with the route of excretion (bladder; see section 5.3.5), as 
well as sites of bioreduction (liver and tumour; see section 3.3.2) of 
SR-4554. It is worth noting that the signal from the liver region could 
be predom inantly from the gall bladder, rather than liver p er se. In 
addition, unabsorbed drug in the peritoneum  could not be definitely 
ruled out. Although the sensitivity of 1 9 p  M RI is insufficien t to 
ach ieve the high reso lu tion  shown by techn iques em ploying  2- 
n itroim idazole probes such as electron energy loss spectroscopy (see 
ch ap te r 4), im m unohistochem istry  (Lord et a l ., 1993), positron
em ission  tom ography (K oh et a l., 1991), and au to rad io g rap h y
(U rtasun et a l.y 1986b), it allows the whole body biodistribution of the 
probe to be studied in mice thus com plem enting these techniques. 
Further m odification of the protocol (including the NM R coil) is, 
however, required to allow for the imaging of SR-4554 at early time 
points and also for enhancing sensitivity.
The distribution of between tissue and body flu id  could
accoun t fo r the b i-exponen tia l nature of the T2 curve. The 
im plication of this is apparent. For instance at the short T2 of 4.6 
m sec, fluorine sensitivity decreases in the order 65, 52, 42, 18, and 
3% at echo times (TE) of 2, 3, 4, 8, and 16 msec respectively. In 
contrast, at a TE of 16 msec, the sensitivity is only decreased to 89% 
when the T2 component is 141 msec. Due to the short T2 com ponent, 
very low TE's are required in the detection of fluorine signal from
86
tissues and thus care should be taken in interpreting the resultant T2 
w eighted images as the exact tissue distribution may not be apparent. 
At present, this is highly undesirable and may, in fact, ham per the 
developm ent of fluorinated 2-nitroim idazoles as MRI (but not MRS) 
agents, unless newer pulse sequences which can overcom e this effect 
are developed.
In g en era l, how ever, MR d e te c tio n  o f f lu o r in a te d  2- 
n itro im idazo le  probes and in particu lar spectroscopy , o ffer great 
potential for the detection and quantitation of tum our hypoxia within 
individual tumours. The data presented in this chapter indicate that 
1 9 F MRS can be employed to detect clinically relevant hypoxia as 
dem onstra ted  by m urine and human tum our xenografts . These 
studies are therefore im portant to the future clinical developm ent of 
SR-4554 as a non-invasive probe for quantifying hypoxia in tumours.
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CHAPTER 7 
Summary and conclusions
The principal aims of this thesis were two fold. Firstly, to study 
the pharm aco log ica l p roperties and tox ic ity  of the novel 2-
nitroim idazole SR-4554 and secondly, to assess the ability of 19p MRS
(of SR-4554) to detect and quantify hypoxia within tumours. Both of 
these aims have been achieved in chapters 2 to 6 and summarised in 
this chapter.
Since the suggestion in 1955 by Thom linson and Gray, that 
tumours may contain viable hypoxic cells which can lim it therapeutic 
outcom e (Thom linson & Gray, 1955), several attem pts have been
made to detect, characterise, and quantify these cells w ithin tumours 
as a prelude to rational therapies designed to kill all cancer cells. In 
this regard , the 2-nitro im idazoles which were previously  of very 
lim ited success as radiosensitizers (Overgaard, 1989), were developed 
as m arkers for hypoxic cells (W orkm an, 1992). E arly  m ethods 
focused on the developm ent of radiolabelled probes of m isonidazole 
as hypoxia markers (Chapman, 1984). Although this formed the basis 
o f c u rren t invasive  and non-invasive  techn iques (T ab le  1.1), 
radiolabelled p robes-w ere  not suitable for clinical use. MRS
offers an easy, com paratively cheap, non-invasive and relatively non­
toxic potential for measuring hypoxia within tumours. In this thesis, 
the characterisation of a rationally designed superior hypoxia probe, 
SR -4554, has been described  and the re la tio n sh ip  betw een  its 
retention and the oxygenation within tumours reported.
Design  features of  SR-4554
Some of the design features of SR-4554, which makes it suitable 
for quantifying hypoxia within tumours, are sum m arised in Fig 7.1. 
The nitro group facilitates bioreductive m etabolism  of the compound 
and binding to hypoxic cells. The reduction potential of the compound 
was found to be sim ilar to that of m isonidazole (G reenstock et a l., 
1978) and will be expected to have sim ilar reduction properties. 
Im portan tly , the am ide side chain was introduced to increase the 
hydrophilic  character of SR-4554, and thus decrease its potential 
toxicity  as in the case of etanidazole (Brown & W orkm an, 1980), 
thereby making it more suitable for clinical use. The MRS detection
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Fig. 7.1. D esign features of the fluorinated 2-nitroim idazole SR- 
4554: non-invasive MRS probe for quantifying tumour hypoxia.
/
: n Oi
Nitro group in 2 position of imidazole 
ring to facilitate bioreductive metabolism 
and binding in hypoxic tumor cells.
Reduction potential (Ex/2 vs SCE) of 
-363 mV is optimal for in vivo activity.
CH2CONHCH2CH(OH)CF3
........................................
/V
Three equivalent fluorine atoms 
3 to provide MRS/MRI detection 
capability
Hydrophilic character and hydrogen bonding 
capability introduced by amide and hydroxyl 
functions. This should discourage penetration 
into the nervous system and reduce the risk of 
neurotoxicity.
capability of this compound is due to the presence of three equivalent 
fluorine atoms. Hence MRS/MRI techniques can be used to detect SR- 
4554 non-invasively and thus enable hypoxia-dependent labelling of 
tum our cells to be measured.
Outline o f  methods developed or used in this thesis
In chapter 2, a rapid, sensitive and selective HPLC assay was 
developed for the analysis of SR-4554 in mouse plasm a and tissues. 
The UV method of detection employed by this technique relies on the 
presence of a nitro chrom ophore attached to the im idazole ring and 
would therefore not m easure bioreduced product in w hich the nitro 
group has been converted to other species. This HPLC technique was, 
h o w e v e r, u sed  to e v a lu a te  the  m e ta b o lic  re d u c tio n  and 
pharm acokinetics of SR-4554 in subsequent chapters o f this thesis. 
In order to elucidate the possible bioreduced products, how ever, a 
high resolution NMR method was developed (chapter 3). Although 
this technique involves a longer sample preparation step, it enabled 
both orig inal and bioreduced fluorinated  2 -n itro im idazo les to be 
characterised with respect to the form ation of reductive m etabolites. 
In addition to HPLC and NMR techniques, UV spectrophotom etric 
m ethods were employed to determ ine both the protein  and enzyme 
content of various tumours and liver microsomes. In the absence of 
radiolabelled  SR-4554, the subcellular localisation of SR-4554 was 
carried out with the aid of EELS (chapter 4), a technique which is only 
now emerging as a useful tool in oncology. This technique measures 
the energy loss of the fluorine atoms in SR-4554 within cells (at the 
m olecu lar level), and offers the po ten tial for m easuring  tum our 
hypoxia on biopsy samples. This could be useful as an additional 
m ethodology during the early development of SR-4554.
In order to non-invasively detect and quantify hypoxia within 
tum ours, both MRS and MRI techniques were em ployed to study the 
selective retention of SR-4554 in mouse tumours (chapter 6). These 
m ethods m easure the concentration and spatial spin d istribution  of 
the equivalent fluorine atoms in SR-4554. In addition, fine needle 
oxygen electrodes (Eppendorf) were also used to d irectly  m easure 
tissue oxygenation in mouse tumours and hence to validate the use of 
SR -4554.
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M e ta b o lic  p ro p e r t ie s  o f SR -4554
SR-4554 was reduced by m ouse liver m icrosom es, SCCVII 
tumour homogenates and purified rat and human NADPH: cytochrome 
P450 reductase (chapter 3). Reduction of SR-4554 by m ouse liver 
m icrosom es (loss of parent drug) was linear w ith time and protein 
co n cen tra tio n , and was charac terised  by an apparen t Km and 
apparen t V m ax  of 590 |iM  and 16 nmol SR-4554 reduced/m in/m g 
p ro te in  respective ly . Inhib ito ry  studies ind icated  tha t NADPH: 
cytochrom e P450 reductase was the m ost im portant enzym e involved 
in the reductive activation of SR-4554. A panel of murine and human 
tum our xenografts were profiled to investigate w hether the activity 
of NADPH: cytochrom e P450 reductase varied m arkedly and would 
influence the in vivo  retention of SR-4554 w ithin tum ours. The 
activity of this enzyme in tumours only varied between 3.4 and 11.9 
nmol cytochrom e c reduced/m in/m g protein. Its unlikely that these 
differences will m arkedly influence the in vivo  retention profile of 
SR-4554 w ithin the tumours studied in chapter 6. Im portantly, the 
reduction rate of SR-4554 was dependent on oxygen tension. The 
concentration of oxygen which produced 50% inhibition of SR-4554 
reduction  betw een nitrogen and air (half-m axim al inh ib ition) was 
found to be 0.48%.
H ypoxia-dependent m etabolites of SR-4554 were detected  by 
high resolution NMR spectroscopy. In this regard, loss of parent drug 
was found to be associated with the formation of m etabolites. Both 
processes were inhibited under aerobic conditions. These m etabolites 
were found to be low molecular weight species. Sim ilar m etabolites 
were detected in liver and urine from SR-4554 treated mice, but were 
not found in brain which also had low levels of SR-4554 itself. Other 
m etabolites unrelated to these hypoxia dependent m etabolites were 
also observed in the urine samples, but by far the major contribution 
in u rine  was the orig inal paren t com pound, SR -4554. O ther 
fluorinated  2-nitroim idazoles (CCI-103F, Ro 07-2044, KU-2285 and 
fluo rom ison idazo le) were also characterised  w ith regard  to the 
form ation  of reductive m etabolites. The chem ical sh ifts of the 
m etabolites were found to be sim ilar to in trace llu lar/ex trace llu lar 
shifts previously reported in NMR literature (London, 1994; Xu et a l., 
1993), and were related to the partition coefficient of the compounds. 
Only small chemical shifts (up to 1.5 ppm in general; 0.05 to 0.1 ppm
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fo r S R -4554) betw een the o rig in a l 2 -n itro im id a zo le  and its 
m etabolites were observed. It is unlikely that such shifts would be 
resolved in in vivo  MRS studies (at currently available clinically  
relevant field strengths), to allow m etabolite m apping to be carried 
out. This also implies that in vivo  MRS spectra of SR-4554, for 
in s tan c e , w ill com prise  of both the o rig in a l com pound  and 
m e ta b o lite s .
Loca l i sa t io n  o f  SR-4554
Following the uptake of SR-4554 into cells of the human ovarian 
carcinom a m ulticellular spheroid, A2780, the compound localised to a 
greater extent (at least 8 fold) in the inner hypoxic regions of the 
sphero id  com pared to the outer more aerobic reg ions. D etailed  
subcellular localisation studies with EELS revealed that SR-4554 does 
not significantly  bind to m itochondria and plasm a m em brane. The 
com pound was mainly localised to the nuclear periphery, nucleus and 
cy to p lasm . T his is in agreem ent w ith  p rev io u s su b ce llu la r 
fractionation studies with radiolabelled m isonidazole by M iller et al.
(1992) which indicated that reduced m isonidazole was predom inantly 
bound to RNA, DNA lipids and proteins (M iller et a l ., 1982). In 
addition, reactive m etabolites of SR-4554 do not appear to m igrate 
out of the cells within which they are activated. This is a useful 
property of good marker compound.
T oxic i ty  and pharm acokinet ics  o f  SR-4554
SR-4554 was designed to have low toxicity  by including an 
amide side chain sim ilar to that of etanidazole (Brown & W orkman, 
1980). Although the actual LD50 or LD 10 of SR-4554 could not be 
determ ined, due to the limited solubility of the com pound in saline 
(m axim um  solubility  in saline = 6.5 m g/m l), dose ranging studies 
indicated that SR-4554 was non-toxic in mice up to a dose of 1300 
m g/kg. This dose was well in excess of the dose required for MRS 
studies (180 mg/kg). SR-4554 plasma pharm acokinetics fitted  a one 
com partm ent open model following i.p. or p.o. adm inistration. On the 
other hand, plasm a pharm acokinetics following an i.v. dose, fitted a 
two com partm ent open m odel. In addition, a linear rela tionsh ip  
between dose of SR-4554 and plasma AUC was observed. The tumour 
to plasm a ratios of SR-4554 (between 30 and 120 min post-injection)
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were found to be between 0.86 and 1.27 and consistent with trends 
shown by other 2-nitro im idazoles of sim ilar partition  coeffic ien ts 
(Brown & W orkman, 1980; Workman & Brown, 1981). Interestingly, 
brain to plasma ratios of SR-4554 were found to be low er (0.05 to
0.19) than is consistent with the trends reported in the literature 
(B row n & W orkm an, 1980; W orkm an & Brow n, 1981). This 
unexpected and unique property of SR-4554 may be due to the 
additional hydrophilic character and hydrogen bonding capability  of 
the amide group in SR-4554. B ioavailability studies indicated that 
SR-4554 was alm ost com pletely absorbed from  i.p. (100% ) and oral 
(96%) adm inistration. Both data from chapter 3 and 5 showed that 
SR -4554 was m etabolised in m ouse liver. The com pound was, 
however, excreted mainly as unchanged drug in the urine (68%), and 
show ed m inim al binding to mouse and human plasm a pro teins (< 
20%).
Non-invasive  detection of  hypoxia by M RS/M RI
The selective retention of SR-4554 in m ouse tum ours was 
dem onstrated using a modification of the m ulti-tuned MRS technique 
previously described by Thulborn & Ackerman, 1983). SR-4554 was
adm inistered  at a dose of 180 m g/kg in these studies. It was 
assumed that the retention of high levels of fluorinated probe at 6 hr, 
despite  the much low er (20 fold) concentration  of o rig inal drug 
detected  by HPLC at 7 hr, represen t one or m ore b ioreduced  
m etabolites. The 19p  retention index (the MRS index for hypoxia) 
was found to vary w ithin tum ours of the sam e and of d ifferen t 
histological classifications. The mean 19p retention for each tumour 
type, however, correlated in general, with the reported radiobiological 
hypoxic  frac tion  of the tum ours. P rovided red u c tiv e  enzym e 
ac tiv itie s  w ithin tum ours are not m arkedly d iffe ren t than those 
described  here, this MRS technique should provide a quantita tive  
m easure of hypoxia within tumours. The 1 9 p  retention index was 
found to increase with increasing tumour mass, but, interestingly, did 
not correlate with bioenergetic status of (KHT) tumours as determ ined 
by 31p MRS.
Using various mouse tumour models, both 19p  retention index 
and p 0 2  (oxygen needle electrodes) were m easured from  the same 
tumour. Although a precise correlation between 19p  retention index
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and p 0 2  param eters was not observed, substantial trapping of SR- 
4554 was always associated with tumours with a hypoxic fraction of > 
10%. The retention index was found to increase (2 fold) with
decreased tum our blood flow, following pre-treatm ent of m ice with 
hydralazine. In contrast, the retention index decreased (6 fold) when 
m ice were made to breath carbogen gas. Surprising ly , however, 
carbon m onoxide breathing which has previously  been show n to 
decrease tum our oxygenation (Grau et al„ 1994), did not increase the 
1 9 f  retention, but caused a decrease.
Using MRI techniques, SR-4554 was dem onstrated to localise in 
bladder, tumour and liver of mice. The sensitivity of the technique is, 
however, low. This is due to a short T2 com ponent o f SR-4554 in 
tissues (4.6 m sec) and implies that extrem ely short echo tim es are 
required to image SR-4554.
C o n c lu d in g  rem ark s
It has been shown, in this thesis, that SR-4554 has suitable
m etabolic, pharm acological and MRS properties for use in the non- 
invasive quantification of critical levels of clinically relevant hypoxia 
that have been reported to lim it radiocurability  of hum an tum ours 
(G atenby et a l., 1988). On the basis of these prom ising results, the 
com pound has been approved by the CRC phase I/II com m ittee for 
clin ical developm ent.
In te re s tin g  aspec ts  of the w ork  w h ich  n eed s  fu rth e r  
experim entation include the following:
1. To fully characterise the reductive m etabolites of SR-4554 and
other related fluorinated 2-nitroim idazoles.
2. To evaluate the binding kinetics of SR-4554 with radiolabelled
com pound .
3. To characterise the relationship between partition coefficient and 
b ra in  to p lasm a ra tio s of new er and m ore h y d ro p h ilic  2- 
n itro im idazole analogues.
4. To fully characterise the exact relationship between 19p  retention 
index and tumour oxygenation status.
It is my ultimate goal that the work reported in this thesis will 
provide further impetus to the continued developm ent o f SR-4554, as 
well as other more superior fluorinated 2-nitro im idazoles as probes
for the m easurem ent of hypoxia within human tumours.
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APPENDIX A 
S y n th e s is  o f S R -4554
T he sy n th esis  o f N -(2 -h y d ro x y -3 ,3 ,3 - tr if lu o ro p ro p y l)-2 -(2 -  
n i tro - l- im id a z o ly l)  ace tam id e  (S R -4554 ) is i l lu s tra te d . 2- 
n itro im idazo le  (I) was converted to it sodium salt by treatm ent with 
sodium  methoxide in methanol-DM F at 150°C for 10 min. Subsequent 
reaction with methyl bromoacetate in DMF at 85°C for 20 min gave 
the m ethyl ester ( I I ) . The methyl ester was then converted to the 
carboxylic acid ( I I I )  by treatment with 0.1 N NaOH at 100°C for 15 
min followed by acidification with 1 M HC1. The fluorine labelled side 
chain was prepared by reaction of trifluoroacetaldehyde hem iacetal 
( I V )  and nitrom ethane in the presence of potassium  carbonate at 
6 0 ° C  for 3 h. Pure nitro compound (V ) was obtained from  the 
reaction mixture by distillation at 115°C at 60 mmHg. V was reduced 
by halogenation at 40 psi with Raney-nickel catalysis, follow ed by 
treatm ent of the filtered reaction mixture with ethereal HC1 at -20°C 
to give the amino-compound (V I) as its HC1 salt. Coupling of I I I  with 
V I was carried out by first converting the acid group of I I I  to the 
m ix e d  a n h y d rid e  u sing  is  o - b u ty lc h lo r o f o r m a te  a n d  N- 
m ethylm orpholine in tetrahydrofuran (THF) at 0°C. Addition of V I  
and a fu rther equivalent of N -m ethylm orpholine resu lted  in the 
form ation of SR-4554, which was purified by column chrom atography 
and recrystallization from ethyl acetate-hexanes.
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A l .  Synthesis of SR-4554.
GO
5*IALn
ui
f = \
Oa
X'Z
trt ffi
O ^  
a  »*3
/ = \
tc z .T
2
oho
td>-$n
a
hon
oK>
2fl>
2
P
o
2Q
2<T>O
a
r ' r
O OK)
f = \
2 .  . 2
O
s<T>
an
2 :
po
r= \
3
Oa -4 2o  oK>
APPENDIX B 
Molecular models of 2-nitroimidazoles
The molecular models of SR-4554, etanidazole and misonidazole. 
The models were derived using a computer generated minimisation 
programme (CSC Chem 3D, Cambridge Scientific Computing Inc., MA, 
USA).
The minimised steric energies in all the models ranged between 
6 and 9 kcal/mole. Stippled circles represent oxygen atoms, circles 
with stripes represent fluorine atoms, white circles represent 
hydrogen atoms or lone pairs of electrons, black circles represent 
carbon atoms, and yellow coloured circles represent nitrogen atoms. 
The imidazole ring, C-N02 bond and the side chain were all planar. It 
should be noted that due to rotation about single bonds, other 
conformations are possible. In SR-4554 and etanidazole, the side 
chain bends further into the ring than in misonidazole. In addition, 
hydrogen bonding between the terminal hydroxyl group and the 
carboxyl group or amide nitrogen in SR-4554 and etanidazole 
stabilises these compounds, increases their hydrophilic character and 
decreases their resemblance to lipid-like molecules. Such hydrogen 
bonding is not possible in misonidazole.
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Bl. Molecular model of SR-4554.
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